,ligandIdx,targetIdx,instance_id,pref_name,outcome,assayname
0,315225,72,CHEMBL535,Serine/threonine-protein kinase PIM1,Inactive,Average Binding Constant for PIM1; NA=Not Active at 10 uM
1,315225,72,CHEMBL535,Serine/threonine-protein kinase PIM1,Unspecified,Binding constant for PIM1 kinase domain
2,315225,72,CHEMBL535,Serine/threonine-protein kinase PIM1,Unspecified,Binding affinity to PIM1
3,315225,72,CHEMBL535,Serine/threonine-protein kinase PIM1,Unspecified,Binding constant for PIM1 kinase domain
4,315225,72,CHEMBL535,Serine/threonine-protein kinase PIM1,Unspecified,Delta TM value showing the stabilisation of PIM1 produced by compound binding
5,118834,72,CHEMBL265470,Serine/threonine-protein kinase PIM1,Active,Percentage PIM1 activity remaining in the presence of 1uM inhibitor
6,325135,138,CHEMBL590109,Vascular endothelial growth factor receptor 2,Unspecified,Selectivity for MK2 over KDR
7,325135,138,CHEMBL590109,Vascular endothelial growth factor receptor 2,Unspecified,Inhibition of KDR
8,42629,149,CHEMBL1725279,Tyrosine-protein kinase JAK2,Inactive,Average Binding Constant for JAK2 (Kin.Dom. 2); NA=Not Active at 10 uM
9,42629,149,CHEMBL1725279,Tyrosine-protein kinase JAK2,Unspecified,"Millipore: Percentage of residual kinase activity of JAK2 at 1uM relative to control. Control inhibitor: Staurosporine at 10.0uM. Buffer: 8 mM MOPS pH 7.0, 0.2 mM EDTA"
10,42629,149,CHEMBL1725279,Tyrosine-protein kinase JAK2,Unspecified,"Millipore: Percentage of residual kinase activity of JAK2 at 10uM relative to control. Control inhibitor: Staurosporine at 10.0uM. Buffer: 8 mM MOPS pH 7.0, 0.2 mM EDTA"
11,303829,72,CHEMBL475251,Serine/threonine-protein kinase PIM1,Unspecified,Binding constant for PIM1 kinase domain
12,314179,72,CHEMBL522892,Serine/threonine-protein kinase PIM1,Unspecified,Binding constant for PIM1 kinase domain
13,314179,72,CHEMBL522892,Serine/threonine-protein kinase PIM1,Unspecified,Binding constant for PIM1 kinase domain
14,42522,72,CHEMBL1721885,Serine/threonine-protein kinase PIM1,Unspecified,Binding constant for PIM1 kinase domain
15,42522,72,CHEMBL1721885,Serine/threonine-protein kinase PIM1,Unspecified,Binding constant for PIM1 kinase domain
16,126071,149,CHEMBL302449,Tyrosine-protein kinase JAK2,Unspecified,"Millipore: Percentage of residual kinase activity of JAK2 at 1uM relative to control. Control inhibitor: Staurosporine at 10.0uM. Buffer: 8 mM MOPS pH 7.0, 0.2 mM EDTA"
17,126071,149,CHEMBL302449,Tyrosine-protein kinase JAK2,Unspecified,"Millipore: Percentage of residual kinase activity of JAK2 at 10uM relative to control. Control inhibitor: Staurosporine at 10.0uM. Buffer: 8 mM MOPS pH 7.0, 0.2 mM EDTA"
18,325135,149,CHEMBL590109,Tyrosine-protein kinase JAK2,Unspecified,Selectivity for MK2 over JAK2
19,325135,149,CHEMBL590109,Tyrosine-protein kinase JAK2,Unspecified,Inhibition of JAK2
20,42522,224,CHEMBL1721885,Serine/threonine-protein kinase Aurora-A,Unspecified,Binding constant for AURKA kinase domain
21,42522,224,CHEMBL1721885,Serine/threonine-protein kinase Aurora-A,Unspecified,Binding constant for AURKA kinase domain
22,10566,138,CHEMBL1164265,Vascular endothelial growth factor receptor 2,Unspecified,Inhibition of VEGFR2 at 1 uM
23,313876,149,CHEMBL521851,Tyrosine-protein kinase JAK2,Unspecified,Binding constant for JAK2(JH1domain-catalytic) kinase domain
24,61894,52,CHEMBL1934664,Carbonic anhydrase II,Unspecified,Inhibition of human CA2 pre-incubated for 15 mins to 24 hrs measured after 6 hrs by phenol red-based stopped-flow CO2 hydrase assay
25,61893,52,CHEMBL1934663,Carbonic anhydrase II,Unspecified,Inhibition of human CA2 pre-incubated for 15 mins to 24 hrs measured after 6 hrs by phenol red-based stopped-flow CO2 hydrase assay
26,61895,52,CHEMBL1934665,Carbonic anhydrase II,Unspecified,Inhibition of human CA2 pre-incubated for 15 mins to 24 hrs measured after 6 hrs by phenol red-based stopped-flow CO2 hydrase assay
27,54432,52,CHEMBL183419,Carbonic anhydrase II,Active,Inhibition of human recombinant CA2 by stopped-flow CO2 hydration assay
28,54432,52,CHEMBL183419,Carbonic anhydrase II,Active,Inhibition of human CA2 incubated for 15 mins prior to testing by stopped flow CO2 hydrase assay
29,317136,52,CHEMBL55078,Carbonic anhydrase II,Unspecified,Inhibition of human CA2 pre-incubated for 15 mins to 24 hrs measured after 6 hrs by phenol red-based stopped-flow CO2 hydrase assay
30,335526,52,CHEMBL89295,Carbonic anhydrase II,Unspecified,Inhibition of human recombinant wild type CA2 by stopped-flow CO2 hydration method
31,335526,52,CHEMBL89295,Carbonic anhydrase II,Unspecified,Inhibition of human recombinant CA2 by CO2 hydration assay
32,335526,52,CHEMBL89295,Carbonic anhydrase II,Unspecified,Inhibition of human CA2 after 15 mins by stopped-flow/Co2 hydration assay
33,335526,52,CHEMBL89295,Carbonic anhydrase II,Unspecified,Inhibition of human CA2 incubated for 15 mins by stopped-flow CO2 hydration assay
34,276435,138,CHEMBL4068896,Vascular endothelial growth factor receptor 2,Unspecified,Inhibition of human VEGFR2 at 10 uM using poly[Glu:Tyr] (4:1) as substrate measured after 120 mins in presence of [gamma33P]ATP by P81 ion exchange chromatographic method relative to control
35,276435,138,CHEMBL4068896,Vascular endothelial growth factor receptor 2,Unspecified,Inhibition of human VEGFR2 using poly[Glu:Tyr] (4:1) as substrate measured after 120 mins in presence of [gamma33P]ATP by P81 ion exchange chromatographic method
36,144015,127,CHEMBL3310984,Carbonic anhydrase I,Unspecified,Inhibition of CA-1 (unknown origin) after 15 mins by CO2 hydration assay
37,144015,127,CHEMBL3310984,Carbonic anhydrase I,Unspecified,Inhibition of CA-1 (unknown origin) at 10 uM after 15 mins by CO2 hydration assay
38,36100,127,CHEMBL1621411,Carbonic anhydrase I,Unspecified,Inhibition of CA-1 (unknown origin) after 15 mins by CO2 hydration assay
39,36100,127,CHEMBL1621411,Carbonic anhydrase I,Unspecified,Inhibition of CA-1 (unknown origin) at 10 uM after 15 mins by CO2 hydration assay
40,123311,127,CHEMBL287486,Carbonic anhydrase I,Unspecified,Inhibition of CA-1 (unknown origin) after 15 mins by CO2 hydration assay
41,123311,127,CHEMBL287486,Carbonic anhydrase I,Unspecified,Inhibition of CA-1 (unknown origin) at 10 uM after 15 mins by CO2 hydration assay
42,26318,127,CHEMBL14060,Carbonic anhydrase I,Active,Inhibition of human CA1 by stopped-flow CO2 hydration assay
43,26318,127,CHEMBL14060,Carbonic anhydrase I,Active,Inhibition of human CA1 by stopped-flow assay
44,26318,127,CHEMBL14060,Carbonic anhydrase I,Active,Inhibition of human erythrocytes CA1 using 4-nitrophenylacetate as substrate by esterase assay
45,26318,127,CHEMBL14060,Carbonic anhydrase I,Active,Competitive inhibition of human erythrocytes CA1 using 4-nitrophenylacetate as substrate by Lineweaver-Burk plot analysis
46,314179,224,CHEMBL522892,Serine/threonine-protein kinase Aurora-A,Unspecified,Binding constant for AURKA kinase domain
47,314179,224,CHEMBL522892,Serine/threonine-protein kinase Aurora-A,Unspecified,Binding constant for AURKA kinase domain
48,35880,136,CHEMBL1614712,Fibroblast growth factor receptor 3,Unspecified,Inhibition of FGFR3 (unknown origin) in presence of [gamma33P]ATP
49,320406,149,CHEMBL565612,Tyrosine-protein kinase JAK2,Unspecified,Inhibition of human recombinant JAK2
50,322676,149,CHEMBL573339,Tyrosine-protein kinase JAK2,Unspecified,Binding constant for JAK2(Kin.Dom.2/JH1 - catalytic) kinase domain
51,322676,149,CHEMBL573339,Tyrosine-protein kinase JAK2,Unspecified,Binding constant for JAK2(JH1domain-catalytic) kinase domain
52,322676,149,CHEMBL573339,Tyrosine-protein kinase JAK2,Unspecified,"Millipore: Percentage of residual kinase activity of JAK2 at 1uM relative to control. Control inhibitor: Staurosporine at 10.0uM. Buffer: 8 mM MOPS pH 7.0, 0.2 mM EDTA"
53,322676,149,CHEMBL573339,Tyrosine-protein kinase JAK2,Unspecified,"Millipore: Percentage of residual kinase activity of JAK2 at 10uM relative to control. Control inhibitor: Staurosporine at 10.0uM. Buffer: 8 mM MOPS pH 7.0, 0.2 mM EDTA"
54,15417,73,CHEMBL1230609,Tyrosine-protein kinase JAK3,Unspecified,Binding constant for JAK3(JH1domain-catalytic) kinase domain
55,66920,73,CHEMBL1980297,Tyrosine-protein kinase JAK3,Unspecified,Inhibition of JAK3 by TR-FRET assay
56,36210,90,CHEMBL1626,Serotonin transporter,Unspecified,"DRUGMATRIX: Transporter, Serotonin (5-Hydroxytryptamine) (SERT) radioligand binding (ligand: [3H] Paroxetine)"
57,36210,90,CHEMBL1626,Serotonin transporter,Unspecified,"DRUGMATRIX: Transporter, Serotonin (5-Hydroxytryptamine) (SERT) radioligand binding (ligand: [3H] Paroxetine)"
58,86382,90,CHEMBL21731,Serotonin transporter,Unspecified,"DRUGMATRIX: Transporter, Serotonin (5-Hydroxytryptamine) (SERT) radioligand binding (ligand: [3H] Paroxetine)"
59,86382,90,CHEMBL21731,Serotonin transporter,Unspecified,"DRUGMATRIX: Transporter, Serotonin (5-Hydroxytryptamine) (SERT) radioligand binding (ligand: [3H] Paroxetine)"
60,294641,138,CHEMBL428690,Vascular endothelial growth factor receptor 2,Inactive,Average Binding Constant for VEGFR2; NA=Not Active at 10 uM
61,294641,138,CHEMBL428690,Vascular endothelial growth factor receptor 2,Unspecified,Binding constant for VEGFR2 kinase domain
62,294641,138,CHEMBL428690,Vascular endothelial growth factor receptor 2,Unspecified,Binding constant for VEGFR2 kinase domain
63,57881,224,CHEMBL1908395,Serine/threonine-protein kinase Aurora-A,Unspecified,Binding constant for AURKA kinase domain
64,311062,128,CHEMBL509032,Glycogen synthase kinase-3 beta,Unspecified,Binding constant for GSK3B kinase domain
65,311062,128,CHEMBL509032,Glycogen synthase kinase-3 beta,Unspecified,Inhibition of GSK3b assessed as residual activity at 10 uM relative to control
66,311062,128,CHEMBL509032,Glycogen synthase kinase-3 beta,Unspecified,Inhibition of GSK3b assessed as residual activity at 1 uM relative to control
67,12480,90,CHEMBL1200406,Serotonin transporter,Unspecified,"DRUGMATRIX: Transporter, Serotonin (5-Hydroxytryptamine) (SERT) radioligand binding (ligand: [3H] Paroxetine)"
68,12480,90,CHEMBL1200406,Serotonin transporter,Unspecified,"DRUGMATRIX: Transporter, Serotonin (5-Hydroxytryptamine) (SERT) radioligand binding (ligand: [3H] Paroxetine)"
69,148912,166,CHEMBL3353053,Histone deacetylase 1,Active,Inhibition of full length GST-tagged human HDAC1 using Arg-His-Lys-Lys(Ac) substrate incubated for 2 hrs by fluorescence assay
70,147574,166,CHEMBL3338404,Histone deacetylase 1,Active,Inhibition of HDAC1 (unknown origin) using fluorogenic peptide as substrate by fluorescence assay
71,42351,90,CHEMBL17157,Serotonin transporter,Unspecified,"DRUGMATRIX: Transporter, Serotonin (5-Hydroxytryptamine) (SERT) radioligand binding (ligand: [3H] Paroxetine)"
72,42351,90,CHEMBL17157,Serotonin transporter,Unspecified,"DRUGMATRIX: Transporter, Serotonin (5-Hydroxytryptamine) (SERT) radioligand binding (ligand: [3H] Paroxetine)"
73,312587,84,CHEMBL516088,Serotonin 2a (5-HT2a) receptor,Active,Displacement of [3H]MDL from rat 5HT2A receptor expressed in GF62 cells by liquid scintillation analyser
74,81171,178,CHEMBL21156,Fibroblast growth factor receptor 1,Unspecified,"Millipore: Percentage of residual kinase activity of FGFR1 at 1uM relative to control. Control inhibitor: Staurosporine at 10.0uM. Buffer: 8 mM MOPS pH 7.0, 0.2 mM EDTA"
75,81171,178,CHEMBL21156,Fibroblast growth factor receptor 1,Unspecified,"Millipore: Percentage of residual kinase activity of FGFR1 at 10uM relative to control. Control inhibitor: Staurosporine at 10.0uM. Buffer: 8 mM MOPS pH 7.0, 0.2 mM EDTA"
76,47981,138,CHEMBL1784725,Vascular endothelial growth factor receptor 2,Unspecified,Inhibition of VEGFR2 expressed in Bac-to-Bac Baculovirus expression system using poly(Glu-Tyr)4:1 as substrate after 60 mins by ELISA
77,37771,90,CHEMBL1643900,Serotonin transporter,Unspecified,Displacement of [3H]citalopram from human SERT expressed in HEK cells
78,37771,90,CHEMBL1643900,Serotonin transporter,Unspecified,Displacement of [3H]-citalopram from human SERT expressed in HEK cell membranes
79,15836,138,CHEMBL1240703,Vascular endothelial growth factor receptor 2,Unspecified,Binding affinity to VEGFR2
80,330286,90,CHEMBL631,Serotonin transporter,Unspecified,"DRUGMATRIX: Transporter, Serotonin (5-Hydroxytryptamine) (SERT) radioligand binding (ligand: [3H] Paroxetine)"
81,330286,90,CHEMBL631,Serotonin transporter,Unspecified,"DRUGMATRIX: Transporter, Serotonin (5-Hydroxytryptamine) (SERT) radioligand binding (ligand: [3H] Paroxetine)"
82,316943,90,CHEMBL55,Serotonin transporter,Unspecified,"DRUGMATRIX: Transporter, Serotonin (5-Hydroxytryptamine) (SERT) radioligand binding (ligand: [3H] Paroxetine)"
83,316943,90,CHEMBL55,Serotonin transporter,Unspecified,"DRUGMATRIX: Transporter, Serotonin (5-Hydroxytryptamine) (SERT) radioligand binding (ligand: [3H] Paroxetine)"
84,123721,90,CHEMBL290106,Serotonin transporter,Unspecified,"DRUGMATRIX: Transporter, Serotonin (5-Hydroxytryptamine) (SERT) radioligand binding (ligand: [3H] Paroxetine)"
85,123721,90,CHEMBL290106,Serotonin transporter,Unspecified,"DRUGMATRIX: Transporter, Serotonin (5-Hydroxytryptamine) (SERT) radioligand binding (ligand: [3H] Paroxetine)"
86,315225,128,CHEMBL535,Glycogen synthase kinase-3 beta,Unspecified,Binding constant for full-length GSK3B
87,315225,128,CHEMBL535,Glycogen synthase kinase-3 beta,Unspecified,Binding affinity to GSK3B
88,315225,128,CHEMBL535,Glycogen synthase kinase-3 beta,Unspecified,Binding constant for GSK3B kinase domain
89,315225,128,CHEMBL535,Glycogen synthase kinase-3 beta,Unspecified,Delta TM value showing the stabilisation of GSK3B produced by compound binding
90,66351,138,CHEMBL1970879,Vascular endothelial growth factor receptor 2,Unspecified,Inhibitory activity against kdr
91,125603,138,CHEMBL300138,Vascular endothelial growth factor receptor 2,Unspecified,Binding constant for VEGFR2 kinase domain
92,333421,90,CHEMBL787,Serotonin transporter,Unspecified,"DRUGMATRIX: Transporter, Serotonin (5-Hydroxytryptamine) (SERT) radioligand binding (ligand: [3H] Paroxetine)"
93,333421,90,CHEMBL787,Serotonin transporter,Unspecified,"DRUGMATRIX: Transporter, Serotonin (5-Hydroxytryptamine) (SERT) radioligand binding (ligand: [3H] Paroxetine)"
94,298891,224,CHEMBL450786,Serine/threonine-protein kinase Aurora-A,Unspecified,Binding constant for AURKA kinase domain
95,12498,90,CHEMBL1200633,Serotonin transporter,Unspecified,"DRUGMATRIX: Transporter, Serotonin (5-Hydroxytryptamine) (SERT) radioligand binding (ligand: [3H] Paroxetine)"
96,12498,90,CHEMBL1200633,Serotonin transporter,Unspecified,"DRUGMATRIX: Transporter, Serotonin (5-Hydroxytryptamine) (SERT) radioligand binding (ligand: [3H] Paroxetine)"
97,269422,166,CHEMBL3981567,Histone deacetylase 1,Unspecified,"Inhibition Assay: The inhibitions of activities of HDAC enzymes by the compounds N1'-[3-fluoro-4-[[7-[4-(hydroxyamino)-4-oxobutoxy]-6-methoxy-4-quinolyl]oxy]phenyl]-N1-(4-fluoro phenyl)cyclopropane-1,1-dicarboxamide prepared in Example 9 and N1'-[3-fluoro-4-[[7-[6-(hydroxyamino)-6-oxohexyloxy]-6-methoxy-4-quinolyl]oxy]phenyl]-N1-(4-fluo rophenyl)cyclopropane-1,1-dicarboxamide prepared in Example 13 were measured by Reaction Biology Corporation (Reaction Biology Corp., One Great Valley Parkway, Suite 2, Malvern, PA 19355, USA . http://www.reactionbiology.com/pages/hdac.htm). The HDAC enzymes tested include the following 11 HDAC isoforms: HDAC1, HDAC2, HDAC3, HDAC4, HDAC5, HDAC6, HDAC7, HDAC8, HDAC9, HDAC10 and HDAC11.Specific steps were as follows: The compound of the present invention was dissolved in dimethyl sulfoxide (DMSO) to make a stock solution of 10 mM. The stock solution was diluted in 4-fold series starting from 10 mM to prepare 10 different dosages."
98,269422,166,CHEMBL3981567,Histone deacetylase 1,Active,"Inhibition Assay: The inhibitions of activities of HDAC enzymes by the compounds N1'-[3-fluoro-4-[[7-[4-(hydroxyamino)-4-oxobutoxy]-6-methoxy-4-quinolyl]oxy]phenyl]-N1-(4-fluoro phenyl)cyclopropane-1,1-dicarboxamide prepared in Example 9 and N1'-[3-fluoro-4-[[7-[6-(hydroxyamino)-6-oxohexyloxy]-6-methoxy-4-quinolyl]oxy]phenyl]-N1-(4-fluo rophenyl)cyclopropane-1,1-dicarboxamide prepared in Example 13 were measured by Reaction Biology Corporation (Reaction Biology Corp., One Great Valley Parkway, Suite 2, Malvern, PA 19355, USA . http://www.reactionbiology.com/pages/hdac.htm). The HDAC enzymes tested include the following 11 HDAC isoforms: HDAC1, HDAC2, HDAC3, HDAC4, HDAC5, HDAC6, HDAC7, HDAC8, HDAC9, HDAC10 and HDAC11.Specific steps were as follows: The compound of the present invention was dissolved in dimethyl sulfoxide (DMSO) to make a stock solution of 10 mM. The stock solution was diluted in 4-fold series starting from 10 mM to prepare 10 different dosages."
99,269422,166,CHEMBL3981567,Histone deacetylase 1,Unspecified,"Inhibition Assay: The inhibitions of activities of HDAC enzymes by the compounds N1'-[3-fluoro-4-[[7-[4-(hydroxyamino)-4-oxobutoxy]-6-methoxy-4-quinolyl]oxy]phenyl]-N1-(4-fluoro phenyl)cyclopropane-1,1-dicarboxamide prepared in Example 9 and N1'-[3-fluoro-4-[[7-[6-(hydroxyamino)-6-oxohexyloxy]-6-methoxy-4-quinolyl]oxy]phenyl]-N1-(4-fluo rophenyl)cyclopropane-1,1-dicarboxamide prepared in Example 13 were measured by Reaction Biology Corporation (Reaction Biology Corp., One Great Valley Parkway, Suite 2, Malvern, PA 19355, USA . http://www.reactionbiology.com/pages/hdac.htm). The HDAC enzymes tested include the following 11 HDAC isoforms: HDAC1, HDAC2, HDAC3, HDAC4, HDAC5, HDAC6, HDAC7, HDAC8, HDAC9, HDAC10 and HDAC11.Specific steps were as follows: The compound of the present invention was dissolved in dimethyl sulfoxide (DMSO) to make a stock solution of 10 mM. The stock solution was diluted in 4-fold series starting from 10 mM to prepare 10 different dosages."
100,269422,166,CHEMBL3981567,Histone deacetylase 1,Unspecified,"Inhibition Assay: The inhibitions of activities of HDAC enzymes by the compounds N1'-[3-fluoro-4-[[7-[4-(hydroxyamino)-4-oxobutoxy]-6-methoxy-4-quinolyl]oxy]phenyl]-N1-(4-fluoro phenyl)cyclopropane-1,1-dicarboxamide prepared in Example 9 and N1'-[3-fluoro-4-[[7-[6-(hydroxyamino)-6-oxohexyloxy]-6-methoxy-4-quinolyl]oxy]phenyl]-N1-(4-fluo rophenyl)cyclopropane-1,1-dicarboxamide prepared in Example 13 were measured by Reaction Biology Corporation (Reaction Biology Corp., One Great Valley Parkway, Suite 2, Malvern, PA 19355, USA . http://www.reactionbiology.com/pages/hdac.htm). The HDAC enzymes tested include the following 11 HDAC isoforms: HDAC1, HDAC2, HDAC3, HDAC4, HDAC5, HDAC6, HDAC7, HDAC8, HDAC9, HDAC10 and HDAC11.Specific steps were as follows: The compound of the present invention was dissolved in dimethyl sulfoxide (DMSO) to make a stock solution of 10 mM. The stock solution was diluted in 4-fold series starting from 10 mM to prepare 10 different dosages."
101,269422,166,CHEMBL3981567,Histone deacetylase 1,Unspecified,"Inhibition Assay: The inhibitions of activities of HDAC enzymes by the compounds N1'-[3-fluoro-4-[[7-[4-(hydroxyamino)-4-oxobutoxy]-6-methoxy-4-quinolyl]oxy]phenyl]-N1-(4-fluoro phenyl)cyclopropane-1,1-dicarboxamide prepared in Example 9 and N1'-[3-fluoro-4-[[7-[6-(hydroxyamino)-6-oxohexyloxy]-6-methoxy-4-quinolyl]oxy]phenyl]-N1-(4-fluo rophenyl)cyclopropane-1,1-dicarboxamide prepared in Example 13 were measured by Reaction Biology Corporation (Reaction Biology Corp., One Great Valley Parkway, Suite 2, Malvern, PA 19355, USA . http://www.reactionbiology.com/pages/hdac.htm). The HDAC enzymes tested include the following 11 HDAC isoforms: HDAC1, HDAC2, HDAC3, HDAC4, HDAC5, HDAC6, HDAC7, HDAC8, HDAC9, HDAC10 and HDAC11.Specific steps were as follows: The compound of the present invention was dissolved in dimethyl sulfoxide (DMSO) to make a stock solution of 10 mM. The stock solution was diluted in 4-fold series starting from 10 mM to prepare 10 different dosages."
102,269422,166,CHEMBL3981567,Histone deacetylase 1,Active,"Inhibition Assay: The inhibitions of activities of HDAC enzymes by the compounds N1'-[3-fluoro-4-[[7-[4-(hydroxyamino)-4-oxobutoxy]-6-methoxy-4-quinolyl]oxy]phenyl]-N1-(4-fluoro phenyl)cyclopropane-1,1-dicarboxamide prepared in Example 9 and N1'-[3-fluoro-4-[[7-[6-(hydroxyamino)-6-oxohexyloxy]-6-methoxy-4-quinolyl]oxy]phenyl]-N1-(4-fluo rophenyl)cyclopropane-1,1-dicarboxamide prepared in Example 13 were measured by Reaction Biology Corporation (Reaction Biology Corp., One Great Valley Parkway, Suite 2, Malvern, PA 19355, USA . http://www.reactionbiology.com/pages/hdac.htm). The HDAC enzymes tested include the following 11 HDAC isoforms: HDAC1, HDAC2, HDAC3, HDAC4, HDAC5, HDAC6, HDAC7, HDAC8, HDAC9, HDAC10 and HDAC11.Specific steps were as follows: The compound of the present invention was dissolved in dimethyl sulfoxide (DMSO) to make a stock solution of 10 mM. The stock solution was diluted in 4-fold series starting from 10 mM to prepare 10 different dosages."
103,269422,166,CHEMBL3981567,Histone deacetylase 1,Unspecified,"Inhibition Assay: The inhibitions of activities of HDAC enzymes by the compounds N1'-[3-fluoro-4-[[7-[4-(hydroxyamino)-4-oxobutoxy]-6-methoxy-4-quinolyl]oxy]phenyl]-N1-(4-fluoro phenyl)cyclopropane-1,1-dicarboxamide prepared in Example 9 and N1'-[3-fluoro-4-[[7-[6-(hydroxyamino)-6-oxohexyloxy]-6-methoxy-4-quinolyl]oxy]phenyl]-N1-(4-fluo rophenyl)cyclopropane-1,1-dicarboxamide prepared in Example 13 were measured by Reaction Biology Corporation (Reaction Biology Corp., One Great Valley Parkway, Suite 2, Malvern, PA 19355, USA . http://www.reactionbiology.com/pages/hdac.htm). The HDAC enzymes tested include the following 11 HDAC isoforms: HDAC1, HDAC2, HDAC3, HDAC4, HDAC5, HDAC6, HDAC7, HDAC8, HDAC9, HDAC10 and HDAC11.Specific steps were as follows: The compound of the present invention was dissolved in dimethyl sulfoxide (DMSO) to make a stock solution of 10 mM. The stock solution was diluted in 4-fold series starting from 10 mM to prepare 10 different dosages."
104,269422,166,CHEMBL3981567,Histone deacetylase 1,Active,"Inhibition Assay: The inhibitions of activities of HDAC enzymes by the compounds N1'-[3-fluoro-4-[[7-[4-(hydroxyamino)-4-oxobutoxy]-6-methoxy-4-quinolyl]oxy]phenyl]-N1-(4-fluoro phenyl)cyclopropane-1,1-dicarboxamide prepared in Example 9 and N1'-[3-fluoro-4-[[7-[6-(hydroxyamino)-6-oxohexyloxy]-6-methoxy-4-quinolyl]oxy]phenyl]-N1-(4-fluo rophenyl)cyclopropane-1,1-dicarboxamide prepared in Example 13 were measured by Reaction Biology Corporation (Reaction Biology Corp., One Great Valley Parkway, Suite 2, Malvern, PA 19355, USA . http://www.reactionbiology.com/pages/hdac.htm). The HDAC enzymes tested include the following 11 HDAC isoforms: HDAC1, HDAC2, HDAC3, HDAC4, HDAC5, HDAC6, HDAC7, HDAC8, HDAC9, HDAC10 and HDAC11.Specific steps were as follows: The compound of the present invention was dissolved in dimethyl sulfoxide (DMSO) to make a stock solution of 10 mM. The stock solution was diluted in 4-fold series starting from 10 mM to prepare 10 different dosages."
105,269422,166,CHEMBL3981567,Histone deacetylase 1,Unspecified,"Inhibition Assay: The inhibitions of activities of HDAC enzymes by the compounds N1'-[3-fluoro-4-[[7-[4-(hydroxyamino)-4-oxobutoxy]-6-methoxy-4-quinolyl]oxy]phenyl]-N1-(4-fluoro phenyl)cyclopropane-1,1-dicarboxamide prepared in Example 9 and N1'-[3-fluoro-4-[[7-[6-(hydroxyamino)-6-oxohexyloxy]-6-methoxy-4-quinolyl]oxy]phenyl]-N1-(4-fluo rophenyl)cyclopropane-1,1-dicarboxamide prepared in Example 13 were measured by Reaction Biology Corporation (Reaction Biology Corp., One Great Valley Parkway, Suite 2, Malvern, PA 19355, USA . http://www.reactionbiology.com/pages/hdac.htm). The HDAC enzymes tested include the following 11 HDAC isoforms: HDAC1, HDAC2, HDAC3, HDAC4, HDAC5, HDAC6, HDAC7, HDAC8, HDAC9, HDAC10 and HDAC11.Specific steps were as follows: The compound of the present invention was dissolved in dimethyl sulfoxide (DMSO) to make a stock solution of 10 mM. The stock solution was diluted in 4-fold series starting from 10 mM to prepare 10 different dosages."
106,269422,166,CHEMBL3981567,Histone deacetylase 1,Unspecified,"Inhibition Assay: The inhibitions of activities of HDAC enzymes by the compounds N1'-[3-fluoro-4-[[7-[4-(hydroxyamino)-4-oxobutoxy]-6-methoxy-4-quinolyl]oxy]phenyl]-N1-(4-fluoro phenyl)cyclopropane-1,1-dicarboxamide prepared in Example 9 and N1'-[3-fluoro-4-[[7-[6-(hydroxyamino)-6-oxohexyloxy]-6-methoxy-4-quinolyl]oxy]phenyl]-N1-(4-fluo rophenyl)cyclopropane-1,1-dicarboxamide prepared in Example 13 were measured by Reaction Biology Corporation (Reaction Biology Corp., One Great Valley Parkway, Suite 2, Malvern, PA 19355, USA . http://www.reactionbiology.com/pages/hdac.htm). The HDAC enzymes tested include the following 11 HDAC isoforms: HDAC1, HDAC2, HDAC3, HDAC4, HDAC5, HDAC6, HDAC7, HDAC8, HDAC9, HDAC10 and HDAC11.Specific steps were as follows: The compound of the present invention was dissolved in dimethyl sulfoxide (DMSO) to make a stock solution of 10 mM. The stock solution was diluted in 4-fold series starting from 10 mM to prepare 10 different dosages."
107,269422,166,CHEMBL3981567,Histone deacetylase 1,Unspecified,"Inhibition Assay: The inhibitions of activities of HDAC enzymes by the compounds N1'-[3-fluoro-4-[[7-[4-(hydroxyamino)-4-oxobutoxy]-6-methoxy-4-quinolyl]oxy]phenyl]-N1-(4-fluoro phenyl)cyclopropane-1,1-dicarboxamide prepared in Example 9 and N1'-[3-fluoro-4-[[7-[6-(hydroxyamino)-6-oxohexyloxy]-6-methoxy-4-quinolyl]oxy]phenyl]-N1-(4-fluo rophenyl)cyclopropane-1,1-dicarboxamide prepared in Example 13 were measured by Reaction Biology Corporation (Reaction Biology Corp., One Great Valley Parkway, Suite 2, Malvern, PA 19355, USA . http://www.reactionbiology.com/pages/hdac.htm). The HDAC enzymes tested include the following 11 HDAC isoforms: HDAC1, HDAC2, HDAC3, HDAC4, HDAC5, HDAC6, HDAC7, HDAC8, HDAC9, HDAC10 and HDAC11.Specific steps were as follows: The compound of the present invention was dissolved in dimethyl sulfoxide (DMSO) to make a stock solution of 10 mM. The stock solution was diluted in 4-fold series starting from 10 mM to prepare 10 different dosages."
108,237445,166,CHEMBL3911566,Histone deacetylase 1,Unspecified,"Inhibition Assay: The inhibitions of activities of HDAC enzymes by the compounds N1'-[3-fluoro-4-[[7-[4-(hydroxyamino)-4-oxobutoxy]-6-methoxy-4-quinolyl]oxy]phenyl]-N1-(4-fluoro phenyl)cyclopropane-1,1-dicarboxamide prepared in Example 9 and N1'-[3-fluoro-4-[[7-[6-(hydroxyamino)-6-oxohexyloxy]-6-methoxy-4-quinolyl]oxy]phenyl]-N1-(4-fluo rophenyl)cyclopropane-1,1-dicarboxamide prepared in Example 13 were measured by Reaction Biology Corporation (Reaction Biology Corp., One Great Valley Parkway, Suite 2, Malvern, PA 19355, USA . http://www.reactionbiology.com/pages/hdac.htm). The HDAC enzymes tested include the following 11 HDAC isoforms: HDAC1, HDAC2, HDAC3, HDAC4, HDAC5, HDAC6, HDAC7, HDAC8, HDAC9, HDAC10 and HDAC11.Specific steps were as follows: The compound of the present invention was dissolved in dimethyl sulfoxide (DMSO) to make a stock solution of 10 mM. The stock solution was diluted in 4-fold series starting from 10 mM to prepare 10 different dosages."
109,237445,166,CHEMBL3911566,Histone deacetylase 1,Active,"Inhibition Assay: The inhibitions of activities of HDAC enzymes by the compounds N1'-[3-fluoro-4-[[7-[4-(hydroxyamino)-4-oxobutoxy]-6-methoxy-4-quinolyl]oxy]phenyl]-N1-(4-fluoro phenyl)cyclopropane-1,1-dicarboxamide prepared in Example 9 and N1'-[3-fluoro-4-[[7-[6-(hydroxyamino)-6-oxohexyloxy]-6-methoxy-4-quinolyl]oxy]phenyl]-N1-(4-fluo rophenyl)cyclopropane-1,1-dicarboxamide prepared in Example 13 were measured by Reaction Biology Corporation (Reaction Biology Corp., One Great Valley Parkway, Suite 2, Malvern, PA 19355, USA . http://www.reactionbiology.com/pages/hdac.htm). The HDAC enzymes tested include the following 11 HDAC isoforms: HDAC1, HDAC2, HDAC3, HDAC4, HDAC5, HDAC6, HDAC7, HDAC8, HDAC9, HDAC10 and HDAC11.Specific steps were as follows: The compound of the present invention was dissolved in dimethyl sulfoxide (DMSO) to make a stock solution of 10 mM. The stock solution was diluted in 4-fold series starting from 10 mM to prepare 10 different dosages."
110,237445,166,CHEMBL3911566,Histone deacetylase 1,Unspecified,"Inhibition Assay: The inhibitions of activities of HDAC enzymes by the compounds N1'-[3-fluoro-4-[[7-[4-(hydroxyamino)-4-oxobutoxy]-6-methoxy-4-quinolyl]oxy]phenyl]-N1-(4-fluoro phenyl)cyclopropane-1,1-dicarboxamide prepared in Example 9 and N1'-[3-fluoro-4-[[7-[6-(hydroxyamino)-6-oxohexyloxy]-6-methoxy-4-quinolyl]oxy]phenyl]-N1-(4-fluo rophenyl)cyclopropane-1,1-dicarboxamide prepared in Example 13 were measured by Reaction Biology Corporation (Reaction Biology Corp., One Great Valley Parkway, Suite 2, Malvern, PA 19355, USA . http://www.reactionbiology.com/pages/hdac.htm). The HDAC enzymes tested include the following 11 HDAC isoforms: HDAC1, HDAC2, HDAC3, HDAC4, HDAC5, HDAC6, HDAC7, HDAC8, HDAC9, HDAC10 and HDAC11.Specific steps were as follows: The compound of the present invention was dissolved in dimethyl sulfoxide (DMSO) to make a stock solution of 10 mM. The stock solution was diluted in 4-fold series starting from 10 mM to prepare 10 different dosages."
111,237445,166,CHEMBL3911566,Histone deacetylase 1,Unspecified,"Inhibition Assay: The inhibitions of activities of HDAC enzymes by the compounds N1'-[3-fluoro-4-[[7-[4-(hydroxyamino)-4-oxobutoxy]-6-methoxy-4-quinolyl]oxy]phenyl]-N1-(4-fluoro phenyl)cyclopropane-1,1-dicarboxamide prepared in Example 9 and N1'-[3-fluoro-4-[[7-[6-(hydroxyamino)-6-oxohexyloxy]-6-methoxy-4-quinolyl]oxy]phenyl]-N1-(4-fluo rophenyl)cyclopropane-1,1-dicarboxamide prepared in Example 13 were measured by Reaction Biology Corporation (Reaction Biology Corp., One Great Valley Parkway, Suite 2, Malvern, PA 19355, USA . http://www.reactionbiology.com/pages/hdac.htm). The HDAC enzymes tested include the following 11 HDAC isoforms: HDAC1, HDAC2, HDAC3, HDAC4, HDAC5, HDAC6, HDAC7, HDAC8, HDAC9, HDAC10 and HDAC11.Specific steps were as follows: The compound of the present invention was dissolved in dimethyl sulfoxide (DMSO) to make a stock solution of 10 mM. The stock solution was diluted in 4-fold series starting from 10 mM to prepare 10 different dosages."
112,237445,166,CHEMBL3911566,Histone deacetylase 1,Unspecified,"Inhibition Assay: The inhibitions of activities of HDAC enzymes by the compounds N1'-[3-fluoro-4-[[7-[4-(hydroxyamino)-4-oxobutoxy]-6-methoxy-4-quinolyl]oxy]phenyl]-N1-(4-fluoro phenyl)cyclopropane-1,1-dicarboxamide prepared in Example 9 and N1'-[3-fluoro-4-[[7-[6-(hydroxyamino)-6-oxohexyloxy]-6-methoxy-4-quinolyl]oxy]phenyl]-N1-(4-fluo rophenyl)cyclopropane-1,1-dicarboxamide prepared in Example 13 were measured by Reaction Biology Corporation (Reaction Biology Corp., One Great Valley Parkway, Suite 2, Malvern, PA 19355, USA . http://www.reactionbiology.com/pages/hdac.htm). The HDAC enzymes tested include the following 11 HDAC isoforms: HDAC1, HDAC2, HDAC3, HDAC4, HDAC5, HDAC6, HDAC7, HDAC8, HDAC9, HDAC10 and HDAC11.Specific steps were as follows: The compound of the present invention was dissolved in dimethyl sulfoxide (DMSO) to make a stock solution of 10 mM. The stock solution was diluted in 4-fold series starting from 10 mM to prepare 10 different dosages."
113,237445,166,CHEMBL3911566,Histone deacetylase 1,Active,"Inhibition Assay: The inhibitions of activities of HDAC enzymes by the compounds N1'-[3-fluoro-4-[[7-[4-(hydroxyamino)-4-oxobutoxy]-6-methoxy-4-quinolyl]oxy]phenyl]-N1-(4-fluoro phenyl)cyclopropane-1,1-dicarboxamide prepared in Example 9 and N1'-[3-fluoro-4-[[7-[6-(hydroxyamino)-6-oxohexyloxy]-6-methoxy-4-quinolyl]oxy]phenyl]-N1-(4-fluo rophenyl)cyclopropane-1,1-dicarboxamide prepared in Example 13 were measured by Reaction Biology Corporation (Reaction Biology Corp., One Great Valley Parkway, Suite 2, Malvern, PA 19355, USA . http://www.reactionbiology.com/pages/hdac.htm). The HDAC enzymes tested include the following 11 HDAC isoforms: HDAC1, HDAC2, HDAC3, HDAC4, HDAC5, HDAC6, HDAC7, HDAC8, HDAC9, HDAC10 and HDAC11.Specific steps were as follows: The compound of the present invention was dissolved in dimethyl sulfoxide (DMSO) to make a stock solution of 10 mM. The stock solution was diluted in 4-fold series starting from 10 mM to prepare 10 different dosages."
114,237445,166,CHEMBL3911566,Histone deacetylase 1,Unspecified,"Inhibition Assay: The inhibitions of activities of HDAC enzymes by the compounds N1'-[3-fluoro-4-[[7-[4-(hydroxyamino)-4-oxobutoxy]-6-methoxy-4-quinolyl]oxy]phenyl]-N1-(4-fluoro phenyl)cyclopropane-1,1-dicarboxamide prepared in Example 9 and N1'-[3-fluoro-4-[[7-[6-(hydroxyamino)-6-oxohexyloxy]-6-methoxy-4-quinolyl]oxy]phenyl]-N1-(4-fluo rophenyl)cyclopropane-1,1-dicarboxamide prepared in Example 13 were measured by Reaction Biology Corporation (Reaction Biology Corp., One Great Valley Parkway, Suite 2, Malvern, PA 19355, USA . http://www.reactionbiology.com/pages/hdac.htm). The HDAC enzymes tested include the following 11 HDAC isoforms: HDAC1, HDAC2, HDAC3, HDAC4, HDAC5, HDAC6, HDAC7, HDAC8, HDAC9, HDAC10 and HDAC11.Specific steps were as follows: The compound of the present invention was dissolved in dimethyl sulfoxide (DMSO) to make a stock solution of 10 mM. The stock solution was diluted in 4-fold series starting from 10 mM to prepare 10 different dosages."
115,237445,166,CHEMBL3911566,Histone deacetylase 1,Active,"Inhibition Assay: The inhibitions of activities of HDAC enzymes by the compounds N1'-[3-fluoro-4-[[7-[4-(hydroxyamino)-4-oxobutoxy]-6-methoxy-4-quinolyl]oxy]phenyl]-N1-(4-fluoro phenyl)cyclopropane-1,1-dicarboxamide prepared in Example 9 and N1'-[3-fluoro-4-[[7-[6-(hydroxyamino)-6-oxohexyloxy]-6-methoxy-4-quinolyl]oxy]phenyl]-N1-(4-fluo rophenyl)cyclopropane-1,1-dicarboxamide prepared in Example 13 were measured by Reaction Biology Corporation (Reaction Biology Corp., One Great Valley Parkway, Suite 2, Malvern, PA 19355, USA . http://www.reactionbiology.com/pages/hdac.htm). The HDAC enzymes tested include the following 11 HDAC isoforms: HDAC1, HDAC2, HDAC3, HDAC4, HDAC5, HDAC6, HDAC7, HDAC8, HDAC9, HDAC10 and HDAC11.Specific steps were as follows: The compound of the present invention was dissolved in dimethyl sulfoxide (DMSO) to make a stock solution of 10 mM. The stock solution was diluted in 4-fold series starting from 10 mM to prepare 10 different dosages."
116,237445,166,CHEMBL3911566,Histone deacetylase 1,Unspecified,"Inhibition Assay: The inhibitions of activities of HDAC enzymes by the compounds N1'-[3-fluoro-4-[[7-[4-(hydroxyamino)-4-oxobutoxy]-6-methoxy-4-quinolyl]oxy]phenyl]-N1-(4-fluoro phenyl)cyclopropane-1,1-dicarboxamide prepared in Example 9 and N1'-[3-fluoro-4-[[7-[6-(hydroxyamino)-6-oxohexyloxy]-6-methoxy-4-quinolyl]oxy]phenyl]-N1-(4-fluo rophenyl)cyclopropane-1,1-dicarboxamide prepared in Example 13 were measured by Reaction Biology Corporation (Reaction Biology Corp., One Great Valley Parkway, Suite 2, Malvern, PA 19355, USA . http://www.reactionbiology.com/pages/hdac.htm). The HDAC enzymes tested include the following 11 HDAC isoforms: HDAC1, HDAC2, HDAC3, HDAC4, HDAC5, HDAC6, HDAC7, HDAC8, HDAC9, HDAC10 and HDAC11.Specific steps were as follows: The compound of the present invention was dissolved in dimethyl sulfoxide (DMSO) to make a stock solution of 10 mM. The stock solution was diluted in 4-fold series starting from 10 mM to prepare 10 different dosages."
117,237445,166,CHEMBL3911566,Histone deacetylase 1,Active,"Inhibition Assay: The inhibitions of activities of HDAC enzymes by the compounds N1'-[3-fluoro-4-[[7-[4-(hydroxyamino)-4-oxobutoxy]-6-methoxy-4-quinolyl]oxy]phenyl]-N1-(4-fluoro phenyl)cyclopropane-1,1-dicarboxamide prepared in Example 9 and N1'-[3-fluoro-4-[[7-[6-(hydroxyamino)-6-oxohexyloxy]-6-methoxy-4-quinolyl]oxy]phenyl]-N1-(4-fluo rophenyl)cyclopropane-1,1-dicarboxamide prepared in Example 13 were measured by Reaction Biology Corporation (Reaction Biology Corp., One Great Valley Parkway, Suite 2, Malvern, PA 19355, USA . http://www.reactionbiology.com/pages/hdac.htm). The HDAC enzymes tested include the following 11 HDAC isoforms: HDAC1, HDAC2, HDAC3, HDAC4, HDAC5, HDAC6, HDAC7, HDAC8, HDAC9, HDAC10 and HDAC11.Specific steps were as follows: The compound of the present invention was dissolved in dimethyl sulfoxide (DMSO) to make a stock solution of 10 mM. The stock solution was diluted in 4-fold series starting from 10 mM to prepare 10 different dosages."
118,237445,166,CHEMBL3911566,Histone deacetylase 1,Active,"Inhibition Assay: The inhibitions of activities of HDAC enzymes by the compounds N1'-[3-fluoro-4-[[7-[4-(hydroxyamino)-4-oxobutoxy]-6-methoxy-4-quinolyl]oxy]phenyl]-N1-(4-fluoro phenyl)cyclopropane-1,1-dicarboxamide prepared in Example 9 and N1'-[3-fluoro-4-[[7-[6-(hydroxyamino)-6-oxohexyloxy]-6-methoxy-4-quinolyl]oxy]phenyl]-N1-(4-fluo rophenyl)cyclopropane-1,1-dicarboxamide prepared in Example 13 were measured by Reaction Biology Corporation (Reaction Biology Corp., One Great Valley Parkway, Suite 2, Malvern, PA 19355, USA . http://www.reactionbiology.com/pages/hdac.htm). The HDAC enzymes tested include the following 11 HDAC isoforms: HDAC1, HDAC2, HDAC3, HDAC4, HDAC5, HDAC6, HDAC7, HDAC8, HDAC9, HDAC10 and HDAC11.Specific steps were as follows: The compound of the present invention was dissolved in dimethyl sulfoxide (DMSO) to make a stock solution of 10 mM. The stock solution was diluted in 4-fold series starting from 10 mM to prepare 10 different dosages."
119,103944,166,CHEMBL2381517,Histone deacetylase 1,Active,Inhibition of HDAC1 in human HeLa cells assessed as increase in histone H3 acetylation at 10 uM after 48 hrs by Western blotting analysis
120,103944,166,CHEMBL2381517,Histone deacetylase 1,Active,Inhibition of HDAC1 (unknown origin) after 60 mins by fluorescence assay
121,107500,166,CHEMBL2408237,Histone deacetylase 1,Unspecified,Inhibition of human recombinant HDAC1 by Michaelis-Menten equation analysis
122,336613,138,CHEMBL941,Vascular endothelial growth factor receptor 2,Inactive,Average Binding Constant for VEGFR2; NA=Not Active at 10 uM
123,336613,138,CHEMBL941,Vascular endothelial growth factor receptor 2,Unspecified,Inhibition of KDR
124,336613,138,CHEMBL941,Vascular endothelial growth factor receptor 2,Unspecified,Selectivity ratio of IC50 for KDR to IC50 for c-kit
125,336613,138,CHEMBL941,Vascular endothelial growth factor receptor 2,Unspecified,Inhibition of KDR by TR-FRET assay
126,336613,138,CHEMBL941,Vascular endothelial growth factor receptor 2,Active,Inhibition of VEGFR2 by liquid scintillation counting
127,336613,138,CHEMBL941,Vascular endothelial growth factor receptor 2,Unspecified,Binding constant for VEGFR2 kinase domain
128,336613,138,CHEMBL941,Vascular endothelial growth factor receptor 2,Unspecified,Inhibition of human KDR activity at 10 uM by radiometric assay
129,336613,138,CHEMBL941,Vascular endothelial growth factor receptor 2,Unspecified,Binding affinity to human Vegfr2 assessed as residual binding at 10 uM by site dependent competitive binding assay
130,336613,138,CHEMBL941,Vascular endothelial growth factor receptor 2,Unspecified,Binding constant for VEGFR2 kinase domain
131,336613,138,CHEMBL941,Vascular endothelial growth factor receptor 2,Unspecified,Inhibition of Tel-fused VEGFR2 (unknown origin) expressed in BAF3 cells assessed as growth inhibition measured after 72 hrs by CellTiter-Glo or CCK8 assay
132,336613,138,CHEMBL941,Vascular endothelial growth factor receptor 2,Unspecified,Inhibition of KDR (unknown origin) transfected in mouse BA/F3 cells assessed as inhibition of cell growth incubated for 72 hrs by MTS assay
133,336613,138,CHEMBL941,Vascular endothelial growth factor receptor 2,Unspecified,Inhibition of TEL-fused VEGFR2 (unknown origin) expressed in mouse BA/F3 cells assessed as growth inhibition after 72 hrs by CellTiter-Glo or CCK-8 assay
134,336613,138,CHEMBL941,Vascular endothelial growth factor receptor 2,Active,Inhibition of VEGFR2 (unknown origin) using FAM-labeled peptide as substrate preincubated for 10 mins followed by substrate addition in presence of ATP by mobility shift assay
135,15946,79,CHEMBL1241674,Serine/threonine-protein kinase Aurora-B,Unspecified,Inhibition of AURKB at 1 uM after 60 mins by FRET assay in presence of 10 uM ATP
136,15946,79,CHEMBL1241674,Serine/threonine-protein kinase Aurora-B,Unspecified,Binding constant for AURKB kinase domain
137,15443,90,CHEMBL1231,Serotonin transporter,Unspecified,"DRUGMATRIX: Transporter, Serotonin (5-Hydroxytryptamine) (SERT) radioligand binding (ligand: [3H] Paroxetine)"
138,15443,90,CHEMBL1231,Serotonin transporter,Unspecified,"DRUGMATRIX: Transporter, Serotonin (5-Hydroxytryptamine) (SERT) radioligand binding (ligand: [3H] Paroxetine)"
139,89191,90,CHEMBL2203551,Serotonin transporter,Unspecified,Displacement of [3H]citalopram from human recombinant SERT at 10 uM after 1.5 hrs by microbeta scintillation counting analysis
140,121572,14,CHEMBL27759,Histone deacetylase 6,Unspecified,Inhibition of HDAC6
141,121572,14,CHEMBL27759,Histone deacetylase 6,Unspecified,Inhibition of HDAC6
142,121572,14,CHEMBL27759,Histone deacetylase 6,Inactive,Inhibition of HDAC6 in HEK293 cells at 10 uM
143,121572,14,CHEMBL27759,Histone deacetylase 6,Unspecified,Inhibition of HDAC6 at 10 uM
144,121572,14,CHEMBL27759,Histone deacetylase 6,Unspecified,Inhibition of C-terminal FLAG-tagged HDAC6 expressed in mammalian cells
145,121572,14,CHEMBL27759,Histone deacetylase 6,Unspecified,Inhibition of Bordetella / Alcaligenes strain FB188 HDAC6 by fluorogenic enzyme assay
146,121572,14,CHEMBL27759,Histone deacetylase 6,Active,Inhibition of HDAC6
147,121572,14,CHEMBL27759,Histone deacetylase 6,Unspecified,Inhibition of HDAC6 by in vitro deacetylation assay
148,121572,14,CHEMBL27759,Histone deacetylase 6,Unspecified,Inhibition of recombinant human HDAC6 using Boc-Lys(Ac)-AMC as substrate by fluorometric analysis
149,121572,14,CHEMBL27759,Histone deacetylase 6,Unspecified,"Selectivity index, ratio of IC50 for recombinant human HDAC1 to IC50 for recombinant human HDAC6"
150,121572,14,CHEMBL27759,Histone deacetylase 6,Active,Inhibition of HDAC6 in human Hela cells assessed as increase in total lysine acetylation at 0.6 uM after 16 hrs by immunofluorescence microscopy
151,121572,14,CHEMBL27759,Histone deacetylase 6,Inactive,Inhibition of HDAC6 in human Hela cells assessed as increase in alpha-tubulin acetylation at 0.6 uM after 16 hrs by immunofluorescence microscopy
152,121572,14,CHEMBL27759,Histone deacetylase 6,Unspecified,Inhibition of HDAC6
153,121572,14,CHEMBL27759,Histone deacetylase 6,Unspecified,Inhibition of human recombinant HDAC6 using p53 residues 379-382 (RHKKAc) as substrate
154,121572,14,CHEMBL27759,Histone deacetylase 6,Unspecified,Inhibition of HDAC6 in human U937 cells assessed as increase in acetyl-alpha-tubulin level at 5 uM by Western blotting method
155,121572,14,CHEMBL27759,Histone deacetylase 6,Inconclusive,Inhibition of human recombinant HDAC6 using Boc-Lys(Ac)-AMC as substrate after 30 mins by fluorescence assay
156,121572,14,CHEMBL27759,Histone deacetylase 6,Active,Inhibition of HDAC6 in human LNCAP cells assessed as inhibition of DHT-induced alpha-tubulin deacetylation by measuring increase in alpha-tubulin acetylation at 10 uM measured after 24 hrs relative to control
157,121572,14,CHEMBL27759,Histone deacetylase 6,Inconclusive,Inhibition of HDAC6 (unknown origin) using fluorogenic Boc-Lys(acetyl)-AMC as substrate preincubated for 5 mins followed by substrate addition measured after 30 mins by fluorescence-based assay
158,121572,14,CHEMBL27759,Histone deacetylase 6,Inactive,Inhibition of HDAC6 in human HeLa cells assessed as increase in intracellular acetyl-tubulin levels at 1 uM after 6 hrs by Western blot analysis
159,121572,14,CHEMBL27759,Histone deacetylase 6,Active,Inhibition of human recombinant HDAC6 using Fluor de Lys-Green as substrate preincubated for 5 mins followed by substrate addition and measured after 1 hr by fluorescence assay
160,121572,14,CHEMBL27759,Histone deacetylase 6,Unspecified,Selectivity ratio of IC50 for human recombinant HDAC1 to IC50 for human recombinant HDAC6
161,121572,14,CHEMBL27759,Histone deacetylase 6,Unspecified,Selectivity ratio of IC50 for human recombinant HDAC2 to IC50 for human recombinant HDAC6
162,121572,14,CHEMBL27759,Histone deacetylase 6,Inactive,Inhibition of HDAC6 in human CAL27 cells assessed as accumulation of acetylated alpha tubulin at 1 uM after 24 hrs by immunoblot analysis
163,121572,14,CHEMBL27759,Histone deacetylase 6,Inactive,Inhibition of HDAC6 in human Cal27CisR cells assessed accumulation of acetylated alpha tubulin at 1 uM after 24 hrs by immunoblot analysis
164,121572,14,CHEMBL27759,Histone deacetylase 6,Unspecified,Inhibition of recombinant human full length HDAC6 using Fluor-de-Lys as substrate after 60 mins by spectrofluorimetric analysis
165,121572,14,CHEMBL27759,Histone deacetylase 6,Unspecified,Inhibition of HDAC6 (unknown origin) at 10 uM using Ac-Leu-GlyLys(Ac)-AMC as substrate preincubated for 10 mins followed by substrate addition measured after 30 mins by fluorescence analysis
166,36363,90,CHEMBL1629810,Serotonin transporter,Unspecified,"DRUGMATRIX: Transporter, Serotonin (5-Hydroxytryptamine) (SERT) radioligand binding (ligand: [3H] Paroxetine)"
167,36363,90,CHEMBL1629810,Serotonin transporter,Unspecified,"DRUGMATRIX: Transporter, Serotonin (5-Hydroxytryptamine) (SERT) radioligand binding (ligand: [3H] Paroxetine)"
168,20634,142,CHEMBL1289926,Tyrosine-protein kinase JAK1,Unspecified,Binding constant for JAK1(JH2domain-pseudokinase) kinase domain
169,20634,142,CHEMBL1289926,Tyrosine-protein kinase JAK1,Unspecified,Binding constant for JAK1(JH1domain-catalytic) kinase domain
170,304356,142,CHEMBL477772,Tyrosine-protein kinase JAK1,Unspecified,Binding constant for JAK1(Kin.Dom.1/JH2 - pseudokinase) kinase domain
171,304356,142,CHEMBL477772,Tyrosine-protein kinase JAK1,Unspecified,Binding constant for JAK1(JH2domain-pseudokinase) kinase domain
172,304356,142,CHEMBL477772,Tyrosine-protein kinase JAK1,Unspecified,Binding constant for JAK1(JH1domain-catalytic) kinase domain
173,323045,128,CHEMBL574738,Glycogen synthase kinase-3 beta,Unspecified,Binding constant for full-length GSK3B
174,323045,128,CHEMBL574738,Glycogen synthase kinase-3 beta,Unspecified,Binding constant for GSK3B kinase domain
175,294726,90,CHEMBL429,Serotonin transporter,Unspecified,"DRUGMATRIX: Transporter, Serotonin (5-Hydroxytryptamine) (SERT) radioligand binding (ligand: [3H] Paroxetine)"
176,294726,90,CHEMBL429,Serotonin transporter,Unspecified,"DRUGMATRIX: Transporter, Serotonin (5-Hydroxytryptamine) (SERT) radioligand binding (ligand: [3H] Paroxetine)"
177,123454,142,CHEMBL288441,Tyrosine-protein kinase JAK1,Unspecified,Binding constant for JAK1(JH2domain-pseudokinase) kinase domain
178,123454,142,CHEMBL288441,Tyrosine-protein kinase JAK1,Unspecified,Binding constant for JAK1(JH1domain-catalytic) kinase domain
179,15417,164,CHEMBL1230609,Rho-associated protein kinase 1,Unspecified,Binding constant for ROCK1 kinase domain
180,92173,123,CHEMBL223360,Tyrosine-protein kinase LCK,Unspecified,Inhibition of LCK
181,92173,123,CHEMBL223360,Tyrosine-protein kinase LCK,Unspecified,Binding constant for LCK kinase domain
182,92173,123,CHEMBL223360,Tyrosine-protein kinase LCK,Unspecified,Binding constant for LCK kinase domain
183,294641,142,CHEMBL428690,Tyrosine-protein kinase JAK1,Inactive,Average Binding Constant for JAK1 (Kin.Dom. 1); NA=Not Active at 10 uM
184,294641,142,CHEMBL428690,Tyrosine-protein kinase JAK1,Unspecified,Binding constant for JAK1(Kin.Dom.1/JH2 - pseudokinase) kinase domain
185,294641,142,CHEMBL428690,Tyrosine-protein kinase JAK1,Unspecified,Binding constant for JAK1(JH2domain-pseudokinase) kinase domain
186,294641,142,CHEMBL428690,Tyrosine-protein kinase JAK1,Unspecified,Binding constant for JAK1(JH1domain-catalytic) kinase domain
187,20045,128,CHEMBL1287853,Glycogen synthase kinase-3 beta,Unspecified,Binding constant for GSK3B kinase domain
188,325091,90,CHEMBL59,Serotonin transporter,Unspecified,Inhibition of [3H]5-HT uptake in HEK cells expressing human SERT
189,325091,90,CHEMBL59,Serotonin transporter,Unspecified,Displacement of [125I]RT155 binding in HEK cells expressing human SERT
190,85441,90,CHEMBL2165447,Serotonin transporter,Unspecified,Displacement of [3H]citalopram from human recombinant SERT at 10 uM after 1.5 hrs by microbeta scintillation counting analysis
191,15379,136,CHEMBL1230020,Fibroblast growth factor receptor 3,Unspecified,Binding constant for FGFR3 kinase domain
192,15379,136,CHEMBL1230020,Fibroblast growth factor receptor 3,Unspecified,Binding constant for FGFR3(G697C) kinase domain
193,278830,72,CHEMBL408019,Serine/threonine-protein kinase PIM1,Unspecified,Binding affinity to human PIM1 at 10 uM relative to control
194,317650,142,CHEMBL553,Tyrosine-protein kinase JAK1,Inactive,Average Binding Constant for JAK1 (Kin.Dom. 1); NA=Not Active at 10 uM
195,317650,142,CHEMBL553,Tyrosine-protein kinase JAK1,Unspecified,Binding constant for JAK1(Kin.Dom.1/JH2 - pseudokinase) kinase domain
196,317650,142,CHEMBL553,Tyrosine-protein kinase JAK1,Unspecified,Binding constant for JAK1(JH2domain-pseudokinase) kinase domain
197,317650,142,CHEMBL553,Tyrosine-protein kinase JAK1,Unspecified,Binding constant for JAK1(JH1domain-catalytic) kinase domain
198,57883,128,CHEMBL1908397,Glycogen synthase kinase-3 beta,Unspecified,Binding constant for GSK3B kinase domain
199,27092,142,CHEMBL1421,Tyrosine-protein kinase JAK1,Unspecified,Binding constant for JAK1(Kin.Dom.1/JH2 - pseudokinase) kinase domain
200,27092,142,CHEMBL1421,Tyrosine-protein kinase JAK1,Unspecified,Binding constant for JAK1(JH2domain-pseudokinase) kinase domain
201,27092,142,CHEMBL1421,Tyrosine-protein kinase JAK1,Unspecified,Binding constant for JAK1(JH1domain-catalytic) kinase domain
202,6430,149,CHEMBL1090360,Tyrosine-protein kinase JAK2,Unspecified,Inhibition of JAK2
203,277995,52,CHEMBL4076291,Carbonic anhydrase II,Unspecified,Inhibition of recombinant human CA2 preincubated for 15 mins by stopped-flow CO2 hydration assay
204,278691,52,CHEMBL4079507,Carbonic anhydrase II,Unspecified,Inhibition of recombinant human CA2 preincubated for 15 mins by stopped-flow CO2 hydration assay
205,24519,52,CHEMBL1372946,Carbonic anhydrase II,Unspecified,Inhibition of CA-2 (unknown origin) after 15 mins by CO2 hydration assay
206,24519,52,CHEMBL1372946,Carbonic anhydrase II,Unspecified,Inhibition of CA-2 (unknown origin) at 10 uM after 15 mins by CO2 hydration assay
207,280375,52,CHEMBL4087725,Carbonic anhydrase II,Unspecified,Inhibition of recombinant human CA2 preincubated for 15 mins by stopped-flow CO2 hydration assay
208,22714,52,CHEMBL1332361,Carbonic anhydrase II,Unspecified,Inhibition of CA-2 (unknown origin) after 15 mins by CO2 hydration assay
209,22714,52,CHEMBL1332361,Carbonic anhydrase II,Unspecified,Inhibition of CA-2 (unknown origin) at 10 uM after 15 mins by CO2 hydration assay
210,282488,52,CHEMBL4097542,Carbonic anhydrase II,Unspecified,Inhibition of recombinant human CA2 preincubated for 15 mins by stopped-flow CO2 hydration assay
211,110265,52,CHEMBL243263,Carbonic anhydrase II,Unspecified,Inhibition of human CA2 by CO2 hydration assay
212,276478,52,CHEMBL4069089,Carbonic anhydrase II,Unspecified,Inhibition of recombinant human CA2 preincubated for 15 mins by stopped-flow CO2 hydration assay
213,283745,52,CHEMBL4103176,Carbonic anhydrase II,Unspecified,Inhibition of recombinant human CA2 preincubated for 15 mins by stopped-flow CO2 hydration assay
214,125812,52,CHEMBL301141,Carbonic anhydrase II,Unspecified,Inhibition of human CA2 by CO2 hydration assay
215,32464,52,CHEMBL1533910,Carbonic anhydrase II,Unspecified,Inhibition of CA-2 (unknown origin) after 15 mins by CO2 hydration assay
216,32464,52,CHEMBL1533910,Carbonic anhydrase II,Unspecified,Inhibition of CA-2 (unknown origin) at 10 uM after 15 mins by CO2 hydration assay
217,9905,90,CHEMBL11493,Serotonin transporter,Unspecified,Displacement of [3H]citalopram from SERT in Sprague-Dawley rat brain stem membranes incubated for 60 mins at 100 uM by radioligand binding assay
218,9905,90,CHEMBL11493,Serotonin transporter,Unspecified,"Selectivity index, ratio of Ki for SERT in Sprague-Dawley rat brain stem membranes to Ki for DAT in Sprague-Dawley rat brain membranes"
219,42522,128,CHEMBL1721885,Glycogen synthase kinase-3 beta,Unspecified,Binding constant for full-length GSK3B
220,42522,128,CHEMBL1721885,Glycogen synthase kinase-3 beta,Unspecified,Binding constant for GSK3B kinase domain
221,310963,170,CHEMBL508461,Matrix metalloproteinase-2,Unspecified,Inhibition of MMP2
222,307346,84,CHEMBL490632,Serotonin 2a (5-HT2a) receptor,Active,Displacement of [3H]MDL from rat 5HT2A receptor expressed in GF62 cells by liquid scintillation analyser
223,164181,90,CHEMBL3612932,Serotonin transporter,Inconclusive,Enhancing of [125I]RTI-55 binding to recombinant human SERT expressed in HEK293 cell membranes preincubated for 10 mins followed by radioligand addition measured after 90 mins by micro beta scintillation counting analysis
224,164181,90,CHEMBL3612932,Serotonin transporter,Inconclusive,Enhancing of [3H]mazindol binding to recombinant human SERT expressed in HEK293 cell membranes preincubated for 10 mins followed by radioligand addition measured after 90 mins by micro beta scintillation counting analysis
225,164181,90,CHEMBL3612932,Serotonin transporter,Inconclusive,Inhibition of recombinant human SERT expressed in HEK293 cell membranes assessed as reduction in [3H]5-HT uptake incubated for 22 mins by micro beta scintillation counting analysis
226,37770,90,CHEMBL1643899,Serotonin transporter,Unspecified,Displacement of [3H]citalopram from human SERT expressed in HEK cells
227,37770,90,CHEMBL1643899,Serotonin transporter,Unspecified,Displacement of [3H]-citalopram from human SERT expressed in HEK cell membranes
228,76712,90,CHEMBL2064645,Serotonin transporter,Inactive,Enhancing of [125I]RTI-55 binding to recombinant human SERT expressed in HEK293 cell membranes preincubated for 10 mins followed by radioligand addition measured after 90 mins by micro beta scintillation counting analysis
229,76712,90,CHEMBL2064645,Serotonin transporter,Unspecified,Enhancing of [125I]RTI-55 binding to recombinant human SERT expressed in HEK293 cell membranes preincubated for 10 mins followed by radioligand addition measured after 90 mins by micro beta scintillation counting analysis
230,76712,90,CHEMBL2064645,Serotonin transporter,Inactive,Enhancing of [3H]mazindol binding to recombinant human SERT expressed in HEK293 cell membranes preincubated for 10 mins followed by radioligand addition measured after 90 mins by micro beta scintillation counting analysis
231,76712,90,CHEMBL2064645,Serotonin transporter,Unspecified,Enhancing of [3H]mazindol binding to recombinant human SERT expressed in HEK293 cell membranes preincubated for 10 mins followed by radioligand addition measured after 90 mins by micro beta scintillation counting analysis
232,76712,90,CHEMBL2064645,Serotonin transporter,Unspecified,Inhibition of recombinant human SERT expressed in HEK293 cell membranes assessed as reduction in [3H]5-HT uptake incubated for 22 mins by micro beta scintillation counting analysis
233,154196,90,CHEMBL3407785,Serotonin transporter,Inactive,Enhancing of [125I]RTI-55 binding to recombinant human SERT expressed in HEK293 cell membranes preincubated for 10 mins followed by radioligand addition measured after 90 mins by micro beta scintillation counting analysis
234,154196,90,CHEMBL3407785,Serotonin transporter,Unspecified,Enhancing of [125I]RTI-55 binding to recombinant human SERT expressed in HEK293 cell membranes preincubated for 10 mins followed by radioligand addition measured after 90 mins by micro beta scintillation counting analysis
235,154196,90,CHEMBL3407785,Serotonin transporter,Inactive,Enhancing of [3H]mazindol binding to recombinant human SERT expressed in HEK293 cell membranes preincubated for 10 mins followed by radioligand addition measured after 90 mins by micro beta scintillation counting analysis
236,154196,90,CHEMBL3407785,Serotonin transporter,Unspecified,Enhancing of [3H]mazindol binding to recombinant human SERT expressed in HEK293 cell membranes preincubated for 10 mins followed by radioligand addition measured after 90 mins by micro beta scintillation counting analysis
237,154196,90,CHEMBL3407785,Serotonin transporter,Unspecified,Inhibition of recombinant human SERT expressed in HEK293 cell membranes assessed as reduction in [3H]5-HT uptake incubated for 22 mins by micro beta scintillation counting analysis
238,154195,90,CHEMBL3407784,Serotonin transporter,Inactive,Enhancing of [125I]RTI-55 binding to recombinant human SERT expressed in HEK293 cell membranes preincubated for 10 mins followed by radioligand addition measured after 90 mins by micro beta scintillation counting analysis
239,154195,90,CHEMBL3407784,Serotonin transporter,Unspecified,Enhancing of [125I]RTI-55 binding to recombinant human SERT expressed in HEK293 cell membranes preincubated for 10 mins followed by radioligand addition measured after 90 mins by micro beta scintillation counting analysis
240,154195,90,CHEMBL3407784,Serotonin transporter,Inactive,Enhancing of [3H]mazindol binding to recombinant human SERT expressed in HEK293 cell membranes preincubated for 10 mins followed by radioligand addition measured after 90 mins by micro beta scintillation counting analysis
241,154195,90,CHEMBL3407784,Serotonin transporter,Unspecified,Enhancing of [3H]mazindol binding to recombinant human SERT expressed in HEK293 cell membranes preincubated for 10 mins followed by radioligand addition measured after 90 mins by micro beta scintillation counting analysis
242,154195,90,CHEMBL3407784,Serotonin transporter,Unspecified,Inhibition of recombinant human SERT expressed in HEK293 cell membranes assessed as reduction in [3H]5-HT uptake incubated for 22 mins by micro beta scintillation counting analysis
243,337080,90,CHEMBL960,Serotonin transporter,Unspecified,"DRUGMATRIX: Transporter, Serotonin (5-Hydroxytryptamine) (SERT) radioligand binding (ligand: [3H] Paroxetine)"
244,337080,90,CHEMBL960,Serotonin transporter,Unspecified,"DRUGMATRIX: Transporter, Serotonin (5-Hydroxytryptamine) (SERT) radioligand binding (ligand: [3H] Paroxetine)"
245,310278,90,CHEMBL503,Serotonin transporter,Unspecified,"DRUGMATRIX: Transporter, Serotonin (5-Hydroxytryptamine) (SERT) radioligand binding (ligand: [3H] Paroxetine)"
246,310278,90,CHEMBL503,Serotonin transporter,Unspecified,"DRUGMATRIX: Transporter, Serotonin (5-Hydroxytryptamine) (SERT) radioligand binding (ligand: [3H] Paroxetine)"
247,277088,90,CHEMBL4071867,Serotonin transporter,Inactive,Enhancing of [125I]RTI-55 binding to recombinant human SERT expressed in HEK293 cell membranes preincubated for 10 mins followed by radioligand addition measured after 90 mins by micro beta scintillation counting analysis
248,277088,90,CHEMBL4071867,Serotonin transporter,Unspecified,Enhancing of [125I]RTI-55 binding to recombinant human SERT expressed in HEK293 cell membranes preincubated for 10 mins followed by radioligand addition measured after 90 mins by micro beta scintillation counting analysis
249,277088,90,CHEMBL4071867,Serotonin transporter,Unspecified,Enhancing of [3H]mazindol binding to recombinant human SERT expressed in HEK293 cell membranes preincubated for 10 mins followed by radioligand addition measured after 90 mins by micro beta scintillation counting analysis
250,277088,90,CHEMBL4071867,Serotonin transporter,Unspecified,Inhibition of recombinant human SERT expressed in HEK293 cell membranes assessed as reduction in [3H]5-HT uptake incubated for 22 mins by micro beta scintillation counting analysis
251,277088,90,CHEMBL4071867,Serotonin transporter,Active,Inhibition of [125I]RTI-55 binding to recombinant human SERT expressed in HEK293 cell membranes preincubated for 10 mins followed by radioligand addition measured after 90 mins by micro beta scintillation counting analysis
252,277088,90,CHEMBL4071867,Serotonin transporter,Active,Inhibition of [3H]mazindol binding to recombinant human SERT expressed in HEK293 cell membranes preincubated for 10 mins followed by radioligand addition measured after 90 mins by micro beta scintillation counting analysis
253,37844,90,CHEMBL1644472,Serotonin transporter,Unspecified,Inhibition of [3H]serotonin reuptake at SERT expressed in HEK293 cells scintillation counting
254,294641,79,CHEMBL428690,Serine/threonine-protein kinase Aurora-B,Unspecified,Binding constant for AURKB kinase domain
255,294641,79,CHEMBL428690,Serine/threonine-protein kinase Aurora-B,Unspecified,Binding constant for AURKB kinase domain
256,318723,149,CHEMBL558752,Tyrosine-protein kinase JAK2,Unspecified,Binding constant for JAK2(Kin.Dom.2/JH1 - catalytic) kinase domain
257,318723,149,CHEMBL558752,Tyrosine-protein kinase JAK2,Unspecified,Binding constant for JAK2(JH1domain-catalytic) kinase domain
258,304184,84,CHEMBL476839,Serotonin 2a (5-HT2a) receptor,Active,Displacement of [3H]MDL from rat 5HT2A receptor expressed in GF62 cells by liquid scintillation analyser
259,310264,164,CHEMBL502835,Rho-associated protein kinase 1,Unspecified,Binding constant for ROCK1 kinase domain
260,917,136,CHEMBL103667,Fibroblast growth factor receptor 3,Inactive,Average Binding Constant for FGFR3; NA=Not Active at 10 uM
261,917,136,CHEMBL103667,Fibroblast growth factor receptor 3,Unspecified,Binding constant for FGFR3 kinase domain
262,917,136,CHEMBL103667,Fibroblast growth factor receptor 3,Unspecified,Binding constant for FGFR3(G697C) kinase domain
263,917,136,CHEMBL103667,Fibroblast growth factor receptor 3,Unspecified,Binding constant for FGFR3 kinase domain
264,917,136,CHEMBL103667,Fibroblast growth factor receptor 3,Unspecified,Binding constant for FGFR3(G697C) kinase domain
265,917,136,CHEMBL103667,Fibroblast growth factor receptor 3,Unspecified,Inhibition of FGFR3
266,15946,224,CHEMBL1241674,Serine/threonine-protein kinase Aurora-A,Unspecified,Inhibition of STK6 at 1 uM after 60 mins by FRET assay in presence of 10 uM ATP
267,15946,224,CHEMBL1241674,Serine/threonine-protein kinase Aurora-A,Unspecified,Binding constant for AURKA kinase domain
268,317650,136,CHEMBL553,Fibroblast growth factor receptor 3,Inactive,Average Binding Constant for FGFR3; NA=Not Active at 10 uM
269,317650,136,CHEMBL553,Fibroblast growth factor receptor 3,Unspecified,Binding constant for FGFR3 kinase domain
270,317650,136,CHEMBL553,Fibroblast growth factor receptor 3,Unspecified,Binding constant for FGFR3(G697C) kinase domain
271,317650,136,CHEMBL553,Fibroblast growth factor receptor 3,Unspecified,Binding constant for FGFR3 kinase domain
272,317650,136,CHEMBL553,Fibroblast growth factor receptor 3,Unspecified,Binding constant for FGFR3(G697C) kinase domain
273,322559,164,CHEMBL572878,Rho-associated protein kinase 1,Unspecified,Binding constant for ROCK1 kinase domain
274,322559,164,CHEMBL572878,Rho-associated protein kinase 1,Unspecified,Inhibition of ROCK1 at 1 uM by 33P kinase hotspot assay
275,315225,205,CHEMBL535,Serine/threonine-protein kinase AKT,Unspecified,Binding constant for AKT1 kinase domain
276,315225,205,CHEMBL535,Serine/threonine-protein kinase AKT,Inactive,Inhibition of AKT1
277,315225,205,CHEMBL535,Serine/threonine-protein kinase AKT,Unspecified,Binding affinity to AKT1
278,315225,205,CHEMBL535,Serine/threonine-protein kinase AKT,Unspecified,Binding constant for AKT1 kinase domain
279,315225,205,CHEMBL535,Serine/threonine-protein kinase AKT,Unspecified,Inhibition of recombinant AKT1 using GSK3 as substrate assessed as inhibition of [33P]Phosphate incorporation into substrate after 80 mins by scintillation counting
280,123454,79,CHEMBL288441,Serine/threonine-protein kinase Aurora-B,Unspecified,Binding constant for AURKB kinase domain
281,32464,127,CHEMBL1533910,Carbonic anhydrase I,Unspecified,Inhibition of CA-1 (unknown origin) after 15 mins by CO2 hydration assay
282,32464,127,CHEMBL1533910,Carbonic anhydrase I,Unspecified,Inhibition of CA-1 (unknown origin) at 10 uM after 15 mins by CO2 hydration assay
283,280375,127,CHEMBL4087725,Carbonic anhydrase I,Unspecified,Inhibition of recombinant human CA1 preincubated for 15 mins by stopped-flow CO2 hydration assay
284,283745,127,CHEMBL4103176,Carbonic anhydrase I,Unspecified,Inhibition of recombinant human CA1 preincubated for 15 mins by stopped-flow CO2 hydration assay
285,282232,127,CHEMBL4096350,Carbonic anhydrase I,Unspecified,Inhibition of recombinant human CA1 preincubated for 15 mins by stopped-flow CO2 hydration assay
286,282488,127,CHEMBL4097542,Carbonic anhydrase I,Unspecified,Inhibition of recombinant human CA1 preincubated for 15 mins by stopped-flow CO2 hydration assay
287,74410,127,CHEMBL2047401,Carbonic anhydrase I,Unspecified,Neuroprotective activity in organotypic Wistar rat hippocampal CA1 region slices assessed as protection from oxygen-deprivation-induced neuronal damage at 1 uM dosed during 30 mins insult and subsequent 24 hrs recovery period by propidium iodide staining-based fluorescence analysis (Rvb = 57 +/- 8%)
288,125812,127,CHEMBL301141,Carbonic anhydrase I,Unspecified,Inhibition of human CA1 by CO2 hydration assay
289,278691,127,CHEMBL4079507,Carbonic anhydrase I,Unspecified,Inhibition of recombinant human CA1 preincubated for 15 mins by stopped-flow CO2 hydration assay
290,22714,127,CHEMBL1332361,Carbonic anhydrase I,Unspecified,Inhibition of CA-1 (unknown origin) after 15 mins by CO2 hydration assay
291,22714,127,CHEMBL1332361,Carbonic anhydrase I,Unspecified,Inhibition of CA-1 (unknown origin) at 10 uM after 15 mins by CO2 hydration assay
292,226720,127,CHEMBL387402,Carbonic anhydrase I,Unspecified,Toxicity in organotypic Wistar rat hippocampal CA1 region slices at 10 uM by propidium iodide staining-based fluorescence analysis
293,226720,127,CHEMBL387402,Carbonic anhydrase I,Unspecified,Antagonist activity at kainate receptor in Wistar rat acute hippocampal CA1 region slices assessed as reduction of kainate-induced field excitatory postsynaptic potential suppression at 1 uM by electrophysiological analysis relative to untreated pre-drug level (Rvb = 52.1 +/- 15.3%)
294,226720,127,CHEMBL387402,Carbonic anhydrase I,Unspecified,Antagonist activity at kainate receptor in Wistar rat acute hippocampal CA1 region slices assessed as reduction in field excitatory postsynaptic potential amplitude at basal conditions at 1 uM by electrophysiological analysis
295,226720,127,CHEMBL387402,Carbonic anhydrase I,Unspecified,Antagonist activity at kainate receptor in Wistar rat acute hippocampal CA1 region slices assessed as reduction in field excitatory postsynaptic potential amplitude at basal conditions at 5 uM by electrophysiological analysis
296,226720,127,CHEMBL387402,Carbonic anhydrase I,Inactive,Neuroprotective activity in Wistar rat acute hippocampal CA1 region assessed as protection from oxygen glucose deprivation-induced anoxia depolarization at 1 uM administered 15 mins before and during 7 mins oxygen-deprivation challenge
297,226720,127,CHEMBL387402,Carbonic anhydrase I,Unspecified,Neuroprotective activity in Wistar rat acute hippocampal CA1 region slices assessed as protection from oxygen glucose deprivation-induced anoxic depolarization at 5 uM administered 15 mins before and during 7 mins oxygen glucose deprivation challenge
298,226720,127,CHEMBL387402,Carbonic anhydrase I,Active,Neuroprotective activity in Wistar rat hippocampal CA1 region assessed as change in field excitatory postsynaptic potential at basal conditions at 1 to 5 uM by electrophysiological analysis
299,97832,127,CHEMBL2326508,Carbonic anhydrase I,Inactive,Inhibition of full length human recombinant full length CA1 cytosolic isoform after 15 mins by stopped-flow CO2 hydration method
300,97832,127,CHEMBL2326508,Carbonic anhydrase I,Unspecified,Inhibition of full length human recombinant CA1 cytosolic isoform after 6 hrs by stopped-flow CO2 hydration method
301,97833,127,CHEMBL2326509,Carbonic anhydrase I,Inactive,Inhibition of full length human recombinant full length CA1 cytosolic isoform after 15 mins by stopped-flow CO2 hydration method
302,97833,127,CHEMBL2326509,Carbonic anhydrase I,Unspecified,Inhibition of full length human recombinant CA1 cytosolic isoform after 6 hrs by stopped-flow CO2 hydration method
303,276478,127,CHEMBL4069089,Carbonic anhydrase I,Unspecified,Inhibition of recombinant human CA1 preincubated for 15 mins by stopped-flow CO2 hydration assay
304,24519,127,CHEMBL1372946,Carbonic anhydrase I,Unspecified,Inhibition of CA-1 (unknown origin) after 15 mins by CO2 hydration assay
305,24519,127,CHEMBL1372946,Carbonic anhydrase I,Unspecified,Inhibition of CA-1 (unknown origin) at 10 uM after 15 mins by CO2 hydration assay
306,277995,127,CHEMBL4076291,Carbonic anhydrase I,Unspecified,Inhibition of recombinant human CA1 preincubated for 15 mins by stopped-flow CO2 hydration assay
307,4534,11,CHEMBL1084546,Macrophage colony stimulating factor receptor,Active,"Human fms related tyrosine kinase 3 (Type III RTKs: PDGFR, CSFR, Kit, FLT3 receptor family)"
308,336613,149,CHEMBL941,Tyrosine-protein kinase JAK2,Inactive,Average Binding Constant for JAK2 (Kin.Dom. 2); NA=Not Active at 10 uM
309,336613,149,CHEMBL941,Tyrosine-protein kinase JAK2,Unspecified,Binding constant for JAK2(Kin.Dom.2/JH1 - catalytic) kinase domain
310,336613,149,CHEMBL941,Tyrosine-protein kinase JAK2,Unspecified,Binding constant for JAK2(JH1domain-catalytic) kinase domain
311,36619,149,CHEMBL1630803,Tyrosine-protein kinase JAK2,Unspecified,"Selectivity index, ratio of IC50 for GST-tagged human JAK2 catalytic domain to IC50 for GST-tagged human JAK3 catalytic domain"
312,275234,149,CHEMBL4062946,Tyrosine-protein kinase JAK2,Unspecified,Inhibition of recombinant human GST-tagged cytoplasmic JAK2 catalytic domain (809 to 1153+9 residues) expressed in baculovirus expression system using FITC-KGGEEEEYFELVKK as substrate in presence of 1 mM ATP by microfluidic assay
313,282077,149,CHEMBL4095629,Tyrosine-protein kinase JAK2,Unspecified,Inhibition of recombinant human GST-tagged cytoplasmic JAK2 catalytic domain (809 to 1153+9 residues) expressed in baculovirus expression system using FITC-KGGEEEEYFELVKK as substrate in presence of 1 mM ATP by microfluidic assay
314,57878,138,CHEMBL1908391,Vascular endothelial growth factor receptor 2,Unspecified,Binding constant for VEGFR2 kinase domain
315,153277,228,CHEMBL3401350,Beta-secretase 1,Unspecified,Inhibition of BACE1 (unknown origin)
316,77590,138,CHEMBL2071457,Vascular endothelial growth factor receptor 2,Unspecified,Inhibition of KDR
317,320184,138,CHEMBL564829,Vascular endothelial growth factor receptor 2,Unspecified,Inhibition of VEGFR2
318,58003,131,CHEMBL191003,Tyrosine-protein kinase SRC,Unspecified,Binding constant for SRC kinase domain
319,58003,131,CHEMBL191003,Tyrosine-protein kinase SRC,Unspecified,"Millipore: Percentage of residual kinase activity of SRC at 1uM relative to control. Control inhibitor: Staurosporine at 10.0uM. Buffer: 8 mM MOPS pH 7.0, 0.2 mM EDTA"
320,58003,131,CHEMBL191003,Tyrosine-protein kinase SRC,Unspecified,"Millipore: Percentage of residual kinase activity of SRC at 10uM relative to control. Control inhibitor: Staurosporine at 10.0uM. Buffer: 8 mM MOPS pH 7.0, 0.2 mM EDTA"
321,130790,166,CHEMBL3109980,Histone deacetylase 1,Active,Inhibition of human recombinant full length HDAC1 using (Ac)Arg-Gly-Lys(Ac) as substrate after 60 mins by fluorescence assay
322,278769,127,CHEMBL4079848,Carbonic anhydrase I,Unspecified,Inhibition of recombinant human CA1 preincubated for 15 mins by stopped-flow CO2 hydration assay
323,130082,86,CHEMBL3104092,Serotonin 2c (5-HT2c) receptor,Unspecified,Displacement of [3H]Mesulergine from 5-HT2C receptor (unknown origin)
324,15417,142,CHEMBL1230609,Tyrosine-protein kinase JAK1,Unspecified,Binding constant for JAK1(JH2domain-pseudokinase) kinase domain
325,15417,142,CHEMBL1230609,Tyrosine-protein kinase JAK1,Unspecified,Binding constant for JAK1(JH1domain-catalytic) kinase domain
326,58003,214,CHEMBL191003,Ribosomal protein S6 kinase 1,Unspecified,"Millipore: Percentage of residual kinase activity of RPS6KB1 at 1uM relative to control. Control inhibitor: Staurosporine at 10.0uM. Buffer: 8 mM MOPS pH 7.0, 0.2 mM EDTA"
327,58003,214,CHEMBL191003,Ribosomal protein S6 kinase 1,Unspecified,"Millipore: Percentage of residual kinase activity of RPS6KB1 at 10uM relative to control. Control inhibitor: Staurosporine at 10.0uM. Buffer: 8 mM MOPS pH 7.0, 0.2 mM EDTA"
328,299389,178,CHEMBL453737,Fibroblast growth factor receptor 1,Unspecified,Selectivity of cMet over Flt2
329,112757,138,CHEMBL247252,Vascular endothelial growth factor receptor 2,Active,Inhibition of human VEGFR2 by HTRF method
330,296603,138,CHEMBL437369,Vascular endothelial growth factor receptor 2,Active,Inhibition of human VEGFR2 by HTRF method
331,112988,138,CHEMBL247790,Vascular endothelial growth factor receptor 2,Active,Inhibition of human VEGFR2 by HTRF method
332,237570,138,CHEMBL391184,Vascular endothelial growth factor receptor 2,Active,Inhibition of human VEGFR2 by HTRF method
333,296475,138,CHEMBL436806,Vascular endothelial growth factor receptor 2,Active,Inhibition of human VEGFR2 by HTRF method
334,120893,138,CHEMBL273564,Vascular endothelial growth factor receptor 2,Active,Inhibition of human VEGFR2 by HTRF method
335,120893,138,CHEMBL273564,Vascular endothelial growth factor receptor 2,Unspecified,GSK_PKIS: KDR mean inhibition at 0.1 uM [Nanosyn]
336,120893,138,CHEMBL273564,Vascular endothelial growth factor receptor 2,Unspecified,GSK_PKIS: KDR mean inhibition at 1 uM [Nanosyn]
337,260543,138,CHEMBL396107,Vascular endothelial growth factor receptor 2,Active,Inhibition of human VEGFR2 by HTRF method
338,260543,138,CHEMBL396107,Vascular endothelial growth factor receptor 2,Unspecified,GSK_PKIS: KDR mean inhibition at 0.1 uM [Nanosyn]
339,260543,138,CHEMBL396107,Vascular endothelial growth factor receptor 2,Unspecified,GSK_PKIS: KDR mean inhibition at 1 uM [Nanosyn]
340,16124,194,CHEMBL1242661,PI3-kinase p110-alpha subunit,Unspecified,Inhibition of recombinant PI3Kalpha by radioactive phosphotransfer assay in presence of 10 uM ATP
341,57881,164,CHEMBL1908395,Rho-associated protein kinase 1,Unspecified,Binding constant for ROCK1 kinase domain
342,311049,138,CHEMBL50894,Vascular endothelial growth factor receptor 2,Unspecified,"Millipore: Percentage of residual kinase activity of KDR at 1uM relative to control. Control inhibitor: Staurosporine at 10.0uM. Buffer: 8 mM MOPS pH 7.0, 0.2 mM EDTA"
343,311049,138,CHEMBL50894,Vascular endothelial growth factor receptor 2,Unspecified,"Millipore: Percentage of residual kinase activity of KDR at 10uM relative to control. Control inhibitor: Staurosporine at 10.0uM. Buffer: 8 mM MOPS pH 7.0, 0.2 mM EDTA"
344,273226,71,CHEMBL402143,Serotonin 1a (5-HT1a) receptor,Unspecified,Inhibition of human cloned 5HT1A receptor by competitive binding experiment
345,57880,194,CHEMBL1908394,PI3-kinase p110-alpha subunit,Unspecified,Binding constant for PIK3CA kinase domain
346,57880,194,CHEMBL1908394,PI3-kinase p110-alpha subunit,Unspecified,Binding constant for PIK3CA(C420R) kinase domain
347,57880,194,CHEMBL1908394,PI3-kinase p110-alpha subunit,Unspecified,Binding constant for PIK3CA(E542K) kinase domain
348,57880,194,CHEMBL1908394,PI3-kinase p110-alpha subunit,Unspecified,Binding constant for PIK3CA(E545A) kinase domain
349,57880,194,CHEMBL1908394,PI3-kinase p110-alpha subunit,Unspecified,Binding constant for PIK3CA(E545K) kinase domain
350,57880,194,CHEMBL1908394,PI3-kinase p110-alpha subunit,Unspecified,Binding constant for PIK3CA(H1047L) kinase domain
351,57880,194,CHEMBL1908394,PI3-kinase p110-alpha subunit,Unspecified,Binding constant for PIK3CA(H1047Y) kinase domain
352,57880,194,CHEMBL1908394,PI3-kinase p110-alpha subunit,Unspecified,Binding constant for PIK3CA(I800L) kinase domain
353,57880,194,CHEMBL1908394,PI3-kinase p110-alpha subunit,Unspecified,Binding constant for PIK3CA(M1043I) kinase domain
354,57880,194,CHEMBL1908394,PI3-kinase p110-alpha subunit,Unspecified,Binding constant for PIK3CA(Q546K) kinase domain
355,63422,194,CHEMBL1945559,PI3-kinase p110-alpha subunit,Unspecified,Inhibition of PI3Kalpha using ATP as substrate
356,311062,72,CHEMBL509032,Serine/threonine-protein kinase PIM1,Unspecified,Binding constant for PIM1 kinase domain
357,311062,72,CHEMBL509032,Serine/threonine-protein kinase PIM1,Unspecified,Inhibition of PIM1 assessed as residual activity at 10 uM relative to control
358,311062,72,CHEMBL509032,Serine/threonine-protein kinase PIM1,Unspecified,Inhibition of PIM1 assessed as residual activity at 1 uM relative to control
359,161015,194,CHEMBL3589324,PI3-kinase p110-alpha subunit,Active,Inhibition of GST-tagged bovine p110alpha expressed in Sf9/Baculovirus system using [gamma-33P]ATP by scintillation proximity assay
360,161015,194,CHEMBL3589324,PI3-kinase p110-alpha subunit,Unspecified,"Selectivity index, ratio of IC50 for GST-tagged human p110beta to IC50 for GST-tagged bovine p110alpha"
361,161015,194,CHEMBL3589324,PI3-kinase p110-alpha subunit,Unspecified,"Selectivity index, ratio of IC50 for His-tagged p110gamma (unknown origin) to IC50 for GST-tagged bovine p110alpha"
362,161015,194,CHEMBL3589324,PI3-kinase p110-alpha subunit,Unspecified,"Selectivity index, ratio of IC50 for GST-tagged p110delta (unknown origin) to IC50 for GST-tagged bovine p110alpha"
363,161015,194,CHEMBL3589324,PI3-kinase p110-alpha subunit,Unspecified,"Selectivity index, ratio of IC50 for Glu-tagged PI3KC2beta (unknown origin) to IC50 for GST-tagged bovine p110alpha"
364,161015,194,CHEMBL3589324,PI3-kinase p110-alpha subunit,Active,Cytotoxic activity against human HeLa cells over-expressing PI3K p110alpha incubated for 72 hrs by SRB assay
365,161015,194,CHEMBL3589324,PI3-kinase p110-alpha subunit,Active,Cytotoxic activity against human SKOV3 cells expressing PIK3CA mutant incubated for 72 hrs by SRB assay
366,161047,194,CHEMBL3589371,PI3-kinase p110-alpha subunit,Active,Inhibition of GST-tagged bovine p110alpha expressed in Sf9/Baculovirus system using [gamma-33P]ATP by scintillation proximity assay
367,161047,194,CHEMBL3589371,PI3-kinase p110-alpha subunit,Unspecified,"Selectivity index, ratio of IC50 for GST-tagged human p110beta to IC50 for GST-tagged bovine p110alpha"
368,161047,194,CHEMBL3589371,PI3-kinase p110-alpha subunit,Unspecified,"Selectivity index, ratio of IC50 for His-tagged p110gamma (unknown origin) to IC50 for GST-tagged bovine p110alpha"
369,161047,194,CHEMBL3589371,PI3-kinase p110-alpha subunit,Unspecified,"Selectivity index, ratio of IC50 for GST-tagged p110delta (unknown origin) to IC50 for GST-tagged bovine p110alpha"
370,161047,194,CHEMBL3589371,PI3-kinase p110-alpha subunit,Unspecified,"Selectivity index, ratio of IC50 for Glu-tagged PI3KC2beta (unknown origin) to IC50 for GST-tagged bovine p110alpha"
371,161047,194,CHEMBL3589371,PI3-kinase p110-alpha subunit,Active,Cytotoxic activity against human HeLa cells over-expressing PI3K p110alpha incubated for 72 hrs by SRB assay
372,161047,194,CHEMBL3589371,PI3-kinase p110-alpha subunit,Active,Cytotoxic activity against human SKOV3 cells expressing PIK3CA mutant incubated for 72 hrs by SRB assay
373,161046,194,CHEMBL3589370,PI3-kinase p110-alpha subunit,Active,Inhibition of GST-tagged bovine p110alpha expressed in Sf9/Baculovirus system using [gamma-33P]ATP by scintillation proximity assay
374,161046,194,CHEMBL3589370,PI3-kinase p110-alpha subunit,Unspecified,"Selectivity index, ratio of IC50 for GST-tagged human p110beta to IC50 for GST-tagged bovine p110alpha"
375,161046,194,CHEMBL3589370,PI3-kinase p110-alpha subunit,Unspecified,"Selectivity index, ratio of IC50 for His-tagged p110gamma (unknown origin) to IC50 for GST-tagged bovine p110alpha"
376,161046,194,CHEMBL3589370,PI3-kinase p110-alpha subunit,Unspecified,"Selectivity index, ratio of IC50 for GST-tagged p110delta (unknown origin) to IC50 for GST-tagged bovine p110alpha"
377,161046,194,CHEMBL3589370,PI3-kinase p110-alpha subunit,Unspecified,"Selectivity index, ratio of IC50 for Glu-tagged PI3KC2beta (unknown origin) to IC50 for GST-tagged bovine p110alpha"
378,161046,194,CHEMBL3589370,PI3-kinase p110-alpha subunit,Active,Cytotoxic activity against human HeLa cells over-expressing PI3K p110alpha incubated for 72 hrs by SRB assay
379,161046,194,CHEMBL3589370,PI3-kinase p110-alpha subunit,Active,Cytotoxic activity against human SKOV3 cells expressing PIK3CA mutant incubated for 72 hrs by SRB assay
380,322560,136,CHEMBL572881,Fibroblast growth factor receptor 3,Unspecified,Binding constant for FGFR3 kinase domain
381,322560,136,CHEMBL572881,Fibroblast growth factor receptor 3,Unspecified,Binding constant for FGFR3(G697C) kinase domain
382,322560,136,CHEMBL572881,Fibroblast growth factor receptor 3,Unspecified,Binding constant for FGFR3 kinase domain
383,322560,136,CHEMBL572881,Fibroblast growth factor receptor 3,Unspecified,Binding constant for FGFR3(G697C) kinase domain
384,12503,52,CHEMBL1200739,Carbonic anhydrase II,Active,Inhibition of human recombinant CA2 by stopped-flow CO2 hydration assay
385,12503,52,CHEMBL1200739,Carbonic anhydrase II,Active,Inhibition of human CA2 incubated for 15 mins prior to testing by stopped flow CO2 hydrase assay
386,90247,52,CHEMBL2207071,Carbonic anhydrase II,Active,Inhibition of human recombinant CA2 by CO2 hydration assay
387,37957,52,CHEMBL1644696,Carbonic anhydrase II,Active,Inhibition of human recombinant wild type CA2 by stopped-flow CO2 hydration method
388,37957,52,CHEMBL1644696,Carbonic anhydrase II,Active,Inhibition of human CA2 after 15 mins by stopped-flow/Co2 hydration assay
389,37957,52,CHEMBL1644696,Carbonic anhydrase II,Active,Inhibition of human CA2 incubated for 15 mins by stopped-flow CO2 hydration assay
390,296920,52,CHEMBL438861,Carbonic anhydrase II,Active,Binding affinity to bovine CA2 by typical isothermal titration calorimetry
391,100307,52,CHEMBL234507,Carbonic anhydrase II,Active,Binding affinity to bovine CA2 by typical isothermal titration calorimetry
392,333562,52,CHEMBL79455,Carbonic anhydrase II,Unspecified,Inhibition of human CA2 incubated for 15 mins prior to testing by stopped flow CO2 hydrase assay
393,130083,86,CHEMBL3104093,Serotonin 2c (5-HT2c) receptor,Unspecified,Displacement of [3H]Mesulergine from 5-HT2C receptor (unknown origin)
394,123454,224,CHEMBL288441,Serine/threonine-protein kinase Aurora-A,Unspecified,Binding constant for AURKA kinase domain
395,322676,72,CHEMBL573339,Serine/threonine-protein kinase PIM1,Unspecified,Percentage PIM1 activity remaining in the presence of 1uM inhibitor
396,322676,72,CHEMBL573339,Serine/threonine-protein kinase PIM1,Unspecified,Binding constant for PIM1 kinase domain
397,322676,72,CHEMBL573339,Serine/threonine-protein kinase PIM1,Unspecified,Binding constant for PIM1 kinase domain
398,322676,72,CHEMBL573339,Serine/threonine-protein kinase PIM1,Unspecified,"Millipore: Percentage of residual kinase activity of PIM1 at 1uM relative to control. Control inhibitor: Staurosporine at 10.0uM. Buffer: 8 mM MOPS pH 7.0, 0.2 mM EDTA"
399,322676,72,CHEMBL573339,Serine/threonine-protein kinase PIM1,Unspecified,"Millipore: Percentage of residual kinase activity of PIM1 at 10uM relative to control. Control inhibitor: Staurosporine at 10.0uM. Buffer: 8 mM MOPS pH 7.0, 0.2 mM EDTA"
400,322676,72,CHEMBL573339,Serine/threonine-protein kinase PIM1,Unspecified,Delta TM value showing the stabilisation of PIM1 produced by compound binding
401,20045,154,CHEMBL1287853,Cyclin-dependent kinase 2,Unspecified,Binding constant for CDK2 kinase domain
402,322560,149,CHEMBL572881,Tyrosine-protein kinase JAK2,Unspecified,Binding constant for JAK2(Kin.Dom.2/JH1 - catalytic) kinase domain
403,322560,149,CHEMBL572881,Tyrosine-protein kinase JAK2,Unspecified,Binding constant for JAK2(JH1domain-catalytic) kinase domain
404,135871,224,CHEMBL31965,Serine/threonine-protein kinase Aurora-A,Unspecified,Binding constant for AURKA kinase domain
405,135871,224,CHEMBL31965,Serine/threonine-protein kinase Aurora-A,Unspecified,Binding constant for AURKA kinase domain
406,15417,128,CHEMBL1230609,Glycogen synthase kinase-3 beta,Unspecified,Binding constant for GSK3B kinase domain
407,221090,138,CHEMBL379218,Vascular endothelial growth factor receptor 2,Unspecified,Inhibition of KDR
408,221090,138,CHEMBL379218,Vascular endothelial growth factor receptor 2,Unspecified,Selectivity for Akt1 over KDR
409,221090,138,CHEMBL379218,Vascular endothelial growth factor receptor 2,Unspecified,Binding constant for VEGFR2 kinase domain
410,312163,149,CHEMBL514409,Tyrosine-protein kinase JAK2,Unspecified,Binding affinity to human JAK2 at 10 uM relative to control
411,22914,149,CHEMBL1336,Tyrosine-protein kinase JAK2,Inactive,Average Binding Constant for JAK2 (Kin.Dom. 2); NA=Not Active at 10 uM
412,22914,149,CHEMBL1336,Tyrosine-protein kinase JAK2,Unspecified,Binding constant for JAK2(Kin.Dom.2/JH1 - catalytic) kinase domain
413,22914,149,CHEMBL1336,Tyrosine-protein kinase JAK2,Unspecified,Binding affinity to JH1 catalytic domain JAK2
414,22914,149,CHEMBL1336,Tyrosine-protein kinase JAK2,Unspecified,Binding constant for JAK2(JH1domain-catalytic) kinase domain
415,31636,215,CHEMBL1516890,Serine/threonine-protein kinase PIM2,Unspecified,GSK_PKIS: PIM2 mean inhibition at 0.1 uM [Nanosyn]
416,31636,215,CHEMBL1516890,Serine/threonine-protein kinase PIM2,Unspecified,GSK_PKIS: PIM2 mean inhibition at 1 uM [Nanosyn]
417,62885,86,CHEMBL1940403,Serotonin 2c (5-HT2c) receptor,Unspecified,Displacement of [3H]mesulergine from rat 5HT2C receptor by liquid scintillation counting
418,294641,224,CHEMBL428690,Serine/threonine-protein kinase Aurora-A,Unspecified,Binding constant for AURKA kinase domain
419,294641,224,CHEMBL428690,Serine/threonine-protein kinase Aurora-A,Unspecified,Binding constant for AURKA kinase domain
420,329496,154,CHEMBL608533,Cyclin-dependent kinase 2,Unspecified,Binding constant for full-length CDK2
421,329496,154,CHEMBL608533,Cyclin-dependent kinase 2,Unspecified,Binding affinity to CDK2
422,329496,154,CHEMBL608533,Cyclin-dependent kinase 2,Unspecified,Binding constant for CDK2 kinase domain
423,329496,154,CHEMBL608533,Cyclin-dependent kinase 2,Unspecified,"Millipore: Percentage of residual kinase activity of CDK2 at 1uM relative to control. Control inhibitor: Staurosporine at 10.0uM. Buffer: 8 mM MOPS pH 7.0, 0.2 mM EDTA"
424,329496,154,CHEMBL608533,Cyclin-dependent kinase 2,Unspecified,"Millipore: Percentage of residual kinase activity of CDK2 at 1uM relative to control. Control inhibitor: Staurosporine at 10.0uM. Buffer: 8 mM MOPS pH 7.0, 0.2 mM EDTA"
425,329496,154,CHEMBL608533,Cyclin-dependent kinase 2,Unspecified,"Millipore: Percentage of residual kinase activity of CDK2 at 1uM relative to control. Control inhibitor: Staurosporine at 10.0uM. Buffer: 8 mM MOPS pH 7.0, 0.2 mM EDTA"
426,329496,154,CHEMBL608533,Cyclin-dependent kinase 2,Unspecified,"Millipore: Percentage of residual kinase activity of CDK2 at 10uM relative to control. Control inhibitor: Staurosporine at 10.0uM. Buffer: 8 mM MOPS pH 7.0, 0.2 mM EDTA"
427,329496,154,CHEMBL608533,Cyclin-dependent kinase 2,Unspecified,"Millipore: Percentage of residual kinase activity of CDK2 at 10uM relative to control. Control inhibitor: Staurosporine at 10.0uM. Buffer: 8 mM MOPS pH 7.0, 0.2 mM EDTA"
428,329496,154,CHEMBL608533,Cyclin-dependent kinase 2,Unspecified,"Millipore: Percentage of residual kinase activity of CDK2 at 10uM relative to control. Control inhibitor: Staurosporine at 10.0uM. Buffer: 8 mM MOPS pH 7.0, 0.2 mM EDTA"
429,329496,154,CHEMBL608533,Cyclin-dependent kinase 2,Unspecified,"Millipore: Percentage of residual kinase activity of CDK2 at 1uM relative to control. Control inhibitor: Staurosporine at 10.0uM. Buffer: 8 mM MOPS pH 7.0, 0.2 mM EDTA"
430,329496,154,CHEMBL608533,Cyclin-dependent kinase 2,Unspecified,"Millipore: Percentage of residual kinase activity of CDK2 at 1uM relative to control. Control inhibitor: Staurosporine at 10.0uM. Buffer: 8 mM MOPS pH 7.0, 0.2 mM EDTA"
431,329496,154,CHEMBL608533,Cyclin-dependent kinase 2,Unspecified,"Millipore: Percentage of residual kinase activity of CDK2 at 1uM relative to control. Control inhibitor: Staurosporine at 10.0uM. Buffer: 8 mM MOPS pH 7.0, 0.2 mM EDTA"
432,329496,154,CHEMBL608533,Cyclin-dependent kinase 2,Unspecified,"Millipore: Percentage of residual kinase activity of CDK2 at 10uM relative to control. Control inhibitor: Staurosporine at 10.0uM. Buffer: 8 mM MOPS pH 7.0, 0.2 mM EDTA"
433,329496,154,CHEMBL608533,Cyclin-dependent kinase 2,Unspecified,"Millipore: Percentage of residual kinase activity of CDK2 at 10uM relative to control. Control inhibitor: Staurosporine at 10.0uM. Buffer: 8 mM MOPS pH 7.0, 0.2 mM EDTA"
434,329496,154,CHEMBL608533,Cyclin-dependent kinase 2,Unspecified,"Millipore: Percentage of residual kinase activity of CDK2 at 10uM relative to control. Control inhibitor: Staurosporine at 10.0uM. Buffer: 8 mM MOPS pH 7.0, 0.2 mM EDTA"
435,62886,86,CHEMBL1940404,Serotonin 2c (5-HT2c) receptor,Unspecified,Displacement of [3H]Mesulergine from rat 5-HT2C receptor by liquid scintillation counting
436,81171,136,CHEMBL21156,Fibroblast growth factor receptor 3,Unspecified,"Millipore: Percentage of residual kinase activity of FGFR3 at 1uM relative to control. Control inhibitor: Staurosporine at 10.0uM. Buffer: 8 mM MOPS pH 7.0, 0.2 mM EDTA"
437,81171,136,CHEMBL21156,Fibroblast growth factor receptor 3,Unspecified,"Millipore: Percentage of residual kinase activity of FGFR3 at 10uM relative to control. Control inhibitor: Staurosporine at 10.0uM. Buffer: 8 mM MOPS pH 7.0, 0.2 mM EDTA"
438,219065,36,CHEMBL377300,Tyrosine-protein kinase receptor FLT3,Unspecified,Binding constant for FLT3 kinase domain
439,219065,36,CHEMBL377300,Tyrosine-protein kinase receptor FLT3,Unspecified,Binding constant for FLT3(D835H) kinase domain
440,219065,36,CHEMBL377300,Tyrosine-protein kinase receptor FLT3,Unspecified,Binding constant for FLT3(D835Y) kinase domain
441,219065,36,CHEMBL377300,Tyrosine-protein kinase receptor FLT3,Unspecified,Binding constant for FLT3(ITD) kinase domain
442,219065,36,CHEMBL377300,Tyrosine-protein kinase receptor FLT3,Unspecified,Binding constant for FLT3(K663Q) kinase domain
443,219065,36,CHEMBL377300,Tyrosine-protein kinase receptor FLT3,Unspecified,Binding constant for FLT3(N841I) kinase domain
444,219065,36,CHEMBL377300,Tyrosine-protein kinase receptor FLT3,Unspecified,Binding constant for FLT3(R834Q) kinase domain
445,315225,89,CHEMBL535,c-Jun N-terminal kinase 1,Inactive,Average Binding Constant for JNK1; NA=Not Active at 10 uM
446,315225,89,CHEMBL535,c-Jun N-terminal kinase 1,Unspecified,Binding constant for full-length JNK1
447,315225,89,CHEMBL535,c-Jun N-terminal kinase 1,Unspecified,Binding affinity to JNK1
448,315225,89,CHEMBL535,c-Jun N-terminal kinase 1,Unspecified,Binding constant for JNK1 kinase domain
449,221090,150,CHEMBL379218,Rho-associated protein kinase 2,Unspecified,Binding constant for ROCK2 kinase domain
450,0,149,CHEMBL10,Tyrosine-protein kinase JAK2,Inactive,Average Binding Constant for JAK2 (Kin.Dom. 2); NA=Not Active at 10 uM
451,0,149,CHEMBL10,Tyrosine-protein kinase JAK2,Unspecified,Binding constant for JAK2(Kin.Dom.2/JH1 - catalytic) kinase domain
452,0,149,CHEMBL10,Tyrosine-protein kinase JAK2,Unspecified,Binding constant for JAK2(JH1domain-catalytic) kinase domain
453,0,149,CHEMBL10,Tyrosine-protein kinase JAK2,Unspecified,"Millipore: Percentage of residual kinase activity of JAK2 at 1uM relative to control. Control inhibitor: Staurosporine at 10.0uM. Buffer: 8 mM MOPS pH 7.0, 0.2 mM EDTA"
454,0,149,CHEMBL10,Tyrosine-protein kinase JAK2,Unspecified,"Millipore: Percentage of residual kinase activity of JAK2 at 10uM relative to control. Control inhibitor: Staurosporine at 10.0uM. Buffer: 8 mM MOPS pH 7.0, 0.2 mM EDTA"
455,286846,86,CHEMBL411,Serotonin 2c (5-HT2c) receptor,Active,DRUGMATRIX: Serotonin (5-Hydroxytryptamine) 5-HT2C radioligand binding (ligand: [3H] Mesulergine)
456,286846,86,CHEMBL411,Serotonin 2c (5-HT2c) receptor,Unspecified,DRUGMATRIX: Serotonin (5-Hydroxytryptamine) 5-HT2C radioligand binding (ligand: [3H] Mesulergine)
457,135871,149,CHEMBL31965,Tyrosine-protein kinase JAK2,Inactive,Average Binding Constant for JAK2 (Kin.Dom. 2); NA=Not Active at 10 uM
458,135871,149,CHEMBL31965,Tyrosine-protein kinase JAK2,Unspecified,Binding constant for JAK2(Kin.Dom.2/JH1 - catalytic) kinase domain
459,135871,149,CHEMBL31965,Tyrosine-protein kinase JAK2,Unspecified,Binding constant for JAK2(JH1domain-catalytic) kinase domain
460,135871,149,CHEMBL31965,Tyrosine-protein kinase JAK2,Active,human JAK2 kinase inhibition-screen
461,57883,154,CHEMBL1908397,Cyclin-dependent kinase 2,Unspecified,Binding constant for CDK2 kinase domain
462,298891,16,CHEMBL450786,Vascular endothelial growth factor receptor 1,Unspecified,Binding constant for FLT1 kinase domain
463,20634,131,CHEMBL1289926,Tyrosine-protein kinase SRC,Unspecified,Binding constant for SRC kinase domain
464,91850,136,CHEMBL2220486,Fibroblast growth factor receptor 3,Active,Inhibition of FGFR3 (unknown origin)
465,54670,142,CHEMBL1834657,Tyrosine-protein kinase JAK1,Unspecified,Inhibition of recombinant JAK1
466,119418,72,CHEMBL269538,Serine/threonine-protein kinase PIM1,Unspecified,Percentage PIM1 activity remaining in the presence of 1uM inhibitor
467,119418,72,CHEMBL269538,Serine/threonine-protein kinase PIM1,Unspecified,Inhibition of human recombinant PIM1 expressed in Escherichia coli using histone H1 as substrate and [gamma33P]ATP after 30 mins by scintillation counting
468,119418,72,CHEMBL269538,Serine/threonine-protein kinase PIM1,Unspecified,Inhibition of human PIM1 expressed in bacterial expression system assessed as remaining enzyme activity at 10 uM by kinome scan assay
469,113187,164,CHEMBL24828,Rho-associated protein kinase 1,Unspecified,Binding constant for ROCK1 kinase domain
470,322104,178,CHEMBL571040,Fibroblast growth factor receptor 1,Unspecified,Inhibition of FGFR1
471,123454,178,CHEMBL288441,Fibroblast growth factor receptor 1,Unspecified,Binding constant for FGFR1 kinase domain
472,145161,86,CHEMBL3321791,Serotonin 2c (5-HT2c) receptor,Active,Displacement of [3H]Mesulergine from rat 5-HT2C receptor by liquid scintillation counting
473,54627,86,CHEMBL183460,Serotonin 2c (5-HT2c) receptor,Active,Displacement of [3H]mesulergine from human cloned 5HT2C receptor expressed in HEK293 cells
474,69408,149,CHEMBL2012519,Tyrosine-protein kinase JAK2,Unspecified,Inhibition of JAK2 by TR-FRET based LanthaScreen assay
475,3267,36,CHEMBL1081312,Tyrosine-protein kinase receptor FLT3,Unspecified,Inhibition of FLT3 at 1 uM after 60 mins by FRET assay in presence of 10 uM ATP
476,3267,36,CHEMBL1081312,Tyrosine-protein kinase receptor FLT3,Unspecified,Inhibition of FLT3 D835Y mutant at 1 uM after 60 mins by FRET assay in presence of 10 uM ATP
477,3267,36,CHEMBL1081312,Tyrosine-protein kinase receptor FLT3,Active,"Human platelet derived growth factor receptor alpha (Type III RTKs: PDGFR, CSFR, Kit, FLT3 receptor family)"
478,224432,86,CHEMBL3819153,Serotonin 2c (5-HT2c) receptor,Unspecified,Displacement of [3H]Mesulergine from human recombinant 5HT2C receptor incubated for 1.5 hrs by microbeta scintillation counting method
479,1980,72,CHEMBL1076555,Serine/threonine-protein kinase PIM1,Unspecified,"Millipore: Percentage of residual kinase activity of PIM1 at 1uM relative to control. Control inhibitor: Staurosporine at 10.0uM. Buffer: 8 mM MOPS pH 7.0, 0.2 mM EDTA"
480,1980,72,CHEMBL1076555,Serine/threonine-protein kinase PIM1,Unspecified,"Millipore: Percentage of residual kinase activity of PIM1 at 10uM relative to control. Control inhibitor: Staurosporine at 10.0uM. Buffer: 8 mM MOPS pH 7.0, 0.2 mM EDTA"
481,280556,72,CHEMBL4088576,Serine/threonine-protein kinase PIM1,Inactive,Inhibition of human PIM1 using KKRNRTLTK as substrate in presence of [gamma-33P]-ATP
482,113772,149,CHEMBL249697,Tyrosine-protein kinase JAK2,Unspecified,Binding constant for JAK2(JH1domain-catalytic) kinase domain
483,78516,138,CHEMBL208775,Vascular endothelial growth factor receptor 2,Active,Inhibition of VEGFR2
484,74398,138,CHEMBL204727,Vascular endothelial growth factor receptor 2,Active,Inhibitory activity against VEGFR2
485,219779,138,CHEMBL378003,Vascular endothelial growth factor receptor 2,Active,Inhibition of VEGFR2
486,74163,138,CHEMBL204524,Vascular endothelial growth factor receptor 2,Active,Inhibitory activity against VEGFR2
487,75116,138,CHEMBL204985,Vascular endothelial growth factor receptor 2,Active,Inhibitory activity against VEGFR2
488,225787,138,CHEMBL383990,Vascular endothelial growth factor receptor 2,Active,Inhibition of VEGFR2
489,105513,82,CHEMBL2391541,Norepinephrine transporter,Active,Inhibition of [3H]norepinephrine uptake at human NET expressed in HEK293 cells preincubated for 10 mins prior to substrate addition measured after 4 mins by FLIPR assay
490,105513,82,CHEMBL2391541,Norepinephrine transporter,Active,Inhibition of [3H]norepinephrine uptake at human NET expressed in HEK293 cells preincubated for 10 mins prior to substrate addition measured after 4 mins by FLIPR assay
491,105513,82,CHEMBL2391541,Norepinephrine transporter,Active,Binding affinity to NET (unknown origin) by competition binding assay
492,310264,150,CHEMBL502835,Rho-associated protein kinase 2,Inactive,Inhibition of human ROCK2 at 10 umol/L
493,310264,150,CHEMBL502835,Rho-associated protein kinase 2,Unspecified,Binding constant for ROCK2 kinase domain
494,15417,191,CHEMBL1230609,Fibroblast growth factor receptor 4,Unspecified,Binding constant for FGFR4 kinase domain
495,309450,86,CHEMBL497963,Serotonin 2c (5-HT2c) receptor,Unspecified,Displacement of radioligand from human cloned 5HT2C receptor
496,57881,191,CHEMBL1908395,Fibroblast growth factor receptor 4,Unspecified,Binding constant for FGFR4 kinase domain
497,329496,191,CHEMBL608533,Fibroblast growth factor receptor 4,Unspecified,Binding constant for FGFR4 kinase domain
498,329496,191,CHEMBL608533,Fibroblast growth factor receptor 4,Unspecified,Binding affinity to FGFR4
499,329496,191,CHEMBL608533,Fibroblast growth factor receptor 4,Unspecified,Binding constant for FGFR4 kinase domain
500,329496,191,CHEMBL608533,Fibroblast growth factor receptor 4,Unspecified,"Millipore: Percentage of residual kinase activity of FGFR4 at 1uM relative to control. Control inhibitor: Staurosporine at 100.0uM. Buffer: 8 mM MOPS pH 7.0, 0.2 mM EDTA, 10 mM MnCl2"
501,329496,191,CHEMBL608533,Fibroblast growth factor receptor 4,Unspecified,"Millipore: Percentage of residual kinase activity of FGFR4 at 10uM relative to control. Control inhibitor: Staurosporine at 100.0uM. Buffer: 8 mM MOPS pH 7.0, 0.2 mM EDTA, 10 mM MnCl2"
502,42522,154,CHEMBL1721885,Cyclin-dependent kinase 2,Unspecified,Binding constant for full-length CDK2
503,42522,154,CHEMBL1721885,Cyclin-dependent kinase 2,Unspecified,Binding constant for CDK2 kinase domain
504,336569,215,CHEMBL939,Serine/threonine-protein kinase PIM2,Inactive,Average Binding Constant for PIM2; NA=Not Active at 10 uM
505,336569,215,CHEMBL939,Serine/threonine-protein kinase PIM2,Unspecified,Binding constant for PIM2 kinase domain
506,336569,215,CHEMBL939,Serine/threonine-protein kinase PIM2,Unspecified,Binding constant for PIM2 kinase domain
507,336569,215,CHEMBL939,Serine/threonine-protein kinase PIM2,Unspecified,Delta TM value showing the stabilisation of PIM2 produced by compound binding
508,322559,150,CHEMBL572878,Rho-associated protein kinase 2,Unspecified,Percentage ROCK2 activity remaining in the presence of 1uM inhibitor
509,322559,150,CHEMBL572878,Rho-associated protein kinase 2,Unspecified,Binding constant for ROCK2 kinase domain
510,42522,89,CHEMBL1721885,c-Jun N-terminal kinase 1,Unspecified,Binding constant for full-length JNK1
511,42522,89,CHEMBL1721885,c-Jun N-terminal kinase 1,Unspecified,Binding constant for JNK1 kinase domain
512,38622,149,CHEMBL1651521,Tyrosine-protein kinase JAK2,Unspecified,Inhibition of JAK2 by TR-FRET based LanthaScreen assay
513,15836,215,CHEMBL1240703,Serine/threonine-protein kinase PIM2,Unspecified,Binding affinity to PIM2
514,198060,199,CHEMBL3686883,Fibroblast growth factor receptor 2,Active,"ADP-Glo Kinase Assay: In this assay, the inhibitory activity of a test substance against the tyrosine kinase activity of FGFR2 protein is measured.To each well of a flat bottom 96 well white plate (Sumitomo Bakelite Co., Ltd., MS-8496W), 10 ul of FGFR2 protein (Cama Biosciences, Inc., 08434) solution diluted to 1 ug/mL with an assay buffer (20 mM HEPES-NaOH, 0.01% Triton X-100, 2 mM DTT, and 5 mM MgCl2), 10 uL of an assay buffer solution containing CSK-tide substrate (Ana Spec Inc., 63843) in a final concentration of 1000 nM and ATP (Promega Corporation, V9102) in a final concentration of 35 uM, and 5 ul of a test substance diluted with the assay buffer were added, and the reaction was performed at room temperature for 1 hour (kinase reaction). For measuring kinase activity, ADP-Glo Kinase Assay (Promega Corporation, V9102) was used. After the reaction, 25 uL of ADP-Glo reagent was added to each well of the plate, and the reaction was performed at room temperature for 40 minutes."
515,198060,199,CHEMBL3686883,Fibroblast growth factor receptor 2,Active,"ADP-Glo Kinase Assay: In this assay, the inhibitory activity of a test substance against the tyrosine kinase activity of FGFR2 protein is measured.To each well of a flat bottom 96 well white plate (Sumitomo Bakelite Co., Ltd., MS-8496W), 10 ul of FGFR2 protein (Cama Biosciences, Inc., 08434) solution diluted to 1 ug/mL with an assay buffer (20 mM HEPES-NaOH, 0.01% Triton X-100, 2 mM DTT, and 5 mM MgCl2), 10 uL of an assay buffer solution containing CSK-tide substrate (Ana Spec Inc., 63843) in a final concentration of 1000 nM and ATP (Promega Corporation, V9102) in a final concentration of 35 uM, and 5 ul of a test substance diluted with the assay buffer were added, and the reaction was performed at room temperature for 1 hour (kinase reaction). For measuring kinase activity, ADP-Glo Kinase Assay (Promega Corporation, V9102) was used. After the reaction, 25 uL of ADP-Glo reagent was added to each well of the plate, and the reaction was performed at room temperature for 40 minutes."
516,198039,199,CHEMBL3686864,Fibroblast growth factor receptor 2,Active,"ADP-Glo Kinase Assay: In this assay, the inhibitory activity of a test substance against the tyrosine kinase activity of FGFR2 protein is measured.To each well of a flat bottom 96 well white plate (Sumitomo Bakelite Co., Ltd., MS-8496W), 10 ul of FGFR2 protein (Cama Biosciences, Inc., 08434) solution diluted to 1 ug/mL with an assay buffer (20 mM HEPES-NaOH, 0.01% Triton X-100, 2 mM DTT, and 5 mM MgCl2), 10 uL of an assay buffer solution containing CSK-tide substrate (Ana Spec Inc., 63843) in a final concentration of 1000 nM and ATP (Promega Corporation, V9102) in a final concentration of 35 uM, and 5 ul of a test substance diluted with the assay buffer were added, and the reaction was performed at room temperature for 1 hour (kinase reaction). For measuring kinase activity, ADP-Glo Kinase Assay (Promega Corporation, V9102) was used. After the reaction, 25 uL of ADP-Glo reagent was added to each well of the plate, and the reaction was performed at room temperature for 40 minutes."
517,198039,199,CHEMBL3686864,Fibroblast growth factor receptor 2,Active,"ADP-Glo Kinase Assay: In this assay, the inhibitory activity of a test substance against the tyrosine kinase activity of FGFR2 protein is measured.To each well of a flat bottom 96 well white plate (Sumitomo Bakelite Co., Ltd., MS-8496W), 10 ul of FGFR2 protein (Cama Biosciences, Inc., 08434) solution diluted to 1 ug/mL with an assay buffer (20 mM HEPES-NaOH, 0.01% Triton X-100, 2 mM DTT, and 5 mM MgCl2), 10 uL of an assay buffer solution containing CSK-tide substrate (Ana Spec Inc., 63843) in a final concentration of 1000 nM and ATP (Promega Corporation, V9102) in a final concentration of 35 uM, and 5 ul of a test substance diluted with the assay buffer were added, and the reaction was performed at room temperature for 1 hour (kinase reaction). For measuring kinase activity, ADP-Glo Kinase Assay (Promega Corporation, V9102) was used. After the reaction, 25 uL of ADP-Glo reagent was added to each well of the plate, and the reaction was performed at room temperature for 40 minutes."
518,198061,199,CHEMBL3686884,Fibroblast growth factor receptor 2,Active,"ADP-Glo Kinase Assay: In this assay, the inhibitory activity of a test substance against the tyrosine kinase activity of FGFR2 protein is measured.To each well of a flat bottom 96 well white plate (Sumitomo Bakelite Co., Ltd., MS-8496W), 10 ul of FGFR2 protein (Cama Biosciences, Inc., 08434) solution diluted to 1 ug/mL with an assay buffer (20 mM HEPES-NaOH, 0.01% Triton X-100, 2 mM DTT, and 5 mM MgCl2), 10 uL of an assay buffer solution containing CSK-tide substrate (Ana Spec Inc., 63843) in a final concentration of 1000 nM and ATP (Promega Corporation, V9102) in a final concentration of 35 uM, and 5 ul of a test substance diluted with the assay buffer were added, and the reaction was performed at room temperature for 1 hour (kinase reaction). For measuring kinase activity, ADP-Glo Kinase Assay (Promega Corporation, V9102) was used. After the reaction, 25 uL of ADP-Glo reagent was added to each well of the plate, and the reaction was performed at room temperature for 40 minutes."
519,198061,199,CHEMBL3686884,Fibroblast growth factor receptor 2,Active,"ADP-Glo Kinase Assay: In this assay, the inhibitory activity of a test substance against the tyrosine kinase activity of FGFR2 protein is measured.To each well of a flat bottom 96 well white plate (Sumitomo Bakelite Co., Ltd., MS-8496W), 10 ul of FGFR2 protein (Cama Biosciences, Inc., 08434) solution diluted to 1 ug/mL with an assay buffer (20 mM HEPES-NaOH, 0.01% Triton X-100, 2 mM DTT, and 5 mM MgCl2), 10 uL of an assay buffer solution containing CSK-tide substrate (Ana Spec Inc., 63843) in a final concentration of 1000 nM and ATP (Promega Corporation, V9102) in a final concentration of 35 uM, and 5 ul of a test substance diluted with the assay buffer were added, and the reaction was performed at room temperature for 1 hour (kinase reaction). For measuring kinase activity, ADP-Glo Kinase Assay (Promega Corporation, V9102) was used. After the reaction, 25 uL of ADP-Glo reagent was added to each well of the plate, and the reaction was performed at room temperature for 40 minutes."
520,83102,178,CHEMBL215152,Fibroblast growth factor receptor 1,Unspecified,Binding constant for FGFR1 kinase domain
521,83102,178,CHEMBL215152,Fibroblast growth factor receptor 1,Unspecified,Binding constant for FGFR1 kinase domain
522,57881,214,CHEMBL1908395,Ribosomal protein S6 kinase 1,Unspecified,Binding constant for S6K1 kinase domain
523,54670,73,CHEMBL1834657,Tyrosine-protein kinase JAK3,Unspecified,Inhibition of recombinant JAK3
524,298547,170,CHEMBL448246,Matrix metalloproteinase-2,Unspecified,Inhibition recombinant MMP2 at 100 uM
525,298547,170,CHEMBL448246,Matrix metalloproteinase-2,Active,Inhibition of human recombinant MMP2 at 200 uM by HxBPyne probe-based competitive activity based protein profiling assay in presence of 5 uM HxBpane competitor
526,292540,38,CHEMBL42,Serotonin 1d (5-HT1d) receptor,Unspecified,Binding affinity to serotonin 5-HT1D receptor (unknown origin) by PDSP assay
527,292540,38,CHEMBL42,Serotonin 1d (5-HT1d) receptor,Active,Human 5-HT1D receptor (5-Hydroxytryptamine receptors)
528,310264,48,CHEMBL502835,Epidermal growth factor receptor erbB1,Unspecified,Inhibition of human EGFR
529,310264,48,CHEMBL502835,Epidermal growth factor receptor erbB1,Unspecified,Inhibition of human EGFR
530,310264,48,CHEMBL502835,Epidermal growth factor receptor erbB1,Unspecified,Binding constant for EGFR kinase domain
531,310264,48,CHEMBL502835,Epidermal growth factor receptor erbB1,Unspecified,Binding constant for EGFR(E746-A750del) kinase domain
532,310264,48,CHEMBL502835,Epidermal growth factor receptor erbB1,Unspecified,Binding constant for EGFR(G719C) kinase domain
533,310264,48,CHEMBL502835,Epidermal growth factor receptor erbB1,Unspecified,Binding constant for EGFR(G719S) kinase domain
534,310264,48,CHEMBL502835,Epidermal growth factor receptor erbB1,Unspecified,"Binding constant for EGFR(L747-E749del, A750P) kinase domain"
535,310264,48,CHEMBL502835,Epidermal growth factor receptor erbB1,Unspecified,"Binding constant for EGFR(L747-S752del, P753S) kinase domain"
536,310264,48,CHEMBL502835,Epidermal growth factor receptor erbB1,Unspecified,"Binding constant for EGFR(L747-T751del,Sins) kinase domain"
537,310264,48,CHEMBL502835,Epidermal growth factor receptor erbB1,Unspecified,Binding constant for EGFR(L858R) kinase domain
538,310264,48,CHEMBL502835,Epidermal growth factor receptor erbB1,Unspecified,"Binding constant for EGFR(L858R,T790M) kinase domain"
539,310264,48,CHEMBL502835,Epidermal growth factor receptor erbB1,Unspecified,Binding constant for EGFR(L861Q) kinase domain
540,310264,48,CHEMBL502835,Epidermal growth factor receptor erbB1,Unspecified,Binding constant for EGFR(S752-I759del) kinase domain
541,310264,48,CHEMBL502835,Epidermal growth factor receptor erbB1,Unspecified,Binding constant for EGFR(T790M) kinase domain
542,58003,191,CHEMBL191003,Fibroblast growth factor receptor 4,Unspecified,Binding constant for FGFR4 kinase domain
543,58003,191,CHEMBL191003,Fibroblast growth factor receptor 4,Unspecified,"Millipore: Percentage of residual kinase activity of FGFR4 at 1uM relative to control. Control inhibitor: Staurosporine at 100.0uM. Buffer: 8 mM MOPS pH 7.0, 0.2 mM EDTA, 10 mM MnCl2"
544,58003,191,CHEMBL191003,Fibroblast growth factor receptor 4,Unspecified,"Millipore: Percentage of residual kinase activity of FGFR4 at 10uM relative to control. Control inhibitor: Staurosporine at 100.0uM. Buffer: 8 mM MOPS pH 7.0, 0.2 mM EDTA, 10 mM MnCl2"
545,304062,82,CHEMBL476108,Norepinephrine transporter,Active,Binding affinity to rat NET
546,304184,71,CHEMBL476839,Serotonin 1a (5-HT1a) receptor,Unspecified,Inhibition of human cloned 5HT1A receptor by competitive binding experiment
547,332065,38,CHEMBL715,Serotonin 1d (5-HT1d) receptor,Unspecified,Binding affinity to serotonin 5-HT1D receptor (unknown origin) by PDSP assay
548,332065,38,CHEMBL715,Serotonin 1d (5-HT1d) receptor,Active,Human 5-HT1D receptor (5-Hydroxytryptamine receptors)
549,20045,72,CHEMBL1287853,Serine/threonine-protein kinase PIM1,Unspecified,Binding constant for PIM1 kinase domain
550,305625,166,CHEMBL48310,Histone deacetylase 1,Unspecified,Inhibition of human recombinant HDAC1 by Michaelis-Menten equation analysis
551,107508,166,CHEMBL2408245,Histone deacetylase 1,Unspecified,Selectivity ratio of Ki for human recombinant HDAC1 to Ki for human recombinant HDAC2
552,107508,166,CHEMBL2408245,Histone deacetylase 1,Unspecified,Inhibition of human recombinant HDAC1 by Michaelis-Menten equation analysis
553,107507,166,CHEMBL2408244,Histone deacetylase 1,Unspecified,Selectivity ratio of Ki for human recombinant HDAC1 to Ki for human recombinant HDAC2
554,107507,166,CHEMBL2408244,Histone deacetylase 1,Unspecified,Inhibition of human recombinant HDAC1 by Michaelis-Menten equation analysis
555,107502,166,CHEMBL2408239,Histone deacetylase 1,Unspecified,Selectivity ratio of Ki for human recombinant HDAC1 to Ki for human recombinant HDAC2
556,107502,166,CHEMBL2408239,Histone deacetylase 1,Unspecified,Inhibition of human recombinant HDAC1 by Michaelis-Menten equation analysis
557,107503,166,CHEMBL2408240,Histone deacetylase 1,Unspecified,Selectivity ratio of Ki for human recombinant HDAC1 to Ki for human recombinant HDAC2
558,107503,166,CHEMBL2408240,Histone deacetylase 1,Unspecified,Inhibition of human recombinant HDAC1 by Michaelis-Menten equation analysis
559,107506,166,CHEMBL2408243,Histone deacetylase 1,Unspecified,Inhibition of human recombinant HDAC1 by Michaelis-Menten equation analysis
560,107504,166,CHEMBL2408241,Histone deacetylase 1,Unspecified,Selectivity ratio of Ki for human recombinant HDAC1 to Ki for human recombinant HDAC2
561,107504,166,CHEMBL2408241,Histone deacetylase 1,Unspecified,Inhibition of human recombinant HDAC1 by Michaelis-Menten equation analysis
562,107501,166,CHEMBL2408238,Histone deacetylase 1,Unspecified,Selectivity ratio of Ki for human recombinant HDAC1 to Ki for human recombinant HDAC2
563,107501,166,CHEMBL2408238,Histone deacetylase 1,Unspecified,Inhibition of human recombinant HDAC1 by Michaelis-Menten equation analysis
564,107509,166,CHEMBL2408246,Histone deacetylase 1,Unspecified,Inhibition of human recombinant HDAC1 by Michaelis-Menten equation analysis
565,307056,84,CHEMBL489408,Serotonin 2a (5-HT2a) receptor,Active,Displacement of [3H]MDL from rat 5HT2A receptor expressed in GF62 cells by liquid scintillation analyser
566,101389,14,CHEMBL235191,Histone deacetylase 6,Unspecified,Inhibition of human recombinant HDAC6 at 20 uM
567,101389,14,CHEMBL235191,Histone deacetylase 6,Unspecified,Inhibition of HDAC6 (unknown origin) by fluorimetric assay
568,101389,14,CHEMBL235191,Histone deacetylase 6,Unspecified,Inhibition of mouse HDAC6 expressed in 293T cells at 100 uM using Ac-KGLGK(Ac)-MCA as substrate measured after 30 mins by fluorescence assay relative to control
569,101389,14,CHEMBL235191,Histone deacetylase 6,Unspecified,Inhibition of human recombinant HDAC6 using Fluor de Lys-Green as substrate preincubated for 5 mins followed by substrate addition and measured after 1 hr by fluorescence assay
570,101389,14,CHEMBL235191,Histone deacetylase 6,Unspecified,Selectivity ratio of IC50 for human recombinant HDAC1 to IC50 for human recombinant HDAC6
571,101389,14,CHEMBL235191,Histone deacetylase 6,Unspecified,Selectivity ratio of IC50 for human recombinant HDAC2 to IC50 for human recombinant HDAC6
572,101389,14,CHEMBL235191,Histone deacetylase 6,Unspecified,Inhibition of human recombinant HDAC6 using Fluor de Lys as substrate after 60 mins by fluorometric assay
573,141956,14,CHEMBL3286732,Histone deacetylase 6,Unspecified,Inhibition of FLAG-tagged full-length human recombinant HDAC6 expressed in HEK293F cells using acetyl-lysine containing peptide as substrate preincubated for 10 mins followed by substrate addition measured after 60 mins by fluorescence assay
574,101584,14,CHEMBL235842,Histone deacetylase 6,Unspecified,Inhibition of human recombinant HDAC6 at 20 uM
575,101584,14,CHEMBL235842,Histone deacetylase 6,Unspecified,Inhibition of HDAC6
576,101584,14,CHEMBL235842,Histone deacetylase 6,Unspecified,Inhibition of HDAC6
577,101584,14,CHEMBL235842,Histone deacetylase 6,Unspecified,Inhibition of recombinant HDAC6
578,101584,14,CHEMBL235842,Histone deacetylase 6,Unspecified,Selectivity for HDAC1/2 (unknown origin) over HDAC6 (unknown origin)
579,101656,14,CHEMBL236061,Histone deacetylase 6,Unspecified,Inhibition of human recombinant HDAC6 at 20 uM
580,336075,205,CHEMBL91829,Serine/threonine-protein kinase AKT,Unspecified,Binding constant for AKT1 kinase domain
581,336075,205,CHEMBL91829,Serine/threonine-protein kinase AKT,Unspecified,Binding constant for AKT1 kinase domain
582,298891,164,CHEMBL450786,Rho-associated protein kinase 1,Unspecified,Binding constant for ROCK1 kinase domain
583,314179,154,CHEMBL522892,Cyclin-dependent kinase 2,Unspecified,Binding constant for full-length CDK2
584,314179,154,CHEMBL522892,Cyclin-dependent kinase 2,Unspecified,Binding constant for CDK2 kinase domain
585,224471,86,CHEMBL3819366,Serotonin 2c (5-HT2c) receptor,Unspecified,Displacement of [3H]Mesulergine from rat 5-HT2C receptor expressed in cell membranes after 1 hr by liquid scintillation counting
586,57883,72,CHEMBL1908397,Serine/threonine-protein kinase PIM1,Unspecified,Binding constant for PIM1 kinase domain
587,20634,191,CHEMBL1289926,Fibroblast growth factor receptor 4,Unspecified,Binding constant for FGFR4 kinase domain
588,57880,215,CHEMBL1908394,Serine/threonine-protein kinase PIM2,Unspecified,Binding constant for PIM2 kinase domain
589,81171,224,CHEMBL21156,Serine/threonine-protein kinase Aurora-A,Unspecified,"Millipore: Percentage of residual kinase activity of AURKA at 1uM relative to control. Control inhibitor: Staurosporine at 10.0uM. Buffer: 8 mM MOPS pH 7.0, 0.2 mM EDTA, 50 mM NaCl, 0.1% v/v Triton-X-100"
590,81171,224,CHEMBL21156,Serine/threonine-protein kinase Aurora-A,Unspecified,"Millipore: Percentage of residual kinase activity of AURKA at 10uM relative to control. Control inhibitor: Staurosporine at 10.0uM. Buffer: 8 mM MOPS pH 7.0, 0.2 mM EDTA, 50 mM NaCl, 0.1% v/v Triton-X-100"
591,42629,142,CHEMBL1725279,Tyrosine-protein kinase JAK1,Inactive,Average Binding Constant for JAK1 (Kin.Dom. 1); NA=Not Active at 10 uM
592,123721,84,CHEMBL290106,Serotonin 2a (5-HT2a) receptor,Unspecified,DRUGMATRIX: Serotonin (5-Hydroxytryptamine) 5-HT2A radioligand binding (ligand: [3H] Ketanserin)
593,123721,84,CHEMBL290106,Serotonin 2a (5-HT2a) receptor,Unspecified,DRUGMATRIX: Serotonin (5-Hydroxytryptamine) 5-HT2A radioligand binding (ligand: [3H] Ketanserin)
594,298891,191,CHEMBL450786,Fibroblast growth factor receptor 4,Unspecified,Binding constant for FGFR4 kinase domain
595,135871,178,CHEMBL31965,Fibroblast growth factor receptor 1,Inactive,Average Binding Constant for FGFR1; NA=Not Active at 10 uM
596,135871,178,CHEMBL31965,Fibroblast growth factor receptor 1,Unspecified,Binding constant for FGFR1 kinase domain
597,135871,178,CHEMBL31965,Fibroblast growth factor receptor 1,Unspecified,Binding constant for FGFR1 kinase domain
598,15946,164,CHEMBL1241674,Rho-associated protein kinase 1,Unspecified,Inhibition of ROCK1 at 1 uM after 60 mins by FRET assay in presence of 10 uM ATP
599,15946,164,CHEMBL1241674,Rho-associated protein kinase 1,Unspecified,Binding constant for ROCK1 kinase domain
600,58003,140,CHEMBL191003,Nerve growth factor receptor Trk-A,Unspecified,Binding constant for TRKA kinase domain
601,58003,140,CHEMBL191003,Nerve growth factor receptor Trk-A,Unspecified,"Millipore: Percentage of residual kinase activity of NTRK1 at 1uM relative to control. Control inhibitor: Staurosporine at 10.0uM. Buffer: 8 mM MOPS pH 7.0, 0.2 mM EDTA"
602,58003,140,CHEMBL191003,Nerve growth factor receptor Trk-A,Unspecified,"Millipore: Percentage of residual kinase activity of NTRK1 at 10uM relative to control. Control inhibitor: Staurosporine at 10.0uM. Buffer: 8 mM MOPS pH 7.0, 0.2 mM EDTA"
603,303829,215,CHEMBL475251,Serine/threonine-protein kinase PIM2,Unspecified,Binding constant for PIM2 kinase domain
604,323045,72,CHEMBL574738,Serine/threonine-protein kinase PIM1,Unspecified,Binding constant for PIM1 kinase domain
605,323045,72,CHEMBL574738,Serine/threonine-protein kinase PIM1,Unspecified,Binding constant for PIM1 kinase domain
606,322559,89,CHEMBL572878,c-Jun N-terminal kinase 1,Unspecified,Binding affinity to human JNK1 at 10 uM relative to control
607,322559,89,CHEMBL572878,c-Jun N-terminal kinase 1,Unspecified,Binding constant for full-length JNK1
608,322559,89,CHEMBL572878,c-Jun N-terminal kinase 1,Unspecified,Percentage JNK1 activity remaining in the presence of 1uM inhibitor
609,322559,89,CHEMBL572878,c-Jun N-terminal kinase 1,Unspecified,Binding constant for JNK1 kinase domain
610,57878,215,CHEMBL1908391,Serine/threonine-protein kinase PIM2,Unspecified,Binding constant for PIM2 kinase domain
611,75058,138,CHEMBL2048912,Vascular endothelial growth factor receptor 2,Unspecified,Inhibition of N-terminus FLAG-tagged VEGFR2 expressed using baculovirus infection system after 10 mins
612,316767,84,CHEMBL549,Serotonin 2a (5-HT2a) receptor,Unspecified,DRUGMATRIX: Serotonin (5-Hydroxytryptamine) 5-HT2A radioligand binding (ligand: [3H] Ketanserin)
613,316767,84,CHEMBL549,Serotonin 2a (5-HT2a) receptor,Unspecified,DRUGMATRIX: Serotonin (5-Hydroxytryptamine) 5-HT2A radioligand binding (ligand: [3H] Ketanserin)
614,221090,79,CHEMBL379218,Serine/threonine-protein kinase Aurora-B,Unspecified,Binding constant for AURKB kinase domain
615,224300,86,CHEMBL3818478,Serotonin 2c (5-HT2c) receptor,Unspecified,Displacement of [3H]Mesulergine from human recombinant 5HT2C receptor incubated for 1.5 hrs by microbeta scintillation counting method
616,88140,142,CHEMBL2181315,Tyrosine-protein kinase JAK1,Unspecified,"Inhibition of recombinant JAK1 using Poly (Glu,Ala,Tyr) as substrate after 2 hrs by luminescence assay"
617,310802,169,CHEMBL507420,Matrix metalloproteinase-1,Unspecified,Inhibition of MMP1
618,22914,191,CHEMBL1336,Fibroblast growth factor receptor 4,Unspecified,Binding constant for FGFR4 kinase domain
619,22914,191,CHEMBL1336,Fibroblast growth factor receptor 4,Unspecified,Binding affinity to FGFR4
620,22914,191,CHEMBL1336,Fibroblast growth factor receptor 4,Unspecified,Binding constant for FGFR4 kinase domain
621,27092,191,CHEMBL1421,Fibroblast growth factor receptor 4,Unspecified,Binding constant for FGFR4 kinase domain
622,27092,191,CHEMBL1421,Fibroblast growth factor receptor 4,Unspecified,Binding constant for FGFR4 kinase domain
623,48303,138,CHEMBL1789941,Vascular endothelial growth factor receptor 2,Unspecified,Binding constant for VEGFR2 kinase domain
624,331888,84,CHEMBL707,Serotonin 2a (5-HT2a) receptor,Unspecified,DRUGMATRIX: Serotonin (5-Hydroxytryptamine) 5-HT2A radioligand binding (ligand: [3H] Ketanserin)
625,331888,84,CHEMBL707,Serotonin 2a (5-HT2a) receptor,Unspecified,DRUGMATRIX: Serotonin (5-Hydroxytryptamine) 5-HT2A radioligand binding (ligand: [3H] Ketanserin)
626,58571,215,CHEMBL191384,Serine/threonine-protein kinase PIM2,Active,Percentage PIM2 activity remaining in the presence of 1uM inhibitor
627,58571,215,CHEMBL191384,Serine/threonine-protein kinase PIM2,Active,Percentage PIM2 activity remaining in the presence of 10uM inhibitor
628,58571,215,CHEMBL191384,Serine/threonine-protein kinase PIM2,Unspecified,"Millipore: Percentage of residual kinase activity of PIM2 at 1uM relative to control. Control inhibitor: Staurosporine at 10.0uM. Buffer: 8 mM MOPS pH 7.0, 0.2 mM EDTA"
629,58571,215,CHEMBL191384,Serine/threonine-protein kinase PIM2,Unspecified,"Millipore: Percentage of residual kinase activity of PIM2 at 10uM relative to control. Control inhibitor: Staurosporine at 10.0uM. Buffer: 8 mM MOPS pH 7.0, 0.2 mM EDTA"
630,58571,215,CHEMBL191384,Serine/threonine-protein kinase PIM2,Unspecified,Delta TM value showing the stabilisation of PIM2 produced by compound binding
631,58003,72,CHEMBL191003,Serine/threonine-protein kinase PIM1,Unspecified,Binding constant for PIM1 kinase domain
632,58003,72,CHEMBL191003,Serine/threonine-protein kinase PIM1,Unspecified,"Millipore: Percentage of residual kinase activity of PIM1 at 1uM relative to control. Control inhibitor: Staurosporine at 10.0uM. Buffer: 8 mM MOPS pH 7.0, 0.2 mM EDTA"
633,58003,72,CHEMBL191003,Serine/threonine-protein kinase PIM1,Unspecified,"Millipore: Percentage of residual kinase activity of PIM1 at 10uM relative to control. Control inhibitor: Staurosporine at 10.0uM. Buffer: 8 mM MOPS pH 7.0, 0.2 mM EDTA"
634,37771,86,CHEMBL1643900,Serotonin 2c (5-HT2c) receptor,Unspecified,Inhibition of 5HT2C receptor at 10 uM
635,37771,86,CHEMBL1643900,Serotonin 2c (5-HT2c) receptor,Unspecified,Inhibition of 5-HT2C receptor (unknown origin) at 10 uM by PDSP assay relative to control
636,317985,86,CHEMBL555146,Serotonin 2c (5-HT2c) receptor,Unspecified,Binding affinity to human recombinant 5HT2C receptor
637,318982,84,CHEMBL56,Serotonin 2a (5-HT2a) receptor,Active,Binding affinity to rat cortical membranes at 5-hydroxytryptamine 2 (5-HT2) receptor using [3H]KET as a radioligand
638,318982,84,CHEMBL56,Serotonin 2a (5-HT2a) receptor,Active,Binding affinity to rat cortical membranes at 5-hydroxytryptamine 2 (5-HT2) receptor using [3H]KET as a radioligand
639,318982,84,CHEMBL56,Serotonin 2a (5-HT2a) receptor,Active,Binding affinity to rat cortical membranes at 5-hydroxytryptamine 2 (5-HT2) receptor using [3H]KET as a radioligand
640,318982,84,CHEMBL56,Serotonin 2a (5-HT2a) receptor,Active,Agonists at Human 5-Hydroxytryptamine receptor 5-HT2A
641,318982,84,CHEMBL56,Serotonin 2a (5-HT2a) receptor,Inactive,Late stage Counterscreen for the probe development effort to identify agonists of the mouse 5-hydroxytryptamine (serotonin) receptor 2A (HTR2A): Luminescence-based cell-based high throughput dose response assay to identify agonists of the mu 1 opioid receptor (OPRM1).
642,318982,84,CHEMBL56,Serotonin 2a (5-HT2a) receptor,Inactive,Late stage for the probe development effort to identify agonists of the mouse 5-hydroxytryptamine (serotonin) receptor 2A (HTR2A): Luminescence-based cell-based high throughput dose response assay for agonists of the mouse 5-hydroxytryptamine (serotonin) receptor 2A (HTR2A).
643,318982,84,CHEMBL56,Serotonin 2a (5-HT2a) receptor,Active,Human 5-HT2A receptor (5-Hydroxytryptamine receptors)
644,337590,215,CHEMBL98350,Serine/threonine-protein kinase PIM2,Unspecified,Percentage PIM2 activity remaining in the presence of 10uM inhibitor
645,337590,215,CHEMBL98350,Serine/threonine-protein kinase PIM2,Unspecified,"Millipore: Percentage of residual kinase activity of PIM2 at 1uM relative to control. Control inhibitor: Staurosporine at 10.0uM. Buffer: 8 mM MOPS pH 7.0, 0.2 mM EDTA"
646,337590,215,CHEMBL98350,Serine/threonine-protein kinase PIM2,Unspecified,"Millipore: Percentage of residual kinase activity of PIM2 at 10uM relative to control. Control inhibitor: Staurosporine at 10.0uM. Buffer: 8 mM MOPS pH 7.0, 0.2 mM EDTA"
647,337590,215,CHEMBL98350,Serine/threonine-protein kinase PIM2,Unspecified,Delta TM value showing the stabilisation of PIM2 produced by compound binding
648,190896,142,CHEMBL3675685,Tyrosine-protein kinase JAK1,Active,"Inhibition Assay: To determine the inhibition constants (Ki) of Examples 1-240, compounds were diluted serially in DMSO and added to 50 &#x3BC;L kinase reactions containing 1.5 nM JAK1, 0.2 nM purified JAK2 or 1 nM purified TYK2 enzyme, 100 mM Hepes pH7.2, 0.015% Brij-35, 1.5 &#x3BC;M peptide substrate, 25 &#x3BC;M ATP, 10 mM MgCl2, 4 mM DTT at a final DMSO concentration of 2%. Reactions were incubated at 22&#xB0; C. in 384-well polypropylene microtiter plates for 30 minutes and then stopped by addition of 25 &#x3BC;L of an EDTA containing solution (100 mM Hepes pH 7.2, 0.015% Brij-35, 150 mM EDTA), resulting in a final EDTA concentration of 50 mM. Ki values were then determined using the Morrison tight binding model. Morrison, J. F., Biochim. Biophys. Acta. 185:269-296 (1969); William, J. W. and Morrison, J. F., Meth. Enzymol., 63:437-467 (1979)."
649,190896,142,CHEMBL3675685,Tyrosine-protein kinase JAK1,Active,"Inhibition Assay: To determine the inhibition constants (Ki) of Examples 1-240, compounds were diluted serially in DMSO and added to 50 &#x3BC;L kinase reactions containing 1.5 nM JAK1, 0.2 nM purified JAK2 or 1 nM purified TYK2 enzyme, 100 mM Hepes pH7.2, 0.015% Brij-35, 1.5 &#x3BC;M peptide substrate, 25 &#x3BC;M ATP, 10 mM MgCl2, 4 mM DTT at a final DMSO concentration of 2%. Reactions were incubated at 22&#xB0; C. in 384-well polypropylene microtiter plates for 30 minutes and then stopped by addition of 25 &#x3BC;L of an EDTA containing solution (100 mM Hepes pH 7.2, 0.015% Brij-35, 150 mM EDTA), resulting in a final EDTA concentration of 50 mM. Ki values were then determined using the Morrison tight binding model. Morrison, J. F., Biochim. Biophys. Acta. 185:269-296 (1969); William, J. W. and Morrison, J. F., Meth. Enzymol., 63:437-467 (1979)."
650,109203,142,CHEMBL2420841,Tyrosine-protein kinase JAK1,Unspecified,Inhibition of JAK1 (unknown origin)
651,22247,84,CHEMBL1323615,Serotonin 2a (5-HT2a) receptor,Inactive,Luminescence-based cell-based primary high throughput screening assay to identify agonists of the mouse 5-hydroxytryptamine (serotonin) receptor 2A (HTR2A)
652,325135,178,CHEMBL590109,Fibroblast growth factor receptor 1,Unspecified,Selectivity for MK2 over FGFR1
653,325135,178,CHEMBL590109,Fibroblast growth factor receptor 1,Unspecified,Inhibition of FGFR1
654,57881,150,CHEMBL1908395,Rho-associated protein kinase 2,Unspecified,Binding constant for ROCK2 kinase domain
655,153286,136,CHEMBL3401370,Fibroblast growth factor receptor 3,Active,Inhibition of FGFR3 (unknown origin) after 90 mins by TR-FRET assay
656,153282,136,CHEMBL3401367,Fibroblast growth factor receptor 3,Unspecified,Inhibition of FGFR3 (unknown origin) after 90 mins by TR-FRET assay
657,153283,136,CHEMBL3401368,Fibroblast growth factor receptor 3,Active,Inhibition of FGFR3 (unknown origin) after 90 mins by TR-FRET assay
658,153284,136,CHEMBL3401369,Fibroblast growth factor receptor 3,Active,Inhibition of FGFR3 (unknown origin) after 90 mins by TR-FRET assay
659,153281,136,CHEMBL3401364,Fibroblast growth factor receptor 3,Active,Inhibition of FGFR3 (unknown origin) after 90 mins by TR-FRET assay
660,153280,136,CHEMBL3401363,Fibroblast growth factor receptor 3,Unspecified,Inhibition of FGFR3 (unknown origin) after 90 mins by TR-FRET assay
661,81171,36,CHEMBL21156,Tyrosine-protein kinase receptor FLT3,Unspecified,"Millipore: Percentage of residual kinase activity of FLT3 at 1uM relative to control. Control inhibitor: Staurosporine at 100.0uM. Buffer: 8 mM MOPS pH 7.0, 0.2 mM EDTA"
662,81171,36,CHEMBL21156,Tyrosine-protein kinase receptor FLT3,Unspecified,"Millipore: Percentage of residual kinase activity of FLT3 at 10uM relative to control. Control inhibitor: Staurosporine at 100.0uM. Buffer: 8 mM MOPS pH 7.0, 0.2 mM EDTA"
663,333482,215,CHEMBL79004,Serine/threonine-protein kinase PIM2,Active,Percentage PIM2 activity remaining in the presence of 10uM inhibitor
664,166940,215,CHEMBL3634785,Serine/threonine-protein kinase PIM2,Active,Inhibition of Pim2 (unknown origin) using 5FAM-ARKRRRHPSGPPTA as substrate after 90 mins
665,73237,215,CHEMBL2036118,Serine/threonine-protein kinase PIM2,Unspecified,Inhibition of Pim-2 using RSRHSSYPAGT as substrate assessed as residual activity at 10 uM after 30 mins
666,73237,215,CHEMBL2036118,Serine/threonine-protein kinase PIM2,Unspecified,Inhibition of Pim-2 using RSRHSSYPAGT as substrate assessed as residual activity at 1 uM after 30 mins
667,73237,215,CHEMBL2036118,Serine/threonine-protein kinase PIM2,Inconclusive,Inhibition of Pim-2 using RSRHSSYPAGT as substrate after 30 mins
668,73236,215,CHEMBL2036117,Serine/threonine-protein kinase PIM2,Unspecified,Inhibition of Pim-2 using RSRHSSYPAGT as substrate assessed as residual activity at 10 uM after 30 mins
669,73236,215,CHEMBL2036117,Serine/threonine-protein kinase PIM2,Unspecified,Inhibition of Pim-2 using RSRHSSYPAGT as substrate assessed as residual activity at 1 uM after 30 mins
670,73236,215,CHEMBL2036117,Serine/threonine-protein kinase PIM2,Inconclusive,Inhibition of Pim-2 using RSRHSSYPAGT as substrate after 30 mins
671,103402,215,CHEMBL2377721,Serine/threonine-protein kinase PIM2,Unspecified,Inhibition of human full length Pim-2 using RSRHSSYPAGT as substrate assessed as residual activity at 1 uM after 30 mins in presence of [gamma-33P]ATP
672,103402,215,CHEMBL2377721,Serine/threonine-protein kinase PIM2,Unspecified,Inhibition of human full length Pim-2 using RSRHSSYPAGT as substrate assessed as residual activity at 10 uM after 30 mins in presence of [gamma-33P]ATP
673,103401,215,CHEMBL2377718,Serine/threonine-protein kinase PIM2,Unspecified,Inhibition of human full length Pim-2 using RSRHSSYPAGT as substrate assessed as residual activity at 1 uM after 30 mins in presence of [gamma-33P]ATP
674,103401,215,CHEMBL2377718,Serine/threonine-protein kinase PIM2,Unspecified,Inhibition of human full length Pim-2 using RSRHSSYPAGT as substrate assessed as residual activity at 10 uM after 30 mins in presence of [gamma-33P]ATP
675,106260,215,CHEMBL2397525,Serine/threonine-protein kinase PIM2,Unspecified,Inhibition of human PIM2 assessed as residual activity using RSRHSSYPAGT as substrate at 1 uM after 30 mins
676,106260,215,CHEMBL2397525,Serine/threonine-protein kinase PIM2,Unspecified,Inhibition of human PIM2 assessed as residual activity using RSRHSSYPAGT as substrate at 10 uM after 30 mins
677,106259,215,CHEMBL2397524,Serine/threonine-protein kinase PIM2,Unspecified,Inhibition of human PIM2 assessed as residual activity using RSRHSSYPAGT as substrate at 1 uM after 30 mins
678,106259,215,CHEMBL2397524,Serine/threonine-protein kinase PIM2,Unspecified,Inhibition of human PIM2 assessed as residual activity using RSRHSSYPAGT as substrate at 10 uM after 30 mins
679,103398,215,CHEMBL2377711,Serine/threonine-protein kinase PIM2,Unspecified,Inhibition of human full length Pim-2 using RSRHSSYPAGT as substrate assessed as residual activity at 1 uM after 30 mins in presence of [gamma-33P]ATP
680,103398,215,CHEMBL2377711,Serine/threonine-protein kinase PIM2,Unspecified,Inhibition of human full length Pim-2 using RSRHSSYPAGT as substrate assessed as residual activity at 10 uM after 30 mins in presence of [gamma-33P]ATP
681,64133,215,CHEMBL1950358,Serine/threonine-protein kinase PIM2,Unspecified,Inhibition of human recombinant PIM2 expressed in Escherichia coli assessed as residual activity using RSRHSSYPAGT as substrate at 10 uM after 30 mins
682,64133,215,CHEMBL1950358,Serine/threonine-protein kinase PIM2,Inconclusive,Inhibition of human recombinant PIM2 expressed in Escherichia coli using RSRHSSYPAGT as substrate after 30 mins
683,106264,215,CHEMBL2397599,Serine/threonine-protein kinase PIM2,Unspecified,Inhibition of human PIM2 assessed as residual activity using RSRHSSYPAGT as substrate at 1 uM after 30 mins
684,106264,215,CHEMBL2397599,Serine/threonine-protein kinase PIM2,Unspecified,Inhibition of human PIM2 assessed as residual activity using RSRHSSYPAGT as substrate at 10 uM after 30 mins
685,106262,215,CHEMBL2397528,Serine/threonine-protein kinase PIM2,Unspecified,Inhibition of human PIM2 assessed as residual activity using RSRHSSYPAGT as substrate at 1 uM after 30 mins
686,106262,215,CHEMBL2397528,Serine/threonine-protein kinase PIM2,Unspecified,Inhibition of human PIM2 assessed as residual activity using RSRHSSYPAGT as substrate at 10 uM after 30 mins
687,280840,215,CHEMBL408982,Serine/threonine-protein kinase PIM2,Active,"Compound Screen Assay, Human PIM2"
688,280840,215,CHEMBL408982,Serine/threonine-protein kinase PIM2,Unspecified,"Millipore: Percentage of residual kinase activity of PIM2 at 1uM relative to control. Control inhibitor: Staurosporine at 10.0uM. Buffer: 8 mM MOPS pH 7.0, 0.2 mM EDTA"
689,280840,215,CHEMBL408982,Serine/threonine-protein kinase PIM2,Unspecified,"Millipore: Percentage of residual kinase activity of PIM2 at 10uM relative to control. Control inhibitor: Staurosporine at 10.0uM. Buffer: 8 mM MOPS pH 7.0, 0.2 mM EDTA"
690,280840,215,CHEMBL408982,Serine/threonine-protein kinase PIM2,Unspecified,Delta TM value showing the stabilisation of PIM2 produced by compound binding
691,146045,215,CHEMBL3326556,Serine/threonine-protein kinase PIM2,Unspecified,Inhibition of full-length human PIM2 using RSRHSSYPAGT as substrate assessed as residual kinase activity at 10 uM after 30 mins in presence of [gamma-33P]ATP
692,146045,215,CHEMBL3326556,Serine/threonine-protein kinase PIM2,Unspecified,Inhibition of full-length human PIM2 using RSRHSSYPAGT as substrate assessed as residual kinase activity at 1 uM after 30 mins in presence of [gamma-33P]ATP
693,146044,215,CHEMBL3326555,Serine/threonine-protein kinase PIM2,Unspecified,Inhibition of full-length human PIM2 using RSRHSSYPAGT as substrate assessed as residual kinase activity at 10 uM after 30 mins in presence of [gamma-33P]ATP
694,146044,215,CHEMBL3326555,Serine/threonine-protein kinase PIM2,Unspecified,Inhibition of full-length human PIM2 using RSRHSSYPAGT as substrate assessed as residual kinase activity at 1 uM after 30 mins in presence of [gamma-33P]ATP
695,42629,131,CHEMBL1725279,Tyrosine-protein kinase SRC,Inactive,Average Binding Constant for SRC; NA=Not Active at 10 uM
696,42629,131,CHEMBL1725279,Tyrosine-protein kinase SRC,Unspecified,Percentage Src activity remaining in the presence of 1uM inhibitor
697,42629,131,CHEMBL1725279,Tyrosine-protein kinase SRC,Inactive,Luminescence-based cell-based primary high throughput screening assay to identify inhibitors of the Steroid Receptor Coactivator 1 (SRC1; NCOA1)
698,42629,131,CHEMBL1725279,Tyrosine-protein kinase SRC,Unspecified,"Millipore: Percentage of residual kinase activity of SRC at 1uM relative to control. Control inhibitor: Staurosporine at 10.0uM. Buffer: 8 mM MOPS pH 7.0, 0.2 mM EDTA"
699,42629,131,CHEMBL1725279,Tyrosine-protein kinase SRC,Unspecified,"Millipore: Percentage of residual kinase activity of SRC at 10uM relative to control. Control inhibitor: Staurosporine at 10.0uM. Buffer: 8 mM MOPS pH 7.0, 0.2 mM EDTA"
700,42522,215,CHEMBL1721885,Serine/threonine-protein kinase PIM2,Unspecified,Binding constant for PIM2 kinase domain
701,42522,215,CHEMBL1721885,Serine/threonine-protein kinase PIM2,Unspecified,Binding constant for PIM2 kinase domain
702,117364,191,CHEMBL259084,Fibroblast growth factor receptor 4,Unspecified,Activity of human FGFR4 kinase at 1 uM
703,117364,191,CHEMBL259084,Fibroblast growth factor receptor 4,Unspecified,Binding constant for FGFR4 kinase domain
704,117364,191,CHEMBL259084,Fibroblast growth factor receptor 4,Unspecified,Binding constant for FGFR4 kinase domain
705,221090,149,CHEMBL379218,Tyrosine-protein kinase JAK2,Unspecified,Binding constant for JAK2(JH1domain-catalytic) kinase domain
706,332646,165,CHEMBL750,Carbonic anhydrase XII,Active,Inhibition of human cloned CA12 catalytic domain by stopped flow CO2 hydration assay
707,332646,165,CHEMBL750,Carbonic anhydrase XII,Active,Inhibition of human recombinant CA12 by stopped flow CO2 hydrase assay
708,73637,82,CHEMBL2037528,Norepinephrine transporter,Unspecified,Displacement of [3H]Nisoxetine from human NET by liquid scintillation assay
709,91014,86,CHEMBL221692,Serotonin 2c (5-HT2c) receptor,Inactive,Displacement of [3H]mesulergine from 5HT2C receptor expressed in CHO cells
710,86814,14,CHEMBL2177582,Histone deacetylase 6,Unspecified,Inhibition of HDAC6 using p53 (379 to 382 residues) based fluorogenic peptide substrate
711,120763,14,CHEMBL272980,Histone deacetylase 6,Unspecified,Inhibition of HDAC6
712,120763,14,CHEMBL272980,Histone deacetylase 6,Unspecified,Inhibition of HDAC6 in HEK293 cells at 2 uM
713,120763,14,CHEMBL272980,Histone deacetylase 6,Unspecified,Inhibition of human recombinant HDAC6 homogeneous fluorescence release assay
714,120763,14,CHEMBL272980,Histone deacetylase 6,Unspecified,Inhibition of HDAC6
715,120763,14,CHEMBL272980,Histone deacetylase 6,Unspecified,Inhibition of human recombinant HDAC6 expressed in Sf9 cells incubated for 2 hrs using RHKK-Ac fluorogenic substrate
716,120763,14,CHEMBL272980,Histone deacetylase 6,Unspecified,Inhibition of recombinant His-tagged HDAC6 (unknown origin) using Fluor-de-Lys SIRT1 as substrate incubated for 3 hrs prior to substrate addition measured after 60 mins by fluorescence plate reader analysis
717,120763,14,CHEMBL272980,Histone deacetylase 6,Unspecified,Inhibition of His-flagged recombinant HDAC6 (unknown origin) at 20 uM pre-incubated for 1 hr before substrate addition by homogeneous fluorogenic HDAC assay
718,120763,14,CHEMBL272980,Histone deacetylase 6,Unspecified,Inhibition of HDAC6 (unknown origin) using Boc-Lys(acetyl)-AMC as substrate preincubated for 5 mins followed by substrate addition by fluorescence assay
719,120763,14,CHEMBL272980,Histone deacetylase 6,Inactive,Inhibition of HDAC6 in human A549 cells assessed as increase in acetylated tubulin expression at 5 uM incubated for 12 hrs by DAPI staining based immunofluorescence microscopy
720,115234,14,CHEMBL253868,Histone deacetylase 6,Unspecified,Inhibition of HDAC6
721,86816,14,CHEMBL2177588,Histone deacetylase 6,Unspecified,Inhibition of HDAC6 using p53 (379 to 382 residues) based fluorogenic peptide substrate
722,225164,14,CHEMBL3827611,Histone deacetylase 6,Unspecified,Inhibition of human recombinant HDAC6 expressed in baculovirus coexpressed in fall armyworm Sf9 cells using carboxyfluorescein (FAM)-labeled acetylated/ trifluoroacetylated peptide as substrate after 60 mins by fluorescence assay
723,86815,14,CHEMBL2177587,Histone deacetylase 6,Unspecified,Inhibition of HDAC6 using p53 (379 to 382 residues) based fluorogenic peptide substrate
724,102173,14,CHEMBL236902,Histone deacetylase 6,Unspecified,Inhibition of recombinant HDAC6
725,114354,14,CHEMBL251144,Histone deacetylase 6,Unspecified,Inhibition of human HDAC6
726,274369,14,CHEMBL405072,Histone deacetylase 6,Unspecified,Inhibition of HDAC6
727,305289,14,CHEMBL481805,Histone deacetylase 6,Unspecified,Inhibition of HDAC6
728,102020,14,CHEMBL236678,Histone deacetylase 6,Unspecified,Inhibition of HDAC6
729,116240,14,CHEMBL256440,Histone deacetylase 6,Unspecified,Inhibition of HDAC6
730,15379,224,CHEMBL1230020,Serine/threonine-protein kinase Aurora-A,Unspecified,Binding constant for AURKA kinase domain
731,31636,36,CHEMBL1516890,Tyrosine-protein kinase receptor FLT3,Unspecified,GSK_PKIS: FLT3 (D835Y mutant) mean inhibition at 1 uM [Nanosyn]
732,31636,36,CHEMBL1516890,Tyrosine-protein kinase receptor FLT3,Unspecified,GSK_PKIS: FLT3 mean inhibition at 0.1 uM [Nanosyn]
733,31636,36,CHEMBL1516890,Tyrosine-protein kinase receptor FLT3,Unspecified,GSK_PKIS: FLT3 mean inhibition at 1 uM [Nanosyn]
734,31636,36,CHEMBL1516890,Tyrosine-protein kinase receptor FLT3,Unspecified,GSK_PKIS: FLT3 (D835Y mutant) mean inhibition at 0.1 uM [Nanosyn]
735,142663,90,CHEMBL3289656,Serotonin transporter,Unspecified,Displacement of [3H]citalopram from human SERT by PDSP assay
736,36778,86,CHEMBL1632158,Serotonin 2c (5-HT2c) receptor,Unspecified,Binding affinity to 5HT2C receptor
737,245013,84,CHEMBL392760,Serotonin 2a (5-HT2a) receptor,Unspecified,Displacement of [125I]DOI from human 5HT2A receptor expressed in CHO cells at 1 uM
738,3267,79,CHEMBL1081312,Serine/threonine-protein kinase Aurora-B,Unspecified,Inhibition of AURKB at 1 uM after 60 mins by FRET assay in presence of 10 uM ATP
739,163245,14,CHEMBL3605503,Histone deacetylase 6,Unspecified,Inhibition of His-flagged recombinant HDAC6 (unknown origin) at 20 uM pre-incubated for 1 hr before substrate addition by homogeneous fluorogenic HDAC assay
740,107337,14,CHEMBL2407736,Histone deacetylase 6,Unspecified,Inhibition of recombinant His-tagged HDAC6 (unknown origin) using Fluor-de-Lys SIRT1 as substrate incubated for 3 hrs prior to substrate addition measured after 60 mins by fluorescence plate reader analysis
741,51150,14,CHEMBL1812335,Histone deacetylase 6,Unspecified,Inhibition of human HDAC6 using rhodamine as substrate after 1 hrs by fluorescence assay
742,107321,14,CHEMBL2407717,Histone deacetylase 6,Unspecified,Inhibition of recombinant His-tagged HDAC6 (unknown origin) using Fluor-de-Lys SIRT1 as substrate incubated for 3 hrs prior to substrate addition measured after 60 mins by fluorescence plate reader analysis
743,163224,14,CHEMBL3605417,Histone deacetylase 6,Unspecified,Inhibition of His-flagged recombinant HDAC6 (unknown origin) at 20 uM pre-incubated for 1 hr before substrate addition by homogeneous fluorogenic HDAC assay
744,163222,14,CHEMBL3605415,Histone deacetylase 6,Unspecified,Inhibition of His-flagged recombinant HDAC6 (unknown origin) at 20 uM pre-incubated for 1 hr before substrate addition by homogeneous fluorogenic HDAC assay
745,107327,14,CHEMBL2407723,Histone deacetylase 6,Inconclusive,Inhibition of recombinant His-tagged HDAC6 (unknown origin) using Fluor-de-Lys SIRT1 as substrate incubated for 3 hrs prior to substrate addition measured after 60 mins by fluorescence plate reader analysis
746,330871,90,CHEMBL657,Serotonin transporter,Unspecified,"DRUGMATRIX: Transporter, Serotonin (5-Hydroxytryptamine) (SERT) radioligand binding (ligand: [3H] Paroxetine)"
747,330871,90,CHEMBL657,Serotonin transporter,Unspecified,"DRUGMATRIX: Transporter, Serotonin (5-Hydroxytryptamine) (SERT) radioligand binding (ligand: [3H] Paroxetine)"
748,57881,154,CHEMBL1908395,Cyclin-dependent kinase 2,Unspecified,Binding constant for CDK2 kinase domain
749,147374,162,CHEMBL3337894,Matrix metalloproteinase 9,Unspecified,Inhibition of human recombinant MMP9 using fluorescence peptide Cy3-PLGLK(Cy5Q)AR-NH2 substrate by fluorescence assay
750,917,199,CHEMBL103667,Fibroblast growth factor receptor 2,Inactive,Average Binding Constant for FGFR2; NA=Not Active at 10 uM
751,917,199,CHEMBL103667,Fibroblast growth factor receptor 2,Unspecified,Binding constant for FGFR2 kinase domain
752,917,199,CHEMBL103667,Fibroblast growth factor receptor 2,Unspecified,Binding constant for FGFR2 kinase domain
753,917,199,CHEMBL103667,Fibroblast growth factor receptor 2,Active,Inhibition of FGFR2
754,329526,84,CHEMBL60889,Serotonin 2a (5-HT2a) receptor,Unspecified,DRUGMATRIX: Serotonin (5-Hydroxytryptamine) 5-HT2A radioligand binding (ligand: [3H] Ketanserin)
755,329526,84,CHEMBL60889,Serotonin 2a (5-HT2a) receptor,Unspecified,DRUGMATRIX: Serotonin (5-Hydroxytryptamine) 5-HT2A radioligand binding (ligand: [3H] Ketanserin)
756,224517,86,CHEMBL3819556,Serotonin 2c (5-HT2c) receptor,Active,Displacement of [3H]Mesulergine from rat 5-HT2C receptor expressed in cell membranes after 1 hr by liquid scintillation counting
757,224517,86,CHEMBL3819556,Serotonin 2c (5-HT2c) receptor,Active,Displacement of [3H]Mesulergine from rat 5-HT2C receptor expressed in cell membranes after 1 hr by liquid scintillation counting
758,4534,31,CHEMBL1084546,Stem cell growth factor receptor,Active,"Human fms related tyrosine kinase 3 (Type III RTKs: PDGFR, CSFR, Kit, FLT3 receptor family)"
759,314179,202,CHEMBL522892,MAP kinase signal-integrating kinase 2,Unspecified,Binding constant for MKNK2 kinase domain
760,314179,202,CHEMBL522892,MAP kinase signal-integrating kinase 2,Unspecified,Binding constant for MKNK2 kinase domain
761,15946,128,CHEMBL1241674,Glycogen synthase kinase-3 beta,Unspecified,Binding constant for GSK3B kinase domain
762,85057,86,CHEMBL2164350,Serotonin 2c (5-HT2c) receptor,Unspecified,Binding affinity to 5HT2C receptor at 10 uM by radioligand binding assay
763,85061,86,CHEMBL2164354,Serotonin 2c (5-HT2c) receptor,Unspecified,Binding affinity to 5HT2C receptor at 10 uM by radioligand binding assay
764,122141,177,CHEMBL280998,Carbonic anhydrase IX,Unspecified,Inhibition of human CA9 by stopped-flow CO2 hydration assay
765,250400,138,CHEMBL3939150,Vascular endothelial growth factor receptor 2,Active,Inhibition of Tel-fused VEGFR2 (unknown origin) expressed in BAF3 cells assessed as growth inhibition measured after 72 hrs by CellTiter-Glo or CCK8 assay
766,294641,178,CHEMBL428690,Fibroblast growth factor receptor 1,Inactive,Average Binding Constant for FGFR1; NA=Not Active at 10 uM
767,294641,178,CHEMBL428690,Fibroblast growth factor receptor 1,Unspecified,Binding constant for FGFR1 kinase domain
768,294641,178,CHEMBL428690,Fibroblast growth factor receptor 1,Unspecified,Binding constant for FGFR1 kinase domain
769,317650,11,CHEMBL553,Macrophage colony stimulating factor receptor,Unspecified,Binding constant for CSF1R kinase domain
770,317650,11,CHEMBL553,Macrophage colony stimulating factor receptor,Unspecified,Binding constant for CSF1R kinase domain
771,317650,11,CHEMBL553,Macrophage colony stimulating factor receptor,Unspecified,Inhibition of CSF1R (unknown origin) at 500 nM
772,317650,11,CHEMBL553,Macrophage colony stimulating factor receptor,Unspecified,Inhibition of His tagged recombinant human FMS cytoplasmic domain (538 to 910 residues) expressed in baculovirus at 500 nM by Z'-LYTE assay
773,321759,178,CHEMBL569880,Fibroblast growth factor receptor 1,Unspecified,Inhibition of FGFR1
774,6430,73,CHEMBL1090360,Tyrosine-protein kinase JAK3,Unspecified,Inhibition of JAK3
775,57882,178,CHEMBL1908396,Fibroblast growth factor receptor 1,Unspecified,Binding constant for FGFR1 kinase domain
776,308892,84,CHEMBL496,Serotonin 2a (5-HT2a) receptor,Inactive,Luminescence-based cell-based primary high throughput screening assay to identify agonists of the mouse 5-hydroxytryptamine (serotonin) receptor 2A (HTR2A)
777,308892,84,CHEMBL496,Serotonin 2a (5-HT2a) receptor,Unspecified,DRUGMATRIX: Serotonin (5-Hydroxytryptamine) 5-HT2A radioligand binding (ligand: [3H] Ketanserin)
778,308892,84,CHEMBL496,Serotonin 2a (5-HT2a) receptor,Unspecified,DRUGMATRIX: Serotonin (5-Hydroxytryptamine) 5-HT2A radioligand binding (ligand: [3H] Ketanserin)
779,135871,11,CHEMBL31965,Macrophage colony stimulating factor receptor,Unspecified,Binding constant for CSF1R kinase domain
780,135871,11,CHEMBL31965,Macrophage colony stimulating factor receptor,Unspecified,Binding constant for CSF1R kinase domain
781,276549,79,CHEMBL4069365,Serine/threonine-protein kinase Aurora-B,Unspecified,Inhibition of AURKB (unknown origin) after 60 mins by TR-FRET assay
782,310264,72,CHEMBL502835,Serine/threonine-protein kinase PIM1,Unspecified,Binding constant for PIM1 kinase domain
783,131542,84,CHEMBL311469,Serotonin 2a (5-HT2a) receptor,Unspecified,DRUGMATRIX: Serotonin (5-Hydroxytryptamine) 5-HT2A radioligand binding (ligand: [3H] Ketanserin)
784,131542,84,CHEMBL311469,Serotonin 2a (5-HT2a) receptor,Unspecified,DRUGMATRIX: Serotonin (5-Hydroxytryptamine) 5-HT2A radioligand binding (ligand: [3H] Ketanserin)
785,74455,170,CHEMBL2047536,Matrix metalloproteinase-2,Unspecified,Inhibition of human recombinant MMP2 using MCA-Pro-Leu-Gly-Leu-Dpa-Ala-Arg-NH2.AcOH as substrate preincubated for 10 mins measured by fluorescence analysis
786,74455,170,CHEMBL2047536,Matrix metalloproteinase-2,Unspecified,Selectivity ratio of IC50 for human recombinant MMP2 to IC50 for human recombinant MMP13
787,917,79,CHEMBL103667,Serine/threonine-protein kinase Aurora-B,Unspecified,Binding constant for AURKB kinase domain
788,917,79,CHEMBL103667,Serine/threonine-protein kinase Aurora-B,Unspecified,Binding constant for AURKB kinase domain
789,81171,150,CHEMBL21156,Rho-associated protein kinase 2,Unspecified,"Millipore: Percentage of residual kinase activity of ROCK2 at 1uM relative to control. Control inhibitor: Staurosporine at 10.0uM. Buffer: 50 mM Tris pH 7.5, 0.1 mM EGTA"
790,81171,150,CHEMBL21156,Rho-associated protein kinase 2,Unspecified,"Millipore: Percentage of residual kinase activity of ROCK2 at 10uM relative to control. Control inhibitor: Staurosporine at 10.0uM. Buffer: 50 mM Tris pH 7.5, 0.1 mM EGTA"
791,110242,86,CHEMBL2432051,Serotonin 2c (5-HT2c) receptor,Unspecified,Inhibition of 5-HT2C receptor (unknown origin) at 10 uM by PDSP assay relative to control
792,294641,123,CHEMBL428690,Tyrosine-protein kinase LCK,Active,Inhibition of p56 Lck tyrosine kinase
793,294641,123,CHEMBL428690,Tyrosine-protein kinase LCK,Inactive,Average Binding Constant for LCK; NA=Not Active at 10 uM
794,294641,123,CHEMBL428690,Tyrosine-protein kinase LCK,Unspecified,Binding constant for LCK kinase domain
795,294641,123,CHEMBL428690,Tyrosine-protein kinase LCK,Unspecified,Binding constant for LCK kinase domain
796,310264,202,CHEMBL502835,MAP kinase signal-integrating kinase 2,Unspecified,Binding constant for MKNK2 kinase domain
797,330665,90,CHEMBL648,Serotonin transporter,Unspecified,"DRUGMATRIX: Transporter, Serotonin (5-Hydroxytryptamine) (SERT) radioligand binding (ligand: [3H] Paroxetine)"
798,330665,90,CHEMBL648,Serotonin transporter,Unspecified,"DRUGMATRIX: Transporter, Serotonin (5-Hydroxytryptamine) (SERT) radioligand binding (ligand: [3H] Paroxetine)"
799,122416,84,CHEMBL282199,Serotonin 2a (5-HT2a) receptor,Unspecified,Binding affinity to 5HT2A receptor in rat cortex
800,122416,84,CHEMBL282199,Serotonin 2a (5-HT2a) receptor,Active,Displacement of [3H]-ketanserin from human 5-HT2A receptor expressed in HEK293 cells
801,328242,128,CHEMBL601719,Glycogen synthase kinase-3 beta,Unspecified,Binding constant for GSK3B kinase domain
802,42629,13,CHEMBL1725279,Tyrosine-protein kinase ABL,Inactive,Average Binding Constant for ABL1; NA=Not Active at 10 uM
803,42629,13,CHEMBL1725279,Tyrosine-protein kinase ABL,Inactive,Average Binding Constant for ABL1(Q252H); NA=Not Active at 10 uM
804,42629,13,CHEMBL1725279,Tyrosine-protein kinase ABL,Inactive,Average Binding Constant for ABL1(E255K); NA=Not Active at 10 uM
805,42629,13,CHEMBL1725279,Tyrosine-protein kinase ABL,Inactive,Average Binding Constant for ABL1(H396P); NA=Not Active at 10 uM
806,42629,13,CHEMBL1725279,Tyrosine-protein kinase ABL,Inactive,Average Binding Constant for ABL1(M351T); NA=Not Active at 10 uM
807,42629,13,CHEMBL1725279,Tyrosine-protein kinase ABL,Inactive,Average Binding Constant for ABL1(T315I); NA=Not Active at 10 uM
808,42629,13,CHEMBL1725279,Tyrosine-protein kinase ABL,Inactive,Average Binding Constant for ABL1(Y253F); NA=Not Active at 10 uM
809,42629,13,CHEMBL1725279,Tyrosine-protein kinase ABL,Inactive,"TRFRET-based biochemical primary high throughput screening assay to identify inhibitors of the interaction of the Ras and Rab interactor 1 protein (Rin1) and the c-abl oncogene 1, non-receptor tyrosine kinase (Abl)"
810,42629,13,CHEMBL1725279,Tyrosine-protein kinase ABL,Inactive,"TRFRET-based biochemical primary high throughput screening assay to identify inhibitors of the interaction of the Ras and Rab interactor 1 protein (Rin1) and the c-abl oncogene 1, non-receptor tyrosine kinase (Abl)"
811,42629,13,CHEMBL1725279,Tyrosine-protein kinase ABL,Unspecified,"Millipore: Percentage of residual kinase activity of ABL1 at 1uM relative to control. Control inhibitor: Staurosporine at 10.0uM. Buffer: 8 mM MOPS pH 7.0, 0.2 mM EDTA"
812,42629,13,CHEMBL1725279,Tyrosine-protein kinase ABL,Unspecified,"Millipore: Percentage of residual kinase activity of ABL1 at 10uM relative to control. Control inhibitor: Staurosporine at 10.0uM. Buffer: 8 mM MOPS pH 7.0, 0.2 mM EDTA"
813,31601,82,CHEMBL1516187,Norepinephrine transporter,Active,Displacement of [3H]nisoxetine from Sprague-Dawley rat brain NET after 180 mins by liquid scintillation counting analysis
814,309630,82,CHEMBL498566,Norepinephrine transporter,Unspecified,Binding affinity at NET
815,329615,82,CHEMBL609908,Norepinephrine transporter,Unspecified,Displacement of [125I]nisoxetine from human NET transfected in human HEK293 cells
816,329615,82,CHEMBL609908,Norepinephrine transporter,Unspecified,Selectivity ratio of IC50 for human NET to IC50 for human SERT
817,974,82,CHEMBL103936,Norepinephrine transporter,Active,Displacement of [125I]RTI55 from human NET expressed in COS1 cell membrane
818,974,82,CHEMBL103936,Norepinephrine transporter,Inconclusive,Inhibition of [3H]DA uptake in human NET expressed in COS1 cell membrane
819,308101,82,CHEMBL493369,Norepinephrine transporter,Unspecified,Binding affinity at NET
820,314899,82,CHEMBL526849,Norepinephrine transporter,Unspecified,Binding affinity at NET
821,146815,82,CHEMBL3331486,Norepinephrine transporter,Unspecified,Inhibition of human NET expressed in HEK293 cells at 0.1 uM incubated for 15 mins by neurotransmitter reuptake assay
822,146815,82,CHEMBL3331486,Norepinephrine transporter,Active,Inhibition of human NET expressed in HEK293 cells at incubated for 15 mins by neurotransmitter reuptake assay
823,146815,82,CHEMBL3331486,Norepinephrine transporter,Unspecified,"Selectivity index, ratio of IC50 for human NET to IC50 for human SERT"
824,72165,82,CHEMBL2030637,Norepinephrine transporter,Unspecified,Inhibition of NET at 10 uM
825,146818,82,CHEMBL3331501,Norepinephrine transporter,Unspecified,Inhibition of human NET expressed in HEK293 cells at 0.1 uM incubated for 15 mins by neurotransmitter reuptake assay
826,146818,82,CHEMBL3331501,Norepinephrine transporter,Active,Inhibition of human NET expressed in HEK293 cells at incubated for 15 mins by neurotransmitter reuptake assay
827,146818,82,CHEMBL3331501,Norepinephrine transporter,Unspecified,"Selectivity index, ratio of IC50 for human NET to IC50 for human SERT"
828,146817,82,CHEMBL3331500,Norepinephrine transporter,Unspecified,Inhibition of human NET expressed in HEK293 cells at 0.1 uM incubated for 15 mins by neurotransmitter reuptake assay
829,146817,82,CHEMBL3331500,Norepinephrine transporter,Active,Inhibition of human NET expressed in HEK293 cells at incubated for 15 mins by neurotransmitter reuptake assay
830,146817,82,CHEMBL3331500,Norepinephrine transporter,Unspecified,"Selectivity index, ratio of IC50 for human NET to IC50 for human SERT"
831,309628,82,CHEMBL498564,Norepinephrine transporter,Unspecified,Binding affinity at NET
832,132889,82,CHEMBL3126730,Norepinephrine transporter,Active,Displacement of [3H]nisoxetine from Sprague-Dawley rat brain NET after 180 mins by liquid scintillation counting analysis
833,132892,82,CHEMBL3126751,Norepinephrine transporter,Active,Displacement of [3H]nisoxetine from Sprague-Dawley rat brain NET after 180 mins by liquid scintillation counting analysis
834,58003,202,CHEMBL191003,MAP kinase signal-integrating kinase 2,Unspecified,Binding constant for MKNK2 kinase domain
835,58003,202,CHEMBL191003,MAP kinase signal-integrating kinase 2,Unspecified,"Millipore: Percentage of residual kinase activity of MKNK2 at 1uM relative to control. Control inhibitor: Staurosporine at 10.0uM. Buffer: 8 mM MOPS pH 7.0, 0.2 mM EDTA"
836,58003,202,CHEMBL191003,MAP kinase signal-integrating kinase 2,Unspecified,"Millipore: Percentage of residual kinase activity of MKNK2 at 10uM relative to control. Control inhibitor: Staurosporine at 10.0uM. Buffer: 8 mM MOPS pH 7.0, 0.2 mM EDTA"
837,336075,149,CHEMBL91829,Tyrosine-protein kinase JAK2,Inactive,Average Binding Constant for JAK2 (Kin.Dom. 2); NA=Not Active at 10 uM
838,336075,149,CHEMBL91829,Tyrosine-protein kinase JAK2,Unspecified,Binding constant for JAK2(Kin.Dom.2/JH1 - catalytic) kinase domain
839,336075,149,CHEMBL91829,Tyrosine-protein kinase JAK2,Unspecified,Binding constant for JAK2(JH1domain-catalytic) kinase domain
840,332779,90,CHEMBL7568,Serotonin transporter,Unspecified,"DRUGMATRIX: Transporter, Serotonin (5-Hydroxytryptamine) (SERT) radioligand binding (ligand: [3H] Paroxetine)"
841,332779,90,CHEMBL7568,Serotonin transporter,Unspecified,"DRUGMATRIX: Transporter, Serotonin (5-Hydroxytryptamine) (SERT) radioligand binding (ligand: [3H] Paroxetine)"
842,6433,48,CHEMBL1090363,Epidermal growth factor receptor erbB1,Active,Inhibition of EGFR L858R mutant by time resolved fluorescence assay
843,6433,48,CHEMBL1090363,Epidermal growth factor receptor erbB1,Active,Inhibition of EGFR L858R mutant by time resolved fluorescence assay
844,6433,48,CHEMBL1090363,Epidermal growth factor receptor erbB1,Active,Inhibition of EGFR L858R mutant by time resolved fluorescence assay
845,6433,48,CHEMBL1090363,Epidermal growth factor receptor erbB1,Active,Inhibition of EGFR L858R mutant by time resolved fluorescence assay
846,110665,86,CHEMBL243712,Serotonin 2c (5-HT2c) receptor,Inactive,Displacement of [3H]mesulergine from 5HT2C receptor expressed in CHO cells
847,83102,131,CHEMBL215152,Tyrosine-protein kinase SRC,Unspecified,Inhibition of human recombinant SRC
848,83102,131,CHEMBL215152,Tyrosine-protein kinase SRC,Unspecified,Binding constant for SRC kinase domain
849,83102,131,CHEMBL215152,Tyrosine-protein kinase SRC,Unspecified,Binding constant for SRC kinase domain
850,18919,38,CHEMBL12713,Serotonin 1d (5-HT1d) receptor,Active,Antagonists at Human 5-Hydroxytryptamine receptor 5-HT1D
851,18919,38,CHEMBL12713,Serotonin 1d (5-HT1d) receptor,Active,Human 5-HT1D receptor (5-Hydroxytryptamine receptors)
852,73007,73,CHEMBL2035042,Tyrosine-protein kinase JAK3,Unspecified,"Inhibition of recombinant JAK3 using poly(Glu,Ala,Tyr) as substrate after 2 hrs by luminometric assay"
853,73012,73,CHEMBL2035047,Tyrosine-protein kinase JAK3,Unspecified,"Inhibition of recombinant JAK3 using poly(Glu,Ala,Tyr) as substrate after 2 hrs by luminometric assay"
854,73009,73,CHEMBL2035044,Tyrosine-protein kinase JAK3,Unspecified,"Inhibition of recombinant JAK3 using poly(Glu,Ala,Tyr) as substrate after 2 hrs by luminometric assay"
855,329465,149,CHEMBL608154,Tyrosine-protein kinase JAK2,Unspecified,Binding constant for JAK2(JH1domain-catalytic) kinase domain
856,322560,199,CHEMBL572881,Fibroblast growth factor receptor 2,Unspecified,Binding constant for FGFR2 kinase domain
857,322560,199,CHEMBL572881,Fibroblast growth factor receptor 2,Unspecified,Binding constant for FGFR2 kinase domain
858,15946,180,CHEMBL1241674,Hepatocyte growth factor receptor,Unspecified,Inhibition of MET at 1 uM after 60 mins by FRET assay in presence of 10 uM ATP
859,15946,180,CHEMBL1241674,Hepatocyte growth factor receptor,Unspecified,Inhibition of MET M1250T mutant at 1 uM after 60 mins by FRET assay in presence of 10 uM ATP
860,15946,180,CHEMBL1241674,Hepatocyte growth factor receptor,Unspecified,Binding constant for MET kinase domain
861,15946,180,CHEMBL1241674,Hepatocyte growth factor receptor,Unspecified,Binding constant for MET(M1250T) kinase domain
862,15946,180,CHEMBL1241674,Hepatocyte growth factor receptor,Unspecified,Binding constant for MET(Y1235D) kinase domain
863,300657,149,CHEMBL460472,Tyrosine-protein kinase JAK2,Active,Inhibition of JAK2
864,329496,155,CHEMBL608533,Cyclin-dependent kinase 1,Unspecified,"Millipore: Percentage of residual kinase activity of CDK1 at 1uM relative to control. Control inhibitor: Staurosporine at 10.0uM. Buffer: 8 mM MOPS pH 7.0, 0.2 mM EDTA"
865,329496,155,CHEMBL608533,Cyclin-dependent kinase 1,Unspecified,"Millipore: Percentage of residual kinase activity of CDK1 at 1uM relative to control. Control inhibitor: Staurosporine at 10.0uM. Buffer: 8 mM MOPS pH 7.0, 0.2 mM EDTA"
866,329496,155,CHEMBL608533,Cyclin-dependent kinase 1,Unspecified,"Millipore: Percentage of residual kinase activity of CDK1 at 10uM relative to control. Control inhibitor: Staurosporine at 10.0uM. Buffer: 8 mM MOPS pH 7.0, 0.2 mM EDTA"
867,329496,155,CHEMBL608533,Cyclin-dependent kinase 1,Unspecified,"Millipore: Percentage of residual kinase activity of CDK1 at 10uM relative to control. Control inhibitor: Staurosporine at 10.0uM. Buffer: 8 mM MOPS pH 7.0, 0.2 mM EDTA"
868,164347,149,CHEMBL3613597,Tyrosine-protein kinase JAK2,Unspecified,Inhibition of JAK2 (unknown origin) at 10 uM
869,190904,149,CHEMBL3675693,Tyrosine-protein kinase JAK2,Active,"Inhibition Assay: To determine the inhibition constants (Ki) of Examples 1-240, compounds were diluted serially in DMSO and added to 50 &#x3BC;L kinase reactions containing 1.5 nM JAK1, 0.2 nM purified JAK2 or 1 nM purified TYK2 enzyme, 100 mM Hepes pH7.2, 0.015% Brij-35, 1.5 &#x3BC;M peptide substrate, 25 &#x3BC;M ATP, 10 mM MgCl2, 4 mM DTT at a final DMSO concentration of 2%. Reactions were incubated at 22&#xB0; C. in 384-well polypropylene microtiter plates for 30 minutes and then stopped by addition of 25 &#x3BC;L of an EDTA containing solution (100 mM Hepes pH 7.2, 0.015% Brij-35, 150 mM EDTA), resulting in a final EDTA concentration of 50 mM. Ki values were then determined using the Morrison tight binding model. Morrison, J. F., Biochim. Biophys. Acta. 185:269-296 (1969); William, J. W. and Morrison, J. F., Meth. Enzymol., 63:437-467 (1979)."
870,190904,149,CHEMBL3675693,Tyrosine-protein kinase JAK2,Active,"Inhibition Assay: To determine the inhibition constants (Ki) of Examples 1-240, compounds were diluted serially in DMSO and added to 50 &#x3BC;L kinase reactions containing 1.5 nM JAK1, 0.2 nM purified JAK2 or 1 nM purified TYK2 enzyme, 100 mM Hepes pH7.2, 0.015% Brij-35, 1.5 &#x3BC;M peptide substrate, 25 &#x3BC;M ATP, 10 mM MgCl2, 4 mM DTT at a final DMSO concentration of 2%. Reactions were incubated at 22&#xB0; C. in 384-well polypropylene microtiter plates for 30 minutes and then stopped by addition of 25 &#x3BC;L of an EDTA containing solution (100 mM Hepes pH 7.2, 0.015% Brij-35, 150 mM EDTA), resulting in a final EDTA concentration of 50 mM. Ki values were then determined using the Morrison tight binding model. Morrison, J. F., Biochim. Biophys. Acta. 185:269-296 (1969); William, J. W. and Morrison, J. F., Meth. Enzymol., 63:437-467 (1979)."
871,312558,71,CHEMBL516,Serotonin 1a (5-HT1a) receptor,Active,DRUGMATRIX: Serotonin (5-Hydroxytryptamine) 5-HT1A radioligand binding (ligand: [3H] 8-OH-DPAT)
872,312558,71,CHEMBL516,Serotonin 1a (5-HT1a) receptor,Active,DRUGMATRIX: Serotonin (5-Hydroxytryptamine) 5-HT1A radioligand binding (ligand: [3H] 8-OH-DPAT)
873,226377,224,CHEMBL386051,Serine/threonine-protein kinase Aurora-A,Unspecified,Binding constant for AURKA kinase domain
874,57881,202,CHEMBL1908395,MAP kinase signal-integrating kinase 2,Unspecified,Binding constant for MKNK2 kinase domain
875,248900,158,CHEMBL3935857,PI3-kinase p110-delta subunit,Active,Inhibition of PI3Kdelta (unknown origin)
876,153226,158,CHEMBL3401255,PI3-kinase p110-delta subunit,Active,"Inhibition of recombinant PI3Kdelta (unknown origin) using PI(3,4)P2 as substrate after 3 hrs incubation by competitive fluorescence polarization kinase activity assay"
877,97971,158,CHEMBL2326965,PI3-kinase p110-delta subunit,Active,Inhibition of PI3K p110delta (unknown origin)
878,292920,170,CHEMBL421699,Matrix metalloproteinase-2,Inconclusive,Inhibition of MMP2 (unknown origin)
879,19427,138,CHEMBL1276179,Vascular endothelial growth factor receptor 2,Unspecified,Inhibition of KDR at 1 uM
880,6420,48,CHEMBL1090350,Epidermal growth factor receptor erbB1,Active,Inhibition of EGFR L858R mutant by time resolved fluorescence assay
881,6420,48,CHEMBL1090350,Epidermal growth factor receptor erbB1,Active,Inhibition of EGFR L858R mutant by time resolved fluorescence assay
882,6420,48,CHEMBL1090350,Epidermal growth factor receptor erbB1,Active,Inhibition of EGFR L858R mutant by time resolved fluorescence assay
883,6420,48,CHEMBL1090350,Epidermal growth factor receptor erbB1,Active,Inhibition of EGFR L858R mutant by time resolved fluorescence assay
884,6422,48,CHEMBL1090352,Epidermal growth factor receptor erbB1,Active,Inhibition of EGFR L858R mutant by time resolved fluorescence assay
885,6422,48,CHEMBL1090352,Epidermal growth factor receptor erbB1,Active,Inhibition of EGFR L858R mutant by time resolved fluorescence assay
886,6422,48,CHEMBL1090352,Epidermal growth factor receptor erbB1,Active,Inhibition of EGFR L858R mutant by time resolved fluorescence assay
887,6422,48,CHEMBL1090352,Epidermal growth factor receptor erbB1,Active,Inhibition of EGFR L858R mutant by time resolved fluorescence assay
888,6425,48,CHEMBL1090355,Epidermal growth factor receptor erbB1,Active,Inhibition of EGFR L858R mutant by time resolved fluorescence assay
889,6425,48,CHEMBL1090355,Epidermal growth factor receptor erbB1,Active,Inhibition of EGFR L858R mutant by time resolved fluorescence assay
890,6425,48,CHEMBL1090355,Epidermal growth factor receptor erbB1,Active,Inhibition of EGFR L858R mutant by time resolved fluorescence assay
891,6425,48,CHEMBL1090355,Epidermal growth factor receptor erbB1,Active,Inhibition of EGFR L858R mutant by time resolved fluorescence assay
892,6424,48,CHEMBL1090354,Epidermal growth factor receptor erbB1,Active,Inhibition of EGFR L858R mutant by time resolved fluorescence assay
893,6424,48,CHEMBL1090354,Epidermal growth factor receptor erbB1,Active,Inhibition of EGFR L858R mutant by time resolved fluorescence assay
894,6424,48,CHEMBL1090354,Epidermal growth factor receptor erbB1,Active,Inhibition of EGFR L858R mutant by time resolved fluorescence assay
895,6424,48,CHEMBL1090354,Epidermal growth factor receptor erbB1,Active,Inhibition of EGFR L858R mutant by time resolved fluorescence assay
896,6423,48,CHEMBL1090353,Epidermal growth factor receptor erbB1,Active,Inhibition of EGFR L858R mutant by time resolved fluorescence assay
897,6423,48,CHEMBL1090353,Epidermal growth factor receptor erbB1,Active,Inhibition of EGFR L858R mutant by time resolved fluorescence assay
898,6423,48,CHEMBL1090353,Epidermal growth factor receptor erbB1,Active,Inhibition of EGFR L858R mutant by time resolved fluorescence assay
899,6423,48,CHEMBL1090353,Epidermal growth factor receptor erbB1,Active,Inhibition of EGFR L858R mutant by time resolved fluorescence assay
900,6001,48,CHEMBL1088931,Epidermal growth factor receptor erbB1,Active,Inhibition of EGFR L858R mutant by time resolved fluorescence assay
901,6001,48,CHEMBL1088931,Epidermal growth factor receptor erbB1,Active,Inhibition of EGFR L858R mutant by time resolved fluorescence assay
902,6001,48,CHEMBL1088931,Epidermal growth factor receptor erbB1,Active,Inhibition of EGFR L858R mutant by time resolved fluorescence assay
903,6001,48,CHEMBL1088931,Epidermal growth factor receptor erbB1,Active,Inhibition of EGFR L858R mutant by time resolved fluorescence assay
904,63994,86,CHEMBL1949930,Serotonin 2c (5-HT2c) receptor,Unspecified,Inhibition of human 5HT2C at 10 uM
905,63994,86,CHEMBL1949930,Serotonin 2c (5-HT2c) receptor,Active,Inhibition of human 5HT2C
906,311049,79,CHEMBL50894,Serine/threonine-protein kinase Aurora-B,Unspecified,"Millipore: Percentage of residual kinase activity of AURKB at 1uM relative to control. Control inhibitor: Staurosporine at 10.0uM. Buffer: 8 mM MOPS pH 7.0, 0.2 mM EDTA, 50 mM NaCl, 0.1% v/v Triton-X-100"
907,311049,79,CHEMBL50894,Serine/threonine-protein kinase Aurora-B,Unspecified,"Millipore: Percentage of residual kinase activity of AURKB at 10uM relative to control. Control inhibitor: Staurosporine at 10.0uM. Buffer: 8 mM MOPS pH 7.0, 0.2 mM EDTA, 50 mM NaCl, 0.1% v/v Triton-X-100"
908,15417,154,CHEMBL1230609,Cyclin-dependent kinase 2,Unspecified,Binding constant for CDK2 kinase domain
909,110246,86,CHEMBL2432058,Serotonin 2c (5-HT2c) receptor,Unspecified,Inhibition of 5-HT2C receptor (unknown origin) at 10 uM by PDSP assay relative to control
910,318723,73,CHEMBL558752,Tyrosine-protein kinase JAK3,Unspecified,Binding constant for JAK3(Kin.Dom.2/JH1 - catalytic) kinase domain
911,318723,73,CHEMBL558752,Tyrosine-protein kinase JAK3,Unspecified,Binding constant for JAK3(JH1domain-catalytic) kinase domain
912,15946,150,CHEMBL1241674,Rho-associated protein kinase 2,Unspecified,Inhibition of ROCK2 at 1 uM after 60 mins by FRET assay in presence of 10 uM ATP
913,15946,150,CHEMBL1241674,Rho-associated protein kinase 2,Unspecified,Binding constant for ROCK2 kinase domain
914,125603,149,CHEMBL300138,Tyrosine-protein kinase JAK2,Unspecified,Binding constant for JAK2(JH1domain-catalytic) kinase domain
915,308297,138,CHEMBL494089,Vascular endothelial growth factor receptor 2,Unspecified,Binding constant for VEGFR2 kinase domain
916,3267,73,CHEMBL1081312,Tyrosine-protein kinase JAK3,Unspecified,Inhibition of JAK3 at 1 uM after 60 mins by FRET assay in presence of 10 uM ATP
917,322559,72,CHEMBL572878,Serine/threonine-protein kinase PIM1,Unspecified,Binding affinity to human PIM1 at 10 uM relative to control
918,322559,72,CHEMBL572878,Serine/threonine-protein kinase PIM1,Unspecified,Percentage PIM1 activity remaining in the presence of 1uM inhibitor
919,322559,72,CHEMBL572878,Serine/threonine-protein kinase PIM1,Unspecified,Binding constant for PIM1 kinase domain
920,322559,72,CHEMBL572878,Serine/threonine-protein kinase PIM1,Unspecified,Binding constant for PIM1 kinase domain
921,67591,149,CHEMBL1990583,Tyrosine-protein kinase JAK2,Unspecified,Inhibition of Jak2 in presence of 10 uM ATP
922,15417,72,CHEMBL1230609,Serine/threonine-protein kinase PIM1,Unspecified,Binding constant for PIM1 kinase domain
923,17772,84,CHEMBL1258671,Serotonin 2a (5-HT2a) receptor,Unspecified,Selectivity ratio Ki for human 5-HT2A receptor to Ki for human 5HT4 receptor
924,17772,84,CHEMBL1258671,Serotonin 2a (5-HT2a) receptor,Unspecified,Binding affinity to human 5-HT2A receptor
925,309857,169,CHEMBL50,Matrix metalloproteinase-1,Inconclusive,Inhibition of human recombinant MMP1 catalytic domain incubated for 20 mins by fluorimetric assay
926,7340,48,CHEMBL1093234,Epidermal growth factor receptor erbB1,Active,Inhibition of EGFR L858R mutant by time resolved fluorescence assay
927,7340,48,CHEMBL1093234,Epidermal growth factor receptor erbB1,Active,Inhibition of EGFR L858R mutant by time resolved fluorescence assay
928,7340,48,CHEMBL1093234,Epidermal growth factor receptor erbB1,Active,Inhibition of EGFR L858R mutant by time resolved fluorescence assay
929,7340,48,CHEMBL1093234,Epidermal growth factor receptor erbB1,Active,Inhibition of EGFR L858R mutant by time resolved fluorescence assay
930,6817,48,CHEMBL1091613,Epidermal growth factor receptor erbB1,Active,Inhibition of EGFR L858R mutant by time resolved fluorescence assay
931,6817,48,CHEMBL1091613,Epidermal growth factor receptor erbB1,Active,Inhibition of EGFR L858R mutant by time resolved fluorescence assay
932,6817,48,CHEMBL1091613,Epidermal growth factor receptor erbB1,Active,Inhibition of EGFR L858R mutant by time resolved fluorescence assay
933,6817,48,CHEMBL1091613,Epidermal growth factor receptor erbB1,Active,Inhibition of EGFR L858R mutant by time resolved fluorescence assay
934,7498,48,CHEMBL1093815,Epidermal growth factor receptor erbB1,Active,Inhibition of EGFR L858R mutant by time resolved fluorescence assay
935,7498,48,CHEMBL1093815,Epidermal growth factor receptor erbB1,Active,Inhibition of EGFR L858R mutant by time resolved fluorescence assay
936,7498,48,CHEMBL1093815,Epidermal growth factor receptor erbB1,Active,Inhibition of EGFR L858R mutant by time resolved fluorescence assay
937,7498,48,CHEMBL1093815,Epidermal growth factor receptor erbB1,Active,Inhibition of EGFR L858R mutant by time resolved fluorescence assay
938,7341,48,CHEMBL1093235,Epidermal growth factor receptor erbB1,Active,Inhibition of EGFR L858R mutant by time resolved fluorescence assay
939,7341,48,CHEMBL1093235,Epidermal growth factor receptor erbB1,Active,Inhibition of EGFR L858R mutant by time resolved fluorescence assay
940,7341,48,CHEMBL1093235,Epidermal growth factor receptor erbB1,Active,Inhibition of EGFR L858R mutant by time resolved fluorescence assay
941,7341,48,CHEMBL1093235,Epidermal growth factor receptor erbB1,Active,Inhibition of EGFR L858R mutant by time resolved fluorescence assay
942,275370,138,CHEMBL406375,Vascular endothelial growth factor receptor 2,Unspecified,Inhibition of KDR
943,275370,138,CHEMBL406375,Vascular endothelial growth factor receptor 2,Unspecified,"Millipore: Percentage of residual kinase activity of KDR at 1uM relative to control. Control inhibitor: Staurosporine at 10.0uM. Buffer: 8 mM MOPS pH 7.0, 0.2 mM EDTA"
944,275370,138,CHEMBL406375,Vascular endothelial growth factor receptor 2,Unspecified,"Millipore: Percentage of residual kinase activity of KDR at 10uM relative to control. Control inhibitor: Staurosporine at 10.0uM. Buffer: 8 mM MOPS pH 7.0, 0.2 mM EDTA"
945,89450,48,CHEMBL2204532,Epidermal growth factor receptor erbB1,Unspecified,Inhibition of EGFR
946,310264,155,CHEMBL502835,Cyclin-dependent kinase 1,Unspecified,Inhibition of human CDK1
947,310264,155,CHEMBL502835,Cyclin-dependent kinase 1,Unspecified,Inhibition of human CDK1
948,67591,150,CHEMBL1990583,Rho-associated protein kinase 2,Unspecified,Inhibition of Rock2 in presence of 10 uM ATP
949,79787,169,CHEMBL210517,Matrix metalloproteinase-1,Unspecified,Inhibition of MMP1
950,133812,38,CHEMBL31354,Serotonin 1d (5-HT1d) receptor,Unspecified,Inhibition of 5HT1D receptor at 10 uM
951,322559,154,CHEMBL572878,Cyclin-dependent kinase 2,Unspecified,Binding affinity to human CDK2 at 10 uM relative to control
952,322559,154,CHEMBL572878,Cyclin-dependent kinase 2,Unspecified,Binding constant for full-length CDK2
953,322559,154,CHEMBL572878,Cyclin-dependent kinase 2,Unspecified,Binding constant for CDK2 kinase domain
954,330679,90,CHEMBL64894,Serotonin transporter,Unspecified,"DRUGMATRIX: Transporter, Serotonin (5-Hydroxytryptamine) (SERT) radioligand binding (ligand: [3H] Paroxetine)"
955,330679,90,CHEMBL64894,Serotonin transporter,Unspecified,"DRUGMATRIX: Transporter, Serotonin (5-Hydroxytryptamine) (SERT) radioligand binding (ligand: [3H] Paroxetine)"
956,313876,73,CHEMBL521851,Tyrosine-protein kinase JAK3,Unspecified,Binding constant for JAK3(JH1domain-catalytic) kinase domain
957,253684,131,CHEMBL394619,Tyrosine-protein kinase SRC,Unspecified,Selectivity for KDR over cytosolic SRC
958,123454,128,CHEMBL288441,Glycogen synthase kinase-3 beta,Unspecified,Binding constant for GSK3B kinase domain
959,10566,224,CHEMBL1164265,Serine/threonine-protein kinase Aurora-A,Unspecified,Inhibition of AURKA at 1 uM
960,22914,164,CHEMBL1336,Rho-associated protein kinase 1,Unspecified,Binding affinity to ROCK1
961,22914,164,CHEMBL1336,Rho-associated protein kinase 1,Unspecified,Binding constant for ROCK1 kinase domain
962,92173,72,CHEMBL223360,Serine/threonine-protein kinase PIM1,Unspecified,Binding constant for PIM1 kinase domain
963,92173,72,CHEMBL223360,Serine/threonine-protein kinase PIM1,Unspecified,Binding constant for PIM1 kinase domain
964,26847,95,CHEMBL1416089,Mu opioid receptor,Inactive,Luminescence-based cell-based primary high throughput screening assay to identify agonists of heterodimerization of the mu 1 (OPRM1) and delta 1 (OPRD1) opioid receptors
965,26847,95,CHEMBL1416089,Mu opioid receptor,Inactive,Luminescence-based cell-based primary high throughput screening assay to identify agonists of heterodimerization of the mu 1 (OPRM1) and delta 1 (OPRD1) opioid receptors
966,26847,95,CHEMBL1416089,Mu opioid receptor,Inactive,Luminescence-based cell-based primary high throughput screening assay to identify inverse agonists of heterodimerization of the mu 1 (OPRM1) and delta 1 (OPRD1) opioid receptors
967,26847,95,CHEMBL1416089,Mu opioid receptor,Inactive,Luminescence-based cell-based primary high throughput screening assay to identify inverse agonists of heterodimerization of the mu 1 (OPRM1) and delta 1 (OPRD1) opioid receptors
968,31295,95,CHEMBL1510156,Mu opioid receptor,Inactive,Luminescence-based cell-based primary high throughput screening assay to identify agonists of heterodimerization of the mu 1 (OPRM1) and delta 1 (OPRD1) opioid receptors
969,31295,95,CHEMBL1510156,Mu opioid receptor,Inactive,Luminescence-based cell-based primary high throughput screening assay to identify agonists of heterodimerization of the mu 1 (OPRM1) and delta 1 (OPRD1) opioid receptors
970,31295,95,CHEMBL1510156,Mu opioid receptor,Inactive,Luminescence-based cell-based primary high throughput screening assay to identify inverse agonists of heterodimerization of the mu 1 (OPRM1) and delta 1 (OPRD1) opioid receptors
971,31295,95,CHEMBL1510156,Mu opioid receptor,Inactive,Luminescence-based cell-based primary high throughput screening assay to identify inverse agonists of heterodimerization of the mu 1 (OPRM1) and delta 1 (OPRD1) opioid receptors
972,23452,95,CHEMBL1350432,Mu opioid receptor,Inactive,Luminescence-based cell-based primary high throughput screening assay to identify agonists of heterodimerization of the mu 1 (OPRM1) and delta 1 (OPRD1) opioid receptors
973,23452,95,CHEMBL1350432,Mu opioid receptor,Inactive,Luminescence-based cell-based primary high throughput screening assay to identify agonists of heterodimerization of the mu 1 (OPRM1) and delta 1 (OPRD1) opioid receptors
974,23452,95,CHEMBL1350432,Mu opioid receptor,Inactive,Luminescence-based cell-based primary high throughput screening assay to identify inverse agonists of heterodimerization of the mu 1 (OPRM1) and delta 1 (OPRD1) opioid receptors
975,23452,95,CHEMBL1350432,Mu opioid receptor,Inactive,Luminescence-based cell-based primary high throughput screening assay to identify inverse agonists of heterodimerization of the mu 1 (OPRM1) and delta 1 (OPRD1) opioid receptors
976,294641,16,CHEMBL428690,Vascular endothelial growth factor receptor 1,Unspecified,Binding constant for FLT1 kinase domain
977,294641,16,CHEMBL428690,Vascular endothelial growth factor receptor 1,Unspecified,Binding constant for FLT1 kinase domain
978,63675,84,CHEMBL1946745,Serotonin 2a (5-HT2a) receptor,Unspecified,Binding affinity at 5-HT2A receptor by radioligand displacement assay
979,92173,89,CHEMBL223360,c-Jun N-terminal kinase 1,Unspecified,Binding constant for full-length JNK1
980,92173,89,CHEMBL223360,c-Jun N-terminal kinase 1,Unspecified,Binding constant for JNK1 kinase domain
981,326582,90,CHEMBL595252,Serotonin transporter,Unspecified,Inhibition of [3H]hydroxytryptamine creatinine sulfate uptake at human SERT expressed in human JAR cells at 1 uM after 10 mins by scintillation counting
982,16409,178,CHEMBL124660,Fibroblast growth factor receptor 1,Inactive,Average Binding Constant for FGFR1; NA=Not Active at 10 uM
983,16409,178,CHEMBL124660,Fibroblast growth factor receptor 1,Unspecified,Binding constant for FGFR1 kinase domain
984,16409,178,CHEMBL124660,Fibroblast growth factor receptor 1,Unspecified,Binding affinity to FGFR1
985,16409,178,CHEMBL124660,Fibroblast growth factor receptor 1,Unspecified,Binding constant for FGFR1 kinase domain
986,126071,136,CHEMBL302449,Fibroblast growth factor receptor 3,Unspecified,"Millipore: Percentage of residual kinase activity of FGFR3 at 1uM relative to control. Control inhibitor: Staurosporine at 10.0uM. Buffer: 8 mM MOPS pH 7.0, 0.2 mM EDTA"
987,126071,136,CHEMBL302449,Fibroblast growth factor receptor 3,Unspecified,"Millipore: Percentage of residual kinase activity of FGFR3 at 10uM relative to control. Control inhibitor: Staurosporine at 10.0uM. Buffer: 8 mM MOPS pH 7.0, 0.2 mM EDTA"
988,311405,138,CHEMBL511337,Vascular endothelial growth factor receptor 2,Unspecified,Binding affinity to human KDR at 10 uM relative to control
989,329496,183,CHEMBL608533,Interleukin-1 receptor-associated kinase 4,Unspecified,Binding constant for IRAK4 kinase domain
990,329496,183,CHEMBL608533,Interleukin-1 receptor-associated kinase 4,Unspecified,"Millipore: Percentage of residual kinase activity of IRAK4 at 1uM relative to control. Control inhibitor: Staurosporine at 100.0uM. Buffer: 8 mM MOPS pH 7.0, 0.2 mM EDTA"
991,329496,183,CHEMBL608533,Interleukin-1 receptor-associated kinase 4,Unspecified,"Millipore: Percentage of residual kinase activity of IRAK4 at 10uM relative to control. Control inhibitor: Staurosporine at 100.0uM. Buffer: 8 mM MOPS pH 7.0, 0.2 mM EDTA"
992,110653,128,CHEMBL2436978,Glycogen synthase kinase-3 beta,Unspecified,Inhibition of wild type human GSK3B by high throughput ATP-[33P] radiolabeled assay
993,96102,73,CHEMBL2322141,Tyrosine-protein kinase JAK3,Active,Inhibition of JAK3 (unknown origin) using biotin-TYR2 peptide as substrate after 60 mins by HTRF assay
994,298891,128,CHEMBL450786,Glycogen synthase kinase-3 beta,Unspecified,Binding constant for GSK3B kinase domain
995,113187,128,CHEMBL24828,Glycogen synthase kinase-3 beta,Unspecified,Binding constant for full-length GSK3B
996,113187,128,CHEMBL24828,Glycogen synthase kinase-3 beta,Unspecified,Binding constant for GSK3B kinase domain
997,336613,73,CHEMBL941,Tyrosine-protein kinase JAK3,Unspecified,Binding constant for JAK3(Kin.Dom.2/JH1 - catalytic) kinase domain
998,336613,73,CHEMBL941,Tyrosine-protein kinase JAK3,Unspecified,Binding affinity to human Jak3 domain 10 assessed as residual binding at 1 uM by site dependent competitive binding assay
999,336613,73,CHEMBL941,Tyrosine-protein kinase JAK3,Unspecified,Binding constant for JAK3(JH1domain-catalytic) kinase domain
1000,48303,36,CHEMBL1789941,Tyrosine-protein kinase receptor FLT3,Unspecified,Binding constant for FLT3 kinase domain
1001,48303,36,CHEMBL1789941,Tyrosine-protein kinase receptor FLT3,Unspecified,Binding constant for FLT3(D835H) kinase domain
1002,48303,36,CHEMBL1789941,Tyrosine-protein kinase receptor FLT3,Unspecified,Binding constant for FLT3(D835Y) kinase domain
1003,48303,36,CHEMBL1789941,Tyrosine-protein kinase receptor FLT3,Unspecified,Binding constant for FLT3(ITD) kinase domain
1004,48303,36,CHEMBL1789941,Tyrosine-protein kinase receptor FLT3,Unspecified,Binding constant for FLT3(K663Q) kinase domain
1005,48303,36,CHEMBL1789941,Tyrosine-protein kinase receptor FLT3,Unspecified,Binding constant for FLT3(N841I) kinase domain
1006,48303,36,CHEMBL1789941,Tyrosine-protein kinase receptor FLT3,Unspecified,Binding constant for FLT3(R834Q) kinase domain
1007,232799,99,CHEMBL3901479,Peroxisome proliferator-activated receptor gamma,Unspecified,Agonist activity at GAL4-tagged human PPARgamma ligand binding domain chimeric receptor expressed in HEK293 cells at <20 uM after 24 hrs by luciferase reporter gene assay
1008,241670,99,CHEMBL3920527,Peroxisome proliferator-activated receptor gamma,Unspecified,Agonist activity at GAL4-tagged human PPARgamma ligand binding domain chimeric receptor expressed in HEK293 cells at <20 uM after 24 hrs by luciferase reporter gene assay
1009,269434,99,CHEMBL3981588,Peroxisome proliferator-activated receptor gamma,Unspecified,Agonist activity at GAL4-tagged human PPARgamma ligand binding domain chimeric receptor expressed in HEK293 cells at <20 uM after 24 hrs by luciferase reporter gene assay
1010,234659,99,CHEMBL3905544,Peroxisome proliferator-activated receptor gamma,Inconclusive,Agonist activity at GAL4-tagged human PPARgamma ligand binding domain chimeric receptor expressed in HEK293 cells after 24 hrs by luciferase reporter gene assay
1011,301323,99,CHEMBL46403,Peroxisome proliferator-activated receptor gamma,Inactive,qHTS assay to identify small molecule agonists of the peroxisome proliferator-activated receptor gamma (PPARg) signaling pathway
1012,301323,99,CHEMBL46403,Peroxisome proliferator-activated receptor gamma,Inactive,qHTS assay to identify small molecule agonists of the peroxisome proliferator-activated receptor gamma (PPARg) signaling pathway
1013,301323,99,CHEMBL46403,Peroxisome proliferator-activated receptor gamma,Inactive,qHTS assay to identify small molecule agonists of the peroxisome proliferator-activated receptor gamma (PPARg) signaling pathway
1014,301323,99,CHEMBL46403,Peroxisome proliferator-activated receptor gamma,Inactive,qHTS assay to identify small molecule agonists of the peroxisome proliferator-activated receptor gamma (PPARg) signaling pathway: Summary
1015,301323,99,CHEMBL46403,Peroxisome proliferator-activated receptor gamma,Inactive,qHTS assay to identify small molecule agonists of the peroxisome proliferator-activated receptor gamma (PPARg) signaling pathway: Summary
1016,301323,99,CHEMBL46403,Peroxisome proliferator-activated receptor gamma,Inactive,qHTS assay to identify small molecule agonists of the peroxisome proliferator-activated receptor gamma (PPARg) signaling pathway: Summary
1017,301323,99,CHEMBL46403,Peroxisome proliferator-activated receptor gamma,Inconclusive,qHTS assay to identify small molecule antagonists of the peroxisome proliferator-activated receptor gamma (PPARg) signaling pathway
1018,301323,99,CHEMBL46403,Peroxisome proliferator-activated receptor gamma,Inactive,qHTS assay to identify small molecule antagonists of the peroxisome proliferator-activated receptor gamma (PPARg) signaling pathway
1019,301323,99,CHEMBL46403,Peroxisome proliferator-activated receptor gamma,Inconclusive,qHTS assay to identify small molecule antagonists of the peroxisome proliferator-activated receptor gamma (PPARg) signaling pathway
1020,301323,99,CHEMBL46403,Peroxisome proliferator-activated receptor gamma,Inactive,qHTS assay to identify small molecule antagonists of the peroxisome proliferator-activated receptor gamma (PPARg) signaling pathway - cell viability counter screen
1021,301323,99,CHEMBL46403,Peroxisome proliferator-activated receptor gamma,Inactive,qHTS assay to identify small molecule antagonists of the peroxisome proliferator-activated receptor gamma (PPARg) signaling pathway - cell viability counter screen
1022,301323,99,CHEMBL46403,Peroxisome proliferator-activated receptor gamma,Inactive,qHTS assay to identify small molecule antagonists of the peroxisome proliferator-activated receptor gamma (PPARg) signaling pathway - cell viability counter screen
1023,301323,99,CHEMBL46403,Peroxisome proliferator-activated receptor gamma,Inactive,qHTS assay to identify small molecule antagonists of the peroxisome proliferator-activated receptor gamma (PPARg) signaling pathway: Summary
1024,301323,99,CHEMBL46403,Peroxisome proliferator-activated receptor gamma,Inactive,qHTS assay to identify small molecule antagonists of the peroxisome proliferator-activated receptor gamma (PPARg) signaling pathway: Summary
1025,301323,99,CHEMBL46403,Peroxisome proliferator-activated receptor gamma,Inactive,qHTS assay to identify small molecule antagonists of the peroxisome proliferator-activated receptor gamma (PPARg) signaling pathway: Summary
1026,301323,99,CHEMBL46403,Peroxisome proliferator-activated receptor gamma,Active,Displacement of [3H]BRL49653 from Homo sapiens (human) PPARgamma receptor by scintillation proximity assay
1027,301323,99,CHEMBL46403,Peroxisome proliferator-activated receptor gamma,Inactive,qHTS assay to identify small molecule antagonists of the estrogen related receptor signaling pathway with the pleiotropic PPARgamma coactivator (PGC) from Tox21 10K library - cell viability counter screen
1028,301323,99,CHEMBL46403,Peroxisome proliferator-activated receptor gamma,Inactive,qHTS assay to identify small molecule antagonists of the estrogen related receptor signaling pathway with the pleiotropic PPARgamma coactivator (PGC) from Tox21 10K library - cell viability counter screen
1029,301323,99,CHEMBL46403,Peroxisome proliferator-activated receptor gamma,Inactive,qHTS assay to identify small molecule antagonists of the estrogen related receptor signaling pathway with the pleiotropic PPARgamma coactivator (PGC) from Tox21 10K library - cell viability counter screen
1030,301323,99,CHEMBL46403,Peroxisome proliferator-activated receptor gamma,Inactive,qHTS assay to identify small molecule antagonists of the estrogen related receptor signaling pathway with the pleiotropic PPARgamma coactivator (PGC) from Tox21 10K library
1031,301323,99,CHEMBL46403,Peroxisome proliferator-activated receptor gamma,Inactive,qHTS assay to identify small molecule antagonists of the estrogen related receptor signaling pathway with the pleiotropic PPARgamma coactivator (PGC) from Tox21 10K library
1032,301323,99,CHEMBL46403,Peroxisome proliferator-activated receptor gamma,Inactive,qHTS assay to identify small molecule antagonists of the estrogen related receptor signaling pathway with the pleiotropic PPARgamma coactivator (PGC) from Tox21 10K library
1033,301323,99,CHEMBL46403,Peroxisome proliferator-activated receptor gamma,Inactive,qHTS assay to identify small molecule agonists of the estrogen related receptor signaling pathway with the pleiotropic PPARgamma coactivator (PGC) from Tox21 10K library
1034,301323,99,CHEMBL46403,Peroxisome proliferator-activated receptor gamma,Inactive,qHTS assay to identify small molecule agonists of the estrogen related receptor signaling pathway with the pleiotropic PPARgamma coactivator (PGC) from Tox21 10K library
1035,301323,99,CHEMBL46403,Peroxisome proliferator-activated receptor gamma,Inactive,qHTS assay to identify small molecule agonists of the estrogen related receptor signaling pathway with the pleiotropic PPARgamma coactivator (PGC) from Tox21 10K library
1036,301323,99,CHEMBL46403,Peroxisome proliferator-activated receptor gamma,Inconclusive,qHTS assay to identify small molecule antagonists of the estrogen related receptor signaling pathway with the pleiotropic PPARgamma coactivator (PGC) from Tox21 10K library: Summary
1037,301323,99,CHEMBL46403,Peroxisome proliferator-activated receptor gamma,Inactive,qHTS assay to identify small molecule antagonists of the estrogen related receptor signaling pathway with the pleiotropic PPARgamma coactivator (PGC) from Tox21 10K library: Summary
1038,301323,99,CHEMBL46403,Peroxisome proliferator-activated receptor gamma,Inactive,qHTS assay to identify small molecule antagonists of the estrogen related receptor signaling pathway with the pleiotropic PPARgamma coactivator (PGC) from Tox21 10K library: Summary
1039,301323,99,CHEMBL46403,Peroxisome proliferator-activated receptor gamma,Inactive,qHTS assay to identify small molecule agonists of the estrogen related receptor signaling pathway with the pleiotropic PPARgamma coactivator (PGC) from Tox21 10K library: Summary
1040,301323,99,CHEMBL46403,Peroxisome proliferator-activated receptor gamma,Inactive,qHTS assay to identify small molecule agonists of the estrogen related receptor signaling pathway with the pleiotropic PPARgamma coactivator (PGC) from Tox21 10K library: Summary
1041,301323,99,CHEMBL46403,Peroxisome proliferator-activated receptor gamma,Inactive,qHTS assay to identify small molecule agonists of the estrogen related receptor signaling pathway with the pleiotropic PPARgamma coactivator (PGC) from Tox21 10K library: Summary
1042,334131,99,CHEMBL82293,Peroxisome proliferator-activated receptor gamma,Inactive,qHTS assay to identify small molecule agonists of the peroxisome proliferator-activated receptor gamma (PPARg) signaling pathway
1043,334131,99,CHEMBL82293,Peroxisome proliferator-activated receptor gamma,Inactive,qHTS assay to identify small molecule agonists of the peroxisome proliferator-activated receptor gamma (PPARg) signaling pathway
1044,334131,99,CHEMBL82293,Peroxisome proliferator-activated receptor gamma,Inactive,qHTS assay to identify small molecule agonists of the peroxisome proliferator-activated receptor gamma (PPARg) signaling pathway
1045,334131,99,CHEMBL82293,Peroxisome proliferator-activated receptor gamma,Inactive,qHTS assay to identify small molecule agonists of the peroxisome proliferator-activated receptor gamma (PPARg) signaling pathway: Summary
1046,334131,99,CHEMBL82293,Peroxisome proliferator-activated receptor gamma,Inactive,qHTS assay to identify small molecule agonists of the peroxisome proliferator-activated receptor gamma (PPARg) signaling pathway: Summary
1047,334131,99,CHEMBL82293,Peroxisome proliferator-activated receptor gamma,Inactive,qHTS assay to identify small molecule agonists of the peroxisome proliferator-activated receptor gamma (PPARg) signaling pathway: Summary
1048,334131,99,CHEMBL82293,Peroxisome proliferator-activated receptor gamma,Inconclusive,qHTS assay to identify small molecule antagonists of the peroxisome proliferator-activated receptor gamma (PPARg) signaling pathway
1049,334131,99,CHEMBL82293,Peroxisome proliferator-activated receptor gamma,Inactive,qHTS assay to identify small molecule antagonists of the peroxisome proliferator-activated receptor gamma (PPARg) signaling pathway
1050,334131,99,CHEMBL82293,Peroxisome proliferator-activated receptor gamma,Inactive,qHTS assay to identify small molecule antagonists of the peroxisome proliferator-activated receptor gamma (PPARg) signaling pathway
1051,334131,99,CHEMBL82293,Peroxisome proliferator-activated receptor gamma,Inactive,qHTS assay to identify small molecule antagonists of the peroxisome proliferator-activated receptor gamma (PPARg) signaling pathway - cell viability counter screen
1052,334131,99,CHEMBL82293,Peroxisome proliferator-activated receptor gamma,Inconclusive,qHTS assay to identify small molecule antagonists of the peroxisome proliferator-activated receptor gamma (PPARg) signaling pathway - cell viability counter screen
1053,334131,99,CHEMBL82293,Peroxisome proliferator-activated receptor gamma,Inactive,qHTS assay to identify small molecule antagonists of the peroxisome proliferator-activated receptor gamma (PPARg) signaling pathway - cell viability counter screen
1054,334131,99,CHEMBL82293,Peroxisome proliferator-activated receptor gamma,Inactive,qHTS assay to identify small molecule antagonists of the peroxisome proliferator-activated receptor gamma (PPARg) signaling pathway: Summary
1055,334131,99,CHEMBL82293,Peroxisome proliferator-activated receptor gamma,Inactive,qHTS assay to identify small molecule antagonists of the peroxisome proliferator-activated receptor gamma (PPARg) signaling pathway: Summary
1056,334131,99,CHEMBL82293,Peroxisome proliferator-activated receptor gamma,Inactive,qHTS assay to identify small molecule antagonists of the peroxisome proliferator-activated receptor gamma (PPARg) signaling pathway: Summary
1057,334131,99,CHEMBL82293,Peroxisome proliferator-activated receptor gamma,Active,Displacement of [3H]BRL49653 from Homo sapiens (human) PPARgamma receptor by scintillation proximity assay
1058,334131,99,CHEMBL82293,Peroxisome proliferator-activated receptor gamma,Inactive,qHTS assay to identify small molecule antagonists of the estrogen related receptor signaling pathway with the pleiotropic PPARgamma coactivator (PGC) from Tox21 10K library - cell viability counter screen
1059,334131,99,CHEMBL82293,Peroxisome proliferator-activated receptor gamma,Inactive,qHTS assay to identify small molecule antagonists of the estrogen related receptor signaling pathway with the pleiotropic PPARgamma coactivator (PGC) from Tox21 10K library - cell viability counter screen
1060,334131,99,CHEMBL82293,Peroxisome proliferator-activated receptor gamma,Inactive,qHTS assay to identify small molecule antagonists of the estrogen related receptor signaling pathway with the pleiotropic PPARgamma coactivator (PGC) from Tox21 10K library - cell viability counter screen
1061,334131,99,CHEMBL82293,Peroxisome proliferator-activated receptor gamma,Inconclusive,qHTS assay to identify small molecule antagonists of the estrogen related receptor signaling pathway with the pleiotropic PPARgamma coactivator (PGC) from Tox21 10K library
1062,334131,99,CHEMBL82293,Peroxisome proliferator-activated receptor gamma,Inactive,qHTS assay to identify small molecule antagonists of the estrogen related receptor signaling pathway with the pleiotropic PPARgamma coactivator (PGC) from Tox21 10K library
1063,334131,99,CHEMBL82293,Peroxisome proliferator-activated receptor gamma,Inactive,qHTS assay to identify small molecule antagonists of the estrogen related receptor signaling pathway with the pleiotropic PPARgamma coactivator (PGC) from Tox21 10K library
1064,334131,99,CHEMBL82293,Peroxisome proliferator-activated receptor gamma,Inactive,qHTS assay to identify small molecule agonists of the estrogen related receptor signaling pathway with the pleiotropic PPARgamma coactivator (PGC) from Tox21 10K library
1065,334131,99,CHEMBL82293,Peroxisome proliferator-activated receptor gamma,Inactive,qHTS assay to identify small molecule agonists of the estrogen related receptor signaling pathway with the pleiotropic PPARgamma coactivator (PGC) from Tox21 10K library
1066,334131,99,CHEMBL82293,Peroxisome proliferator-activated receptor gamma,Inactive,qHTS assay to identify small molecule agonists of the estrogen related receptor signaling pathway with the pleiotropic PPARgamma coactivator (PGC) from Tox21 10K library
1067,334131,99,CHEMBL82293,Peroxisome proliferator-activated receptor gamma,Inconclusive,qHTS assay to identify small molecule antagonists of the estrogen related receptor signaling pathway with the pleiotropic PPARgamma coactivator (PGC) from Tox21 10K library: Summary
1068,334131,99,CHEMBL82293,Peroxisome proliferator-activated receptor gamma,Inconclusive,qHTS assay to identify small molecule antagonists of the estrogen related receptor signaling pathway with the pleiotropic PPARgamma coactivator (PGC) from Tox21 10K library: Summary
1069,334131,99,CHEMBL82293,Peroxisome proliferator-activated receptor gamma,Inactive,qHTS assay to identify small molecule antagonists of the estrogen related receptor signaling pathway with the pleiotropic PPARgamma coactivator (PGC) from Tox21 10K library: Summary
1070,334131,99,CHEMBL82293,Peroxisome proliferator-activated receptor gamma,Inactive,qHTS assay to identify small molecule agonists of the estrogen related receptor signaling pathway with the pleiotropic PPARgamma coactivator (PGC) from Tox21 10K library: Summary
1071,334131,99,CHEMBL82293,Peroxisome proliferator-activated receptor gamma,Inactive,qHTS assay to identify small molecule agonists of the estrogen related receptor signaling pathway with the pleiotropic PPARgamma coactivator (PGC) from Tox21 10K library: Summary
1072,334131,99,CHEMBL82293,Peroxisome proliferator-activated receptor gamma,Inactive,qHTS assay to identify small molecule agonists of the estrogen related receptor signaling pathway with the pleiotropic PPARgamma coactivator (PGC) from Tox21 10K library: Summary
1073,259049,99,CHEMBL3957862,Peroxisome proliferator-activated receptor gamma,Unspecified,Agonist activity at GAL4-tagged human PPARgamma ligand binding domain chimeric receptor expressed in HEK293 cells at <20 uM after 24 hrs by luciferase reporter gene assay
1074,113845,99,CHEMBL249865,Peroxisome proliferator-activated receptor gamma,Unspecified,Agonist activity at PPARgamma expressed in HEK293 cells by GAL4 transactivation assay
1075,113845,99,CHEMBL249865,Peroxisome proliferator-activated receptor gamma,Unspecified,Agonist activity at PPARgamma expressed in HEK293 cells assessed as aP2 gene induction relative to BRL-49653
1076,336075,79,CHEMBL91829,Serine/threonine-protein kinase Aurora-B,Unspecified,Binding constant for AURKB kinase domain
1077,336075,79,CHEMBL91829,Serine/threonine-protein kinase Aurora-B,Unspecified,Binding constant for AURKB kinase domain
1078,219015,138,CHEMBL377193,Vascular endothelial growth factor receptor 2,Unspecified,"Millipore: Percentage of residual kinase activity of KDR at 1uM relative to control. Control inhibitor: Staurosporine at 10.0uM. Buffer: 8 mM MOPS pH 7.0, 0.2 mM EDTA"
1079,219015,138,CHEMBL377193,Vascular endothelial growth factor receptor 2,Unspecified,"Millipore: Percentage of residual kinase activity of KDR at 10uM relative to control. Control inhibitor: Staurosporine at 10.0uM. Buffer: 8 mM MOPS pH 7.0, 0.2 mM EDTA"
1080,22914,128,CHEMBL1336,Glycogen synthase kinase-3 beta,Unspecified,Binding constant for full-length GSK3B
1081,22914,128,CHEMBL1336,Glycogen synthase kinase-3 beta,Unspecified,Binding affinity to GSK3B
1082,22914,128,CHEMBL1336,Glycogen synthase kinase-3 beta,Unspecified,Binding constant for GSK3B kinase domain
1083,324005,90,CHEMBL58,Serotonin transporter,Unspecified,"DRUGMATRIX: Transporter, Serotonin (5-Hydroxytryptamine) (SERT) radioligand binding (ligand: [3H] Paroxetine)"
1084,324005,90,CHEMBL58,Serotonin transporter,Unspecified,"DRUGMATRIX: Transporter, Serotonin (5-Hydroxytryptamine) (SERT) radioligand binding (ligand: [3H] Paroxetine)"
1085,81171,128,CHEMBL21156,Glycogen synthase kinase-3 beta,Unspecified,"Millipore: Percentage of residual kinase activity of GSK3B at 1uM relative to control. Control inhibitor: Staurosporine at 10.0uM. Buffer: 8 mM MOPS pH 7.0, 0.2 mM EDTA"
1086,81171,128,CHEMBL21156,Glycogen synthase kinase-3 beta,Unspecified,"Millipore: Percentage of residual kinase activity of GSK3B at 10uM relative to control. Control inhibitor: Staurosporine at 10.0uM. Buffer: 8 mM MOPS pH 7.0, 0.2 mM EDTA"
1087,81171,128,CHEMBL21156,Glycogen synthase kinase-3 beta,Unspecified,Delta TM value showing the stabilisation of GSK3B produced by compound binding
1088,12311,138,CHEMBL119385,Vascular endothelial growth factor receptor 2,Inactive,Average Binding Constant for VEGFR2; NA=Not Active at 10 uM
1089,12311,138,CHEMBL119385,Vascular endothelial growth factor receptor 2,Unspecified,Binding constant for VEGFR2 kinase domain
1090,12311,138,CHEMBL119385,Vascular endothelial growth factor receptor 2,Unspecified,Binding constant for VEGFR2 kinase domain
1091,12311,138,CHEMBL119385,Vascular endothelial growth factor receptor 2,Unspecified,Inhibition of KDR by filter binding assay
1092,249077,84,CHEMBL3936289,Serotonin 2a (5-HT2a) receptor,Unspecified,Displacement of [3H]Ketanserin from 5-HT2A receptor (unknown origin) measured after 90 mins by microbeta scintillation counting method
1093,333445,170,CHEMBL78826,Matrix metalloproteinase-2,Inconclusive,Inhibition of MMP2 (unknown origin)
1094,20634,164,CHEMBL1289926,Rho-associated protein kinase 1,Unspecified,Binding constant for ROCK1 kinase domain
1095,29834,166,CHEMBL1478023,Histone deacetylase 1,Active,Inhibition of HDAC1 (unknown origin) after 15 mins by fluorescence assay
1096,260497,166,CHEMBL396097,Histone deacetylase 1,Unspecified,Inhibition of recombinant C-terminal FLAG-tagged HDAC1 expressed in baculovirus after 10 mins by fluorimetric analysis
1097,260497,166,CHEMBL396097,Histone deacetylase 1,Inactive,Inhibition of recombinant C-terminal FLAG-tagged HDAC1 expressed in baculovirus at 20 uM after 10 mins by fluorimetric analysis
1098,260497,166,CHEMBL396097,Histone deacetylase 1,Unspecified,Inhibition of human recombinant HDAC1 at 20 uM using Boc-Lys(Ac)-AMC as substrate after 30 to 60 mins by microplate reader assay
1099,36363,84,CHEMBL1629810,Serotonin 2a (5-HT2a) receptor,Unspecified,DRUGMATRIX: Serotonin (5-Hydroxytryptamine) 5-HT2A radioligand binding (ligand: [3H] Ketanserin)
1100,36363,84,CHEMBL1629810,Serotonin 2a (5-HT2a) receptor,Unspecified,DRUGMATRIX: Serotonin (5-Hydroxytryptamine) 5-HT2A radioligand binding (ligand: [3H] Ketanserin)
1101,276549,178,CHEMBL4069365,Fibroblast growth factor receptor 1,Unspecified,Inhibition of FGFR1 (unknown origin) after 60 mins by TR-FRET assay
1102,304356,48,CHEMBL477772,Epidermal growth factor receptor erbB1,Unspecified,Binding constant for EGFR kinase domain
1103,304356,48,CHEMBL477772,Epidermal growth factor receptor erbB1,Unspecified,Binding constant for EGFR(G719C) kinase domain
1104,304356,48,CHEMBL477772,Epidermal growth factor receptor erbB1,Unspecified,Binding constant for EGFR(G719S) kinase domain
1105,304356,48,CHEMBL477772,Epidermal growth factor receptor erbB1,Unspecified,Binding constant for EGFR(L858R) kinase domain
1106,304356,48,CHEMBL477772,Epidermal growth factor receptor erbB1,Unspecified,"Binding constant for EGFR(L747-E749del, A750P) kinase domain"
1107,304356,48,CHEMBL477772,Epidermal growth factor receptor erbB1,Unspecified,"Binding constant for EGFR(L747-S752del, P753S) kinase domain"
1108,304356,48,CHEMBL477772,Epidermal growth factor receptor erbB1,Unspecified,Binding constant for EGFR(E746-A750del) kinase domain
1109,304356,48,CHEMBL477772,Epidermal growth factor receptor erbB1,Unspecified,Binding constant for EGFR(S752-I759del) kinase domain
1110,304356,48,CHEMBL477772,Epidermal growth factor receptor erbB1,Unspecified,"Binding constant for EGFR(L747-T751del,Sins) kinase domain"
1111,304356,48,CHEMBL477772,Epidermal growth factor receptor erbB1,Unspecified,Binding constant for EGFR(L861Q) kinase domain
1112,304356,48,CHEMBL477772,Epidermal growth factor receptor erbB1,Unspecified,Binding constant for EGFR kinase domain
1113,304356,48,CHEMBL477772,Epidermal growth factor receptor erbB1,Unspecified,Binding constant for EGFR(E746-A750del) kinase domain
1114,304356,48,CHEMBL477772,Epidermal growth factor receptor erbB1,Unspecified,Binding constant for EGFR(G719C) kinase domain
1115,304356,48,CHEMBL477772,Epidermal growth factor receptor erbB1,Unspecified,Binding constant for EGFR(G719S) kinase domain
1116,304356,48,CHEMBL477772,Epidermal growth factor receptor erbB1,Unspecified,"Binding constant for EGFR(L747-E749del, A750P) kinase domain"
1117,304356,48,CHEMBL477772,Epidermal growth factor receptor erbB1,Unspecified,"Binding constant for EGFR(L747-S752del, P753S) kinase domain"
1118,304356,48,CHEMBL477772,Epidermal growth factor receptor erbB1,Unspecified,"Binding constant for EGFR(L747-T751del,Sins) kinase domain"
1119,304356,48,CHEMBL477772,Epidermal growth factor receptor erbB1,Unspecified,Binding constant for EGFR(L858R) kinase domain
1120,304356,48,CHEMBL477772,Epidermal growth factor receptor erbB1,Unspecified,"Binding constant for EGFR(L858R,T790M) kinase domain"
1121,304356,48,CHEMBL477772,Epidermal growth factor receptor erbB1,Unspecified,Binding constant for EGFR(L861Q) kinase domain
1122,304356,48,CHEMBL477772,Epidermal growth factor receptor erbB1,Unspecified,Binding constant for EGFR(S752-I759del) kinase domain
1123,304356,48,CHEMBL477772,Epidermal growth factor receptor erbB1,Unspecified,Binding constant for EGFR(T790M) kinase domain
1124,221090,224,CHEMBL379218,Serine/threonine-protein kinase Aurora-A,Unspecified,Binding constant for AURKA kinase domain
1125,94056,73,CHEMBL230011,Tyrosine-protein kinase JAK3,Unspecified,Binding constant for JAK3(JH1domain-catalytic) kinase domain
1126,323045,133,CHEMBL574738,Focal adhesion kinase 1,Unspecified,Binding constant for PTK2 kinase domain
1127,323045,133,CHEMBL574738,Focal adhesion kinase 1,Unspecified,Binding constant for FAK kinase domain
1128,314433,84,CHEMBL523797,Serotonin 2a (5-HT2a) receptor,Unspecified,Displacement of [3H]ketanserin from human 5-HT2A receptor expressed in HEK-T cell membranes at 10 uM incubated for 90 mins under dark condition by microbeta scintillation counting method relative to control
1129,314433,84,CHEMBL523797,Serotonin 2a (5-HT2a) receptor,Unspecified,Displacement of [3H]ketanserin from human 5-HT2A receptor expressed in HEK-T cell membranes incubated for 90 mins under dark condition by microbeta scintillation counting method
1130,124926,79,CHEMBL296468,Serine/threonine-protein kinase Aurora-B,Unspecified,Binding constant for AURKB kinase domain
1131,124926,79,CHEMBL296468,Serine/threonine-protein kinase Aurora-B,Unspecified,Binding constant for AURKB kinase domain
1132,68377,128,CHEMBL2002702,Glycogen synthase kinase-3 beta,Inactive,human GSK3B kinase inhibition-screen
1133,163529,38,CHEMBL3608450,Serotonin 1d (5-HT1d) receptor,Unspecified,Displacement of [3H]GR125743 from 5HT1D receptor (unknown origin) at 10 uM
1134,314786,90,CHEMBL526,Serotonin transporter,Unspecified,"DRUGMATRIX: Transporter, Serotonin (5-Hydroxytryptamine) (SERT) radioligand binding (ligand: [3H] Paroxetine)"
1135,314786,90,CHEMBL526,Serotonin transporter,Unspecified,"DRUGMATRIX: Transporter, Serotonin (5-Hydroxytryptamine) (SERT) radioligand binding (ligand: [3H] Paroxetine)"
1136,280710,138,CHEMBL4089245,Vascular endothelial growth factor receptor 2,Unspecified,Inhibition of human VEGFR2 at 10 uM using poly[Glu:Tyr] (4:1) as substrate measured after 120 mins in presence of [gamma33P]ATP by P81 ion exchange chromatographic method relative to control
1137,280710,138,CHEMBL4089245,Vascular endothelial growth factor receptor 2,Unspecified,Inhibition of human VEGFR2 using poly[Glu:Tyr] (4:1) as substrate measured after 120 mins in presence of [gamma33P]ATP by P81 ion exchange chromatographic method
1138,89191,86,CHEMBL2203551,Serotonin 2c (5-HT2c) receptor,Unspecified,Displacement of [3H]mesulergine from human recombinant 5-HT2C receptor after 1.5 hrs by microbeta scintillation counting analysis
1139,89191,86,CHEMBL2203551,Serotonin 2c (5-HT2c) receptor,Unspecified,Displacement of [3H]mesulergine from human recombinant 5-HT2C receptor at 10 uM after 1.5 hrs by microbeta scintillation counting analysis
1140,243315,84,CHEMBL3923870,Serotonin 2a (5-HT2a) receptor,Unspecified,Displacement of [3H]ketanserin from human 5-HT2A receptor expressed in HEK-T cell membranes at 10 uM incubated for 90 mins under dark condition by microbeta scintillation counting method relative to control
1141,243315,84,CHEMBL3923870,Serotonin 2a (5-HT2a) receptor,Unspecified,Displacement of [3H]ketanserin from human 5-HT2A receptor expressed in HEK-T cell membranes incubated for 90 mins under dark condition by microbeta scintillation counting method
1142,3267,224,CHEMBL1081312,Serine/threonine-protein kinase Aurora-A,Unspecified,Inhibition of STK6 at 1 uM after 60 mins by FRET assay in presence of 10 uM ATP
1143,314786,84,CHEMBL526,Serotonin 2a (5-HT2a) receptor,Inactive,Luminescence-based cell-based primary high throughput screening assay to identify agonists of the mouse 5-hydroxytryptamine (serotonin) receptor 2A (HTR2A)
1144,314786,84,CHEMBL526,Serotonin 2a (5-HT2a) receptor,Unspecified,DRUGMATRIX: Serotonin (5-Hydroxytryptamine) 5-HT2A radioligand binding (ligand: [3H] Ketanserin)
1145,314786,84,CHEMBL526,Serotonin 2a (5-HT2a) receptor,Unspecified,DRUGMATRIX: Serotonin (5-Hydroxytryptamine) 5-HT2A radioligand binding (ligand: [3H] Ketanserin)
1146,278322,138,CHEMBL4077859,Vascular endothelial growth factor receptor 2,Unspecified,Inhibition of human VEGFR2 at 10 uM using poly[Glu:Tyr] (4:1) as substrate measured after 120 mins in presence of [gamma33P]ATP by P81 ion exchange chromatographic method relative to control
1147,278322,138,CHEMBL4077859,Vascular endothelial growth factor receptor 2,Unspecified,Inhibition of human VEGFR2 using poly[Glu:Tyr] (4:1) as substrate measured after 120 mins in presence of [gamma33P]ATP by P81 ion exchange chromatographic method
1148,142663,86,CHEMBL3289656,Serotonin 2c (5-HT2c) receptor,Active,Displacement of [3H]mesulergine from rat 5-HT2C receptor by PDSP assay
1149,142663,86,CHEMBL3289656,Serotonin 2c (5-HT2c) receptor,Active,Displacement of [3H]mesulergine from rat 5-HT2C receptor by PDSP assay
1150,113187,140,CHEMBL24828,Nerve growth factor receptor Trk-A,Inactive,Average Binding Constant for NTRK1; NA=Not Active at 10 uM
1151,113187,140,CHEMBL24828,Nerve growth factor receptor Trk-A,Unspecified,Binding constant for TRKA kinase domain
1152,113187,140,CHEMBL24828,Nerve growth factor receptor Trk-A,Unspecified,Binding constant for TRKA kinase domain
1153,20634,214,CHEMBL1289926,Ribosomal protein S6 kinase 1,Unspecified,Binding constant for S6K1 kinase domain
1154,20634,214,CHEMBL1289926,Ribosomal protein S6 kinase 1,Inactive,human p70S6K1 kinase inhibition-screen
1155,917,224,CHEMBL103667,Serine/threonine-protein kinase Aurora-A,Unspecified,Binding constant for AURKA kinase domain
1156,917,224,CHEMBL103667,Serine/threonine-protein kinase Aurora-A,Unspecified,Binding constant for AURKA kinase domain
1157,150685,162,CHEMBL3359091,Matrix metalloproteinase 9,Unspecified,Inhibition of human recombinant MMP9 using Cy3-PLGLK(Cy5Q)AR-NH2 as substrate after 40 mins by spectrofluorimetry
1158,150685,162,CHEMBL3359091,Matrix metalloproteinase 9,Unspecified,Selectivity ratio of IC50 for human recombinant MMP9 to IC50 for human recombinant MMP13
1159,150685,162,CHEMBL3359091,Matrix metalloproteinase 9,Unspecified,Inhibition of recombinant human AMPA-activated MMP9 using Cy3-PLGLK(Cy5Q)AR-NH2 as substrate measured after 40 mins by spectrofluorimetric method
1160,122416,86,CHEMBL282199,Serotonin 2c (5-HT2c) receptor,Active,Displacement of [3H]-mesulergine from human 5-HT2C receptor expressed in HEK293 cells
1161,72567,90,CHEMBL2031737,Serotonin transporter,Unspecified,Binding affinity to human recombinant SERT
1162,72567,90,CHEMBL2031737,Serotonin transporter,Unspecified,Selectivity ratio of Ki for human recombinant SERT to Ki for human recombinant H3 receptor
1163,159850,86,CHEMBL357995,Serotonin 2c (5-HT2c) receptor,Unspecified,DRUGMATRIX: Serotonin (5-Hydroxytryptamine) 5-HT2C radioligand binding (ligand: [3H] Mesulergine)
1164,159850,86,CHEMBL357995,Serotonin 2c (5-HT2c) receptor,Unspecified,DRUGMATRIX: Serotonin (5-Hydroxytryptamine) 5-HT2C radioligand binding (ligand: [3H] Mesulergine)
1165,65886,48,CHEMBL196363,Epidermal growth factor receptor erbB1,Unspecified,Inhibitory concentration against EGFR
1166,12383,84,CHEMBL119709,Serotonin 2a (5-HT2a) receptor,Inactive,Luminescence-based cell-based primary high throughput screening assay to identify agonists of the mouse 5-hydroxytryptamine (serotonin) receptor 2A (HTR2A)
1167,12383,84,CHEMBL119709,Serotonin 2a (5-HT2a) receptor,Unspecified,Displacement of [3H]ketanserin from human 5-HT2A receptor expressed in HEK-T cell membranes at 10 uM incubated for 90 mins under dark condition by microbeta scintillation counting method relative to control
1168,12383,84,CHEMBL119709,Serotonin 2a (5-HT2a) receptor,Unspecified,Displacement of [3H]ketanserin from human 5-HT2A receptor expressed in HEK-T cell membranes incubated for 90 mins under dark condition by microbeta scintillation counting method
1169,69466,84,CHEMBL2012686,Serotonin 2a (5-HT2a) receptor,Unspecified,Displacement of [3H]ketanserin from human 5-HT2A receptor expressed in HEK-T cell membranes at 10 uM incubated for 90 mins under dark condition by microbeta scintillation counting method relative to control
1170,69466,84,CHEMBL2012686,Serotonin 2a (5-HT2a) receptor,Unspecified,Displacement of [3H]ketanserin from human 5-HT2A receptor expressed in HEK-T cell membranes incubated for 90 mins under dark condition by microbeta scintillation counting method
1171,123205,84,CHEMBL286739,Serotonin 2a (5-HT2a) receptor,Unspecified,Displacement of [3H]ketanserin from human 5-HT2A receptor expressed in HEK-T cell membranes at 10 uM incubated for 90 mins under dark condition by microbeta scintillation counting method relative to control
1172,123205,84,CHEMBL286739,Serotonin 2a (5-HT2a) receptor,Unspecified,Displacement of [3H]ketanserin from human 5-HT2A receptor expressed in HEK-T cell membranes incubated for 90 mins under dark condition by microbeta scintillation counting method
1173,314179,133,CHEMBL522892,Focal adhesion kinase 1,Unspecified,Binding constant for PTK2 kinase domain
1174,314179,133,CHEMBL522892,Focal adhesion kinase 1,Unspecified,Binding constant for FAK kinase domain
1175,57048,84,CHEMBL18840,Serotonin 2a (5-HT2a) receptor,Unspecified,The compound was tested for binding affinity against 5-HT2A receptor
1176,57048,84,CHEMBL18840,Serotonin 2a (5-HT2a) receptor,Active,In Vitro Binding affinity againist 5-HT2A receptor by displacing [3H]-DOB from rat cortex homogenates
1177,57048,84,CHEMBL18840,Serotonin 2a (5-HT2a) receptor,Active,Agonists at Human 5-Hydroxytryptamine receptor 5-HT2A
1178,57048,84,CHEMBL18840,Serotonin 2a (5-HT2a) receptor,Active,Human 5-HT2A receptor (5-Hydroxytryptamine receptors)
1179,323571,178,CHEMBL576982,Fibroblast growth factor receptor 1,Unspecified,Binding affinity to FGFR1
1180,323571,178,CHEMBL576982,Fibroblast growth factor receptor 1,Unspecified,Binding constant for FGFR1 kinase domain
1181,15946,154,CHEMBL1241674,Cyclin-dependent kinase 2,Unspecified,Binding constant for CDK2 kinase domain
1182,267097,84,CHEMBL3976121,Serotonin 2a (5-HT2a) receptor,Unspecified,Displacement of [3H]ketanserin from human 5-HT2A receptor expressed in HEK-T cell membranes at 10 uM incubated for 90 mins under dark condition by microbeta scintillation counting method relative to control
1183,267097,84,CHEMBL3976121,Serotonin 2a (5-HT2a) receptor,Unspecified,Displacement of [3H]ketanserin from human 5-HT2A receptor expressed in HEK-T cell membranes incubated for 90 mins under dark condition by microbeta scintillation counting method
1184,247485,84,CHEMBL3932820,Serotonin 2a (5-HT2a) receptor,Unspecified,Displacement of [3H]ketanserin from human 5-HT2A receptor expressed in HEK-T cell membranes at 10 uM incubated for 90 mins under dark condition by microbeta scintillation counting method relative to control
1185,247485,84,CHEMBL3932820,Serotonin 2a (5-HT2a) receptor,Unspecified,Displacement of [3H]ketanserin from human 5-HT2A receptor expressed in HEK-T cell membranes incubated for 90 mins under dark condition by microbeta scintillation counting method
1186,234324,84,CHEMBL3904817,Serotonin 2a (5-HT2a) receptor,Unspecified,Displacement of [3H]ketanserin from human 5-HT2A receptor expressed in HEK-T cell membranes at 10 uM incubated for 90 mins under dark condition by microbeta scintillation counting method relative to control
1187,234324,84,CHEMBL3904817,Serotonin 2a (5-HT2a) receptor,Unspecified,Displacement of [3H]ketanserin from human 5-HT2A receptor expressed in HEK-T cell membranes incubated for 90 mins under dark condition by microbeta scintillation counting method
1188,257958,84,CHEMBL3955519,Serotonin 2a (5-HT2a) receptor,Unspecified,Displacement of [3H]ketanserin from human 5-HT2A receptor expressed in HEK-T cell membranes at 10 uM incubated for 90 mins under dark condition by microbeta scintillation counting method relative to control
1189,257958,84,CHEMBL3955519,Serotonin 2a (5-HT2a) receptor,Unspecified,Displacement of [3H]ketanserin from human 5-HT2A receptor expressed in HEK-T cell membranes incubated for 90 mins under dark condition by microbeta scintillation counting method
1190,246990,84,CHEMBL3931747,Serotonin 2a (5-HT2a) receptor,Unspecified,Displacement of [3H]ketanserin from human 5-HT2A receptor expressed in HEK-T cell membranes at 10 uM incubated for 90 mins under dark condition by microbeta scintillation counting method relative to control
1191,246990,84,CHEMBL3931747,Serotonin 2a (5-HT2a) receptor,Unspecified,Displacement of [3H]ketanserin from human 5-HT2A receptor expressed in HEK-T cell membranes incubated for 90 mins under dark condition by microbeta scintillation counting method
1192,267292,84,CHEMBL3976579,Serotonin 2a (5-HT2a) receptor,Unspecified,Displacement of [3H]ketanserin from human 5-HT2A receptor expressed in HEK-T cell membranes at 10 uM incubated for 90 mins under dark condition by microbeta scintillation counting method relative to control
1193,267292,84,CHEMBL3976579,Serotonin 2a (5-HT2a) receptor,Unspecified,Displacement of [3H]ketanserin from human 5-HT2A receptor expressed in HEK-T cell membranes incubated for 90 mins under dark condition by microbeta scintillation counting method
1194,234798,84,CHEMBL3905850,Serotonin 2a (5-HT2a) receptor,Unspecified,Displacement of [3H]ketanserin from human 5-HT2A receptor expressed in HEK-T cell membranes at 10 uM incubated for 90 mins under dark condition by microbeta scintillation counting method relative to control
1195,234798,84,CHEMBL3905850,Serotonin 2a (5-HT2a) receptor,Unspecified,Displacement of [3H]ketanserin from human 5-HT2A receptor expressed in HEK-T cell membranes incubated for 90 mins under dark condition by microbeta scintillation counting method
1196,270804,84,CHEMBL3984645,Serotonin 2a (5-HT2a) receptor,Unspecified,Displacement of [3H]ketanserin from human 5-HT2A receptor expressed in HEK-T cell membranes at 10 uM incubated for 90 mins under dark condition by microbeta scintillation counting method relative to control
1197,270804,84,CHEMBL3984645,Serotonin 2a (5-HT2a) receptor,Unspecified,Displacement of [3H]ketanserin from human 5-HT2A receptor expressed in HEK-T cell membranes incubated for 90 mins under dark condition by microbeta scintillation counting method
1198,238993,84,CHEMBL3914843,Serotonin 2a (5-HT2a) receptor,Unspecified,Displacement of [3H]ketanserin from human 5-HT2A receptor expressed in HEK-T cell membranes at 10 uM incubated for 90 mins under dark condition by microbeta scintillation counting method relative to control
1199,238993,84,CHEMBL3914843,Serotonin 2a (5-HT2a) receptor,Unspecified,Displacement of [3H]ketanserin from human 5-HT2A receptor expressed in HEK-T cell membranes incubated for 90 mins under dark condition by microbeta scintillation counting method
1200,323045,183,CHEMBL574738,Interleukin-1 receptor-associated kinase 4,Unspecified,Binding constant for IRAK4 kinase domain
1201,258419,84,CHEMBL3956531,Serotonin 2a (5-HT2a) receptor,Unspecified,Displacement of [3H]ketanserin from human 5-HT2A receptor expressed in HEK-T cell membranes at 10 uM incubated for 90 mins under dark condition by microbeta scintillation counting method relative to control
1202,258419,84,CHEMBL3956531,Serotonin 2a (5-HT2a) receptor,Unspecified,Displacement of [3H]ketanserin from human 5-HT2A receptor expressed in HEK-T cell membranes incubated for 90 mins under dark condition by microbeta scintillation counting method
1203,238264,84,CHEMBL3913293,Serotonin 2a (5-HT2a) receptor,Unspecified,Displacement of [3H]ketanserin from human 5-HT2A receptor expressed in HEK-T cell membranes at 10 uM incubated for 90 mins under dark condition by microbeta scintillation counting method relative to control
1204,238264,84,CHEMBL3913293,Serotonin 2a (5-HT2a) receptor,Unspecified,Displacement of [3H]ketanserin from human 5-HT2A receptor expressed in HEK-T cell membranes incubated for 90 mins under dark condition by microbeta scintillation counting method
1205,264459,84,CHEMBL3970041,Serotonin 2a (5-HT2a) receptor,Unspecified,Displacement of [3H]ketanserin from human 5-HT2A receptor expressed in HEK-T cell membranes at 10 uM incubated for 90 mins under dark condition by microbeta scintillation counting method relative to control
1206,264459,84,CHEMBL3970041,Serotonin 2a (5-HT2a) receptor,Unspecified,Displacement of [3H]ketanserin from human 5-HT2A receptor expressed in HEK-T cell membranes incubated for 90 mins under dark condition by microbeta scintillation counting method
1207,238603,84,CHEMBL3914002,Serotonin 2a (5-HT2a) receptor,Unspecified,Displacement of [3H]ketanserin from human 5-HT2A receptor expressed in HEK-T cell membranes at 10 uM incubated for 90 mins under dark condition by microbeta scintillation counting method relative to control
1208,238603,84,CHEMBL3914002,Serotonin 2a (5-HT2a) receptor,Unspecified,Displacement of [3H]ketanserin from human 5-HT2A receptor expressed in HEK-T cell membranes incubated for 90 mins under dark condition by microbeta scintillation counting method
1209,259674,84,CHEMBL3959210,Serotonin 2a (5-HT2a) receptor,Unspecified,Displacement of [3H]ketanserin from human 5-HT2A receptor expressed in HEK-T cell membranes at 10 uM incubated for 90 mins under dark condition by microbeta scintillation counting method relative to control
1210,259674,84,CHEMBL3959210,Serotonin 2a (5-HT2a) receptor,Unspecified,Displacement of [3H]ketanserin from human 5-HT2A receptor expressed in HEK-T cell membranes incubated for 90 mins under dark condition by microbeta scintillation counting method
1211,249880,84,CHEMBL3938006,Serotonin 2a (5-HT2a) receptor,Unspecified,Displacement of [3H]ketanserin from human 5-HT2A receptor expressed in HEK-T cell membranes at 10 uM incubated for 90 mins under dark condition by microbeta scintillation counting method relative to control
1212,249880,84,CHEMBL3938006,Serotonin 2a (5-HT2a) receptor,Unspecified,Displacement of [3H]ketanserin from human 5-HT2A receptor expressed in HEK-T cell membranes incubated for 90 mins under dark condition by microbeta scintillation counting method
1213,245684,84,CHEMBL3928983,Serotonin 2a (5-HT2a) receptor,Unspecified,Displacement of [3H]ketanserin from human 5-HT2A receptor expressed in HEK-T cell membranes at 10 uM incubated for 90 mins under dark condition by microbeta scintillation counting method relative to control
1214,245684,84,CHEMBL3928983,Serotonin 2a (5-HT2a) receptor,Unspecified,Displacement of [3H]ketanserin from human 5-HT2A receptor expressed in HEK-T cell membranes incubated for 90 mins under dark condition by microbeta scintillation counting method
1215,15033,84,CHEMBL1224031,Serotonin 2a (5-HT2a) receptor,Unspecified,Displacement of [3H]Ketanserin from human 5HT2A receptor at 10 uM
1216,15033,84,CHEMBL1224031,Serotonin 2a (5-HT2a) receptor,Unspecified,Displacement of [3H]Ketanserin from human 5HT2A receptor
1217,263429,84,CHEMBL3967613,Serotonin 2a (5-HT2a) receptor,Unspecified,Displacement of [3H]ketanserin from human 5-HT2A receptor expressed in HEK-T cell membranes at 10 uM incubated for 90 mins under dark condition by microbeta scintillation counting method relative to control
1218,263429,84,CHEMBL3967613,Serotonin 2a (5-HT2a) receptor,Unspecified,Displacement of [3H]ketanserin from human 5-HT2A receptor expressed in HEK-T cell membranes incubated for 90 mins under dark condition by microbeta scintillation counting method
1219,303733,84,CHEMBL474885,Serotonin 2a (5-HT2a) receptor,Unspecified,Agonist activity at human 5HT2A receptor expressed in HEK293 cells at 10 uM assessed as calcium flux by FLIPR assay relative to serotonin
1220,303733,84,CHEMBL474885,Serotonin 2a (5-HT2a) receptor,Inactive,Agonist activity at human 5HT2A receptor expressed in HEK293 cells assessed as calcium flux by FLIPR assay
1221,270090,84,CHEMBL3983143,Serotonin 2a (5-HT2a) receptor,Unspecified,Displacement of [3H]ketanserin from human 5-HT2A receptor expressed in HEK-T cell membranes at 10 uM incubated for 90 mins under dark condition by microbeta scintillation counting method relative to control
1222,270090,84,CHEMBL3983143,Serotonin 2a (5-HT2a) receptor,Unspecified,Displacement of [3H]ketanserin from human 5-HT2A receptor expressed in HEK-T cell membranes incubated for 90 mins under dark condition by microbeta scintillation counting method
1223,251608,84,CHEMBL3941738,Serotonin 2a (5-HT2a) receptor,Unspecified,Displacement of [3H]ketanserin from human 5-HT2A receptor expressed in HEK-T cell membranes at 10 uM incubated for 90 mins under dark condition by microbeta scintillation counting method relative to control
1224,251608,84,CHEMBL3941738,Serotonin 2a (5-HT2a) receptor,Unspecified,Displacement of [3H]ketanserin from human 5-HT2A receptor expressed in HEK-T cell membranes incubated for 90 mins under dark condition by microbeta scintillation counting method
1225,15036,84,CHEMBL1224034,Serotonin 2a (5-HT2a) receptor,Unspecified,Displacement of [3H]Ketanserin from human 5HT2A receptor at 10 uM
1226,15036,84,CHEMBL1224034,Serotonin 2a (5-HT2a) receptor,Unspecified,Displacement of [3H]Ketanserin from human 5HT2A receptor
1227,304356,164,CHEMBL477772,Rho-associated protein kinase 1,Unspecified,Binding constant for ROCK1 kinase domain
1228,49374,79,CHEMBL180022,Serine/threonine-protein kinase Aurora-B,Unspecified,Binding constant for AURKB kinase domain
1229,117364,11,CHEMBL259084,Macrophage colony stimulating factor receptor,Unspecified,Activity of human FMS kinase at 1 uM
1230,117364,11,CHEMBL259084,Macrophage colony stimulating factor receptor,Unspecified,Binding constant for CSF1R kinase domain
1231,117364,11,CHEMBL259084,Macrophage colony stimulating factor receptor,Unspecified,Binding constant for CSF1R kinase domain
1232,42629,204,CHEMBL1725279,ALK tyrosine kinase receptor,Unspecified,"Inhibition of ALK using FL-Peptide 13, 5-FAM-KKSRGDYMTMQIG-CONH2 substrate at 10 uM after 60 mins by mobility shift assay"
1233,42629,204,CHEMBL1725279,ALK tyrosine kinase receptor,Unspecified,"Millipore: Percentage of residual kinase activity of ALK at 1uM relative to control. Control inhibitor: Staurosporine at 10.0uM. Buffer: 8 mM MOPS pH 7.0, 0.2 mM EDTA"
1234,42629,204,CHEMBL1725279,ALK tyrosine kinase receptor,Unspecified,"Millipore: Percentage of residual kinase activity of ALK at 10uM relative to control. Control inhibitor: Staurosporine at 10.0uM. Buffer: 8 mM MOPS pH 7.0, 0.2 mM EDTA"
1235,113187,149,CHEMBL24828,Tyrosine-protein kinase JAK2,Inactive,Average Binding Constant for JAK2 (Kin.Dom. 2); NA=Not Active at 10 uM
1236,113187,149,CHEMBL24828,Tyrosine-protein kinase JAK2,Unspecified,Binding constant for JAK2(Kin.Dom.2/JH1 - catalytic) kinase domain
1237,113187,149,CHEMBL24828,Tyrosine-protein kinase JAK2,Unspecified,Binding constant for JAK2(JH1domain-catalytic) kinase domain
1238,312192,13,CHEMBL514499,Tyrosine-protein kinase ABL,Unspecified,GSK_PKIS: ABL1 (E255K mutant) mean inhibition at 0.1 uM [Nanosyn]
1239,312192,13,CHEMBL514499,Tyrosine-protein kinase ABL,Unspecified,GSK_PKIS: ABL1 (E255K mutant) mean inhibition at 1 uM [Nanosyn]
1240,312192,13,CHEMBL514499,Tyrosine-protein kinase ABL,Unspecified,GSK_PKIS: ABL1 (H396P mutant) mean inhibition at 0.1 uM [Nanosyn]
1241,312192,13,CHEMBL514499,Tyrosine-protein kinase ABL,Unspecified,GSK_PKIS: ABL1 (H396P mutant) mean inhibition at 1 uM [Nanosyn]
1242,312192,13,CHEMBL514499,Tyrosine-protein kinase ABL,Unspecified,GSK_PKIS: ABL1 (M351T mutant) mean inhibition at 0.1 uM [Nanosyn]
1243,312192,13,CHEMBL514499,Tyrosine-protein kinase ABL,Unspecified,GSK_PKIS: ABL1 (M351T mutant) mean inhibition at 1 uM [Nanosyn]
1244,312192,13,CHEMBL514499,Tyrosine-protein kinase ABL,Unspecified,GSK_PKIS: ABL1 (Q252H mutant) mean inhibition at 0.1 uM [Nanosyn]
1245,312192,13,CHEMBL514499,Tyrosine-protein kinase ABL,Unspecified,GSK_PKIS: ABL1 (Q252H mutant) mean inhibition at 1 uM [Nanosyn]
1246,312192,13,CHEMBL514499,Tyrosine-protein kinase ABL,Unspecified,GSK_PKIS: ABL1 (T315I mutant) mean inhibition at 0.1 uM [Nanosyn]
1247,312192,13,CHEMBL514499,Tyrosine-protein kinase ABL,Unspecified,GSK_PKIS: ABL1 (T315I mutant) mean inhibition at 1 uM [Nanosyn]
1248,312192,13,CHEMBL514499,Tyrosine-protein kinase ABL,Unspecified,GSK_PKIS: ABL1 (Y253F mutant) mean inhibition at 0.1 uM [Nanosyn]
1249,312192,13,CHEMBL514499,Tyrosine-protein kinase ABL,Unspecified,GSK_PKIS: ABL1 (Y253F mutant) mean inhibition at 1 uM [Nanosyn]
1250,312192,13,CHEMBL514499,Tyrosine-protein kinase ABL,Unspecified,GSK_PKIS: ABL1 mean inhibition at 0.1 uM [Nanosyn]
1251,312192,13,CHEMBL514499,Tyrosine-protein kinase ABL,Unspecified,GSK_PKIS: ABL1 mean inhibition at 1 uM [Nanosyn]
1252,332818,90,CHEMBL75880,Serotonin transporter,Unspecified,"DRUGMATRIX: Transporter, Serotonin (5-Hydroxytryptamine) (SERT) radioligand binding (ligand: [3H] Paroxetine)"
1253,332818,90,CHEMBL75880,Serotonin transporter,Unspecified,"DRUGMATRIX: Transporter, Serotonin (5-Hydroxytryptamine) (SERT) radioligand binding (ligand: [3H] Paroxetine)"
1254,311049,224,CHEMBL50894,Serine/threonine-protein kinase Aurora-A,Unspecified,"Millipore: Percentage of residual kinase activity of AURKA at 1uM relative to control. Control inhibitor: Staurosporine at 10.0uM. Buffer: 8 mM MOPS pH 7.0, 0.2 mM EDTA, 50 mM NaCl, 0.1% v/v Triton-X-100"
1255,311049,224,CHEMBL50894,Serine/threonine-protein kinase Aurora-A,Unspecified,"Millipore: Percentage of residual kinase activity of AURKA at 10uM relative to control. Control inhibitor: Staurosporine at 10.0uM. Buffer: 8 mM MOPS pH 7.0, 0.2 mM EDTA, 50 mM NaCl, 0.1% v/v Triton-X-100"
1256,324813,84,CHEMBL588119,Serotonin 2a (5-HT2a) receptor,Inactive,Luminescence-based cell-based primary high throughput screening assay to identify agonists of the mouse 5-hydroxytryptamine (serotonin) receptor 2A (HTR2A)
1257,324813,84,CHEMBL588119,Serotonin 2a (5-HT2a) receptor,Unspecified,DRUGMATRIX: Serotonin (5-Hydroxytryptamine) 5-HT2A radioligand binding (ligand: [3H] Ketanserin)
1258,324813,84,CHEMBL588119,Serotonin 2a (5-HT2a) receptor,Unspecified,DRUGMATRIX: Serotonin (5-Hydroxytryptamine) 5-HT2A radioligand binding (ligand: [3H] Ketanserin)
1259,163687,38,CHEMBL3609143,Serotonin 1d (5-HT1d) receptor,Unspecified,Displacement of [3H]GR125743 from 5HT1D receptor (unknown origin) at 10 uM
1260,163684,38,CHEMBL3609140,Serotonin 1d (5-HT1d) receptor,Unspecified,Displacement of [3H]GR125743 from 5HT1D receptor (unknown origin) at 10 uM
1261,320356,149,CHEMBL56543,Tyrosine-protein kinase JAK2,Active,Inhibition of human JAK2 V617F mutant expressed in COS7 cells
1262,320356,149,CHEMBL56543,Tyrosine-protein kinase JAK2,Unspecified,Inhibition of JAK2
1263,320356,149,CHEMBL56543,Tyrosine-protein kinase JAK2,Unspecified,Inhibition of recombinant JAK2 at 20 uM
1264,320356,149,CHEMBL56543,Tyrosine-protein kinase JAK2,Inactive,Inhibition of IL-6-induced JAK2 phosphorylation in human HT-29 cells at 10 to 20 uM by Western blotting
1265,320356,149,CHEMBL56543,Tyrosine-protein kinase JAK2,Active,Inhibition of IL-6-induced JAK2 phosphorylation in human HT-29 cells at 50 to 100 uM by Western blotting
1266,320356,149,CHEMBL56543,Tyrosine-protein kinase JAK2,Unspecified,"Millipore: Percentage of residual kinase activity of JAK2 at 1uM relative to control. Control inhibitor: Staurosporine at 10.0uM. Buffer: 8 mM MOPS pH 7.0, 0.2 mM EDTA"
1267,320356,149,CHEMBL56543,Tyrosine-protein kinase JAK2,Unspecified,"Millipore: Percentage of residual kinase activity of JAK2 at 10uM relative to control. Control inhibitor: Staurosporine at 10.0uM. Buffer: 8 mM MOPS pH 7.0, 0.2 mM EDTA"
1268,281992,149,CHEMBL4095253,Tyrosine-protein kinase JAK2,Unspecified,Inhibition of recombinant human C-terminal His6-tagged JAK2 (808 to end residues) expressed in baculovirus Sf21 insect cells preincubated for 5 mins followed by substrate addition after 30 to 60 mins in presence of ATP by fluorescence assay
1269,281992,149,CHEMBL4095253,Tyrosine-protein kinase JAK2,Unspecified,Selectivity ratio of IC50 for recombinant human C-terminal His6-tagged JAK2 (808 to end residues) to IC50 for human full length N-terminal His6-tagged BMX
1270,315225,125,CHEMBL535,Tyrosine-protein kinase SYK,Inactive,Average Binding Constant for SYK; NA=Not Active at 10 uM
1271,315225,125,CHEMBL535,Tyrosine-protein kinase SYK,Unspecified,Binding constant for SYK kinase domain
1272,315225,125,CHEMBL535,Tyrosine-protein kinase SYK,Inactive,Inhibition of SYK
1273,315225,125,CHEMBL535,Tyrosine-protein kinase SYK,Unspecified,Binding affinity to SYK
1274,315225,125,CHEMBL535,Tyrosine-protein kinase SYK,Unspecified,Binding constant for SYK kinase domain
1275,324813,86,CHEMBL588119,Serotonin 2c (5-HT2c) receptor,Unspecified,DRUGMATRIX: Serotonin (5-Hydroxytryptamine) 5-HT2C radioligand binding (ligand: [3H] Mesulergine)
1276,324813,86,CHEMBL588119,Serotonin 2c (5-HT2c) receptor,Unspecified,DRUGMATRIX: Serotonin (5-Hydroxytryptamine) 5-HT2C radioligand binding (ligand: [3H] Mesulergine)
1277,0,138,CHEMBL10,Vascular endothelial growth factor receptor 2,Inactive,Average Binding Constant for VEGFR2; NA=Not Active at 10 uM
1278,0,138,CHEMBL10,Vascular endothelial growth factor receptor 2,Unspecified,Binding constant for VEGFR2 kinase domain
1279,0,138,CHEMBL10,Vascular endothelial growth factor receptor 2,Unspecified,Binding constant for VEGFR2 kinase domain
1280,0,138,CHEMBL10,Vascular endothelial growth factor receptor 2,Unspecified,"Millipore: Percentage of residual kinase activity of KDR at 1uM relative to control. Control inhibitor: Staurosporine at 10.0uM. Buffer: 8 mM MOPS pH 7.0, 0.2 mM EDTA"
1281,0,138,CHEMBL10,Vascular endothelial growth factor receptor 2,Unspecified,"Millipore: Percentage of residual kinase activity of KDR at 10uM relative to control. Control inhibitor: Staurosporine at 10.0uM. Buffer: 8 mM MOPS pH 7.0, 0.2 mM EDTA"
1282,330564,18,CHEMBL6437,Serotonin 1b (5-HT1b) receptor,Active,Binding affinity (Ki) to rat cortical membranes at 5-HT1B binding site by using [125 I] ICYP as a radioligand.
1283,330564,18,CHEMBL6437,Serotonin 1b (5-HT1b) receptor,Unspecified,DRUGMATRIX: Serotonin (5-Hydroxytryptamine) 5-HT1B radioligand binding (ligand: [125I] Cyanopindolol)
1284,330564,18,CHEMBL6437,Serotonin 1b (5-HT1b) receptor,Unspecified,DRUGMATRIX: Serotonin (5-Hydroxytryptamine) 5-HT1B radioligand binding (ligand: [125I] Cyanopindolol)
1285,330564,18,CHEMBL6437,Serotonin 1b (5-HT1b) receptor,Active,Mouse 5-HT1B receptor (5-Hydroxytryptamine receptors)
1286,10059,90,CHEMBL115769,Serotonin transporter,Unspecified,"DRUGMATRIX: Transporter, Serotonin (5-Hydroxytryptamine) (SERT) radioligand binding (ligand: [3H] Paroxetine)"
1287,10059,90,CHEMBL115769,Serotonin transporter,Unspecified,"DRUGMATRIX: Transporter, Serotonin (5-Hydroxytryptamine) (SERT) radioligand binding (ligand: [3H] Paroxetine)"
1288,304356,214,CHEMBL477772,Ribosomal protein S6 kinase 1,Unspecified,Binding constant for S6K1 kinase domain
1289,304356,214,CHEMBL477772,Ribosomal protein S6 kinase 1,Inactive,human p70S6K1 kinase inhibition-screen
1290,56823,84,CHEMBL18772,Serotonin 2a (5-HT2a) receptor,Active,Binding affinity to rat cortical membranes at 5-hydroxytryptamine 2 (5-HT2) receptor using [3H]KET as a radioligand
1291,56823,84,CHEMBL18772,Serotonin 2a (5-HT2a) receptor,Active,Binding affinity to rat cortical membranes at 5-hydroxytryptamine 2 (5-HT2) receptor using [3H]KET as a radioligand
1292,56823,84,CHEMBL18772,Serotonin 2a (5-HT2a) receptor,Active,Binding affinity to rat cortical membranes at 5-hydroxytryptamine 2 (5-HT2) receptor using [3H]KET as a radioligand
1293,56823,84,CHEMBL18772,Serotonin 2a (5-HT2a) receptor,Unspecified,Ratio of the binding constants for 5-HT3 receptor and 5-HT2 receptor
1294,56823,84,CHEMBL18772,Serotonin 2a (5-HT2a) receptor,Unspecified,Selectivity the ratio of binding affinity against 5-HT2A receptor to that of 5-HT3 receptor
1295,56823,84,CHEMBL18772,Serotonin 2a (5-HT2a) receptor,Active,Displacement of [3H]ketanserin from 5HT2A receptor in rat cortex
1296,56823,84,CHEMBL18772,Serotonin 2a (5-HT2a) receptor,Active,Displacement of [3H]ketanserin from 5HT2A receptor in rat cortex
1297,56823,84,CHEMBL18772,Serotonin 2a (5-HT2a) receptor,Active,Agonists at Human 5-Hydroxytryptamine receptor 5-HT2A
1298,56823,84,CHEMBL18772,Serotonin 2a (5-HT2a) receptor,Active,Human 5-HT2A receptor (5-Hydroxytryptamine receptors)
1299,56823,84,CHEMBL18772,Serotonin 2a (5-HT2a) receptor,Active,Agonist activity at 5-HT2A receptor in human MCF7 cells assessed as increase in calcium flux at 5 uM measured at 5 secs time interval for 2 mins by Fluo-4AM dye based fluorescence microscopic analysis
1300,126071,202,CHEMBL302449,MAP kinase signal-integrating kinase 2,Active,Percentage MNK2 activity remaining in the presence of 0.1uM inhibitor
1301,126071,202,CHEMBL302449,MAP kinase signal-integrating kinase 2,Unspecified,"Millipore: Percentage of residual kinase activity of MKNK2 at 1uM relative to control. Control inhibitor: Staurosporine at 10.0uM. Buffer: 8 mM MOPS pH 7.0, 0.2 mM EDTA"
1302,126071,202,CHEMBL302449,MAP kinase signal-integrating kinase 2,Unspecified,"Millipore: Percentage of residual kinase activity of MKNK2 at 10uM relative to control. Control inhibitor: Staurosporine at 10.0uM. Buffer: 8 mM MOPS pH 7.0, 0.2 mM EDTA"
1303,334232,90,CHEMBL828,Serotonin transporter,Unspecified,"DRUGMATRIX: Transporter, Serotonin (5-Hydroxytryptamine) (SERT) radioligand binding (ligand: [3H] Paroxetine)"
1304,334232,90,CHEMBL828,Serotonin transporter,Unspecified,"DRUGMATRIX: Transporter, Serotonin (5-Hydroxytryptamine) (SERT) radioligand binding (ligand: [3H] Paroxetine)"
1305,329424,79,CHEMBL607707,Serine/threonine-protein kinase Aurora-B,Unspecified,Binding constant for AURKB kinase domain
1306,151037,149,CHEMBL3360347,Tyrosine-protein kinase JAK2,Unspecified,"Selectivity index, ratio of IC50 for human recombinant JAK2 to IC50 for human recombinant JAK1"
1307,151036,149,CHEMBL3360344,Tyrosine-protein kinase JAK2,Unspecified,"Selectivity index, ratio of IC50 for human recombinant JAK2 to IC50 for human recombinant JAK1"
1308,151035,149,CHEMBL3360343,Tyrosine-protein kinase JAK2,Unspecified,"Selectivity index, ratio of IC50 for human recombinant JAK2 to IC50 for human recombinant JAK1"
1309,151034,149,CHEMBL3360342,Tyrosine-protein kinase JAK2,Unspecified,"Selectivity index, ratio of IC50 for human recombinant JAK2 to IC50 for human recombinant JAK1"
1310,151033,149,CHEMBL3360341,Tyrosine-protein kinase JAK2,Unspecified,"Selectivity index, ratio of IC50 for human recombinant JAK2 to IC50 for human recombinant JAK1"
1311,151021,149,CHEMBL3360328,Tyrosine-protein kinase JAK2,Unspecified,"Selectivity index, ratio of IC50 for human recombinant JAK2 to IC50 for human recombinant JAK1"
1312,151020,149,CHEMBL3360319,Tyrosine-protein kinase JAK2,Unspecified,"Selectivity index, ratio of IC50 for human recombinant JAK2 to IC50 for human recombinant JAK1"
1313,151024,149,CHEMBL3360331,Tyrosine-protein kinase JAK2,Unspecified,"Selectivity index, ratio of IC50 for human recombinant JAK2 to IC50 for human recombinant JAK1"
1314,151029,149,CHEMBL3360336,Tyrosine-protein kinase JAK2,Unspecified,"Selectivity index, ratio of IC50 for human recombinant JAK2 to IC50 for human recombinant JAK1"
1315,151028,149,CHEMBL3360335,Tyrosine-protein kinase JAK2,Unspecified,"Selectivity index, ratio of IC50 for human recombinant JAK2 to IC50 for human recombinant JAK1"
1316,104818,149,CHEMBL2386630,Tyrosine-protein kinase JAK2,Unspecified,Selectivity ratio of EC50 for JAK2 in human TF1 cells to EC50 for JAK1 in human TF1 cells
1317,104818,149,CHEMBL2386630,Tyrosine-protein kinase JAK2,Unspecified,Selectivity ratio of Ki for recombinant JAK2 (unknown origin) to Ki for recombinant JAK1 (unknown origin)
1318,104819,149,CHEMBL2386631,Tyrosine-protein kinase JAK2,Unspecified,Selectivity ratio of EC50 for JAK2 in human TF1 cells to EC50 for JAK1 in human TF1 cells
1319,104819,149,CHEMBL2386631,Tyrosine-protein kinase JAK2,Unspecified,Selectivity ratio of Ki for recombinant JAK2 (unknown origin) to Ki for recombinant JAK1 (unknown origin)
1320,104819,149,CHEMBL2386631,Tyrosine-protein kinase JAK2,Unspecified,Selectivity ratio of Ki for recombinant JAK2 (unknown origin) to Ki for recombinant JAK1 (unknown origin)
1321,304356,140,CHEMBL477772,Nerve growth factor receptor Trk-A,Unspecified,Binding constant for TRKA kinase domain
1322,304356,140,CHEMBL477772,Nerve growth factor receptor Trk-A,Unspecified,Binding constant for TRKA kinase domain
1323,49374,178,CHEMBL180022,Fibroblast growth factor receptor 1,Unspecified,Binding constant for FGFR1 kinase domain
1324,329424,178,CHEMBL607707,Fibroblast growth factor receptor 1,Inactive,Average Binding Constant for FGFR1; NA=Not Active at 10 uM
1325,329424,178,CHEMBL607707,Fibroblast growth factor receptor 1,Unspecified,Binding constant for FGFR1 kinase domain
1326,68616,72,CHEMBL2006765,Serine/threonine-protein kinase PIM1,Unspecified,Inhibition of PIM1 (unknown origin) after 60 mins by TR-FRET assay
1327,337180,90,CHEMBL964,Serotonin transporter,Unspecified,"DRUGMATRIX: Transporter, Serotonin (5-Hydroxytryptamine) (SERT) radioligand binding (ligand: [3H] Paroxetine)"
1328,337180,90,CHEMBL964,Serotonin transporter,Unspecified,"DRUGMATRIX: Transporter, Serotonin (5-Hydroxytryptamine) (SERT) radioligand binding (ligand: [3H] Paroxetine)"
1329,224180,84,CHEMBL3817911,Serotonin 2a (5-HT2a) receptor,Unspecified,Displacement of [3H]Ketanserin from human 5-HT2A receptor expressed in cell membranes after 1 hr by liquid scintillation counting
1330,88083,194,CHEMBL2181110,PI3-kinase p110-alpha subunit,Active,Inhibition of PI3Kalpha (unknown origin)
1331,320556,194,CHEMBL566046,PI3-kinase p110-alpha subunit,Unspecified,Inhibition of mouse recombinant PI3Kalpha expressed in baculovirus-infected Sf21 cells at 100 uM
1332,320556,194,CHEMBL566046,PI3-kinase p110-alpha subunit,Active,Inhibition of mouse recombinant PI3Kalpha expressed in baculovirus-infected Sf21 cells
1333,161051,194,CHEMBL3589377,PI3-kinase p110-alpha subunit,Active,Inhibition of GST-tagged bovine p110alpha expressed in Sf9/Baculovirus system using [gamma-33P]ATP by scintillation proximity assay
1334,161051,194,CHEMBL3589377,PI3-kinase p110-alpha subunit,Unspecified,"Selectivity index, ratio of IC50 for GST-tagged human p110beta to IC50 for GST-tagged bovine p110alpha"
1335,161051,194,CHEMBL3589377,PI3-kinase p110-alpha subunit,Unspecified,"Selectivity index, ratio of IC50 for His-tagged p110gamma (unknown origin) to IC50 for GST-tagged bovine p110alpha"
1336,161051,194,CHEMBL3589377,PI3-kinase p110-alpha subunit,Unspecified,"Selectivity index, ratio of IC50 for GST-tagged p110delta (unknown origin) to IC50 for GST-tagged bovine p110alpha"
1337,161051,194,CHEMBL3589377,PI3-kinase p110-alpha subunit,Unspecified,"Selectivity index, ratio of IC50 for Glu-tagged PI3KC2beta (unknown origin) to IC50 for GST-tagged bovine p110alpha"
1338,161051,194,CHEMBL3589377,PI3-kinase p110-alpha subunit,Active,Cytotoxic activity against human HeLa cells over-expressing PI3K p110alpha incubated for 72 hrs by SRB assay
1339,161051,194,CHEMBL3589377,PI3-kinase p110-alpha subunit,Active,Cytotoxic activity against human SKOV3 cells expressing PIK3CA mutant incubated for 72 hrs by SRB assay
1340,161052,194,CHEMBL3589378,PI3-kinase p110-alpha subunit,Active,Inhibition of GST-tagged bovine p110alpha expressed in Sf9/Baculovirus system using [gamma-33P]ATP by scintillation proximity assay
1341,161052,194,CHEMBL3589378,PI3-kinase p110-alpha subunit,Unspecified,"Selectivity index, ratio of IC50 for GST-tagged human p110beta to IC50 for GST-tagged bovine p110alpha"
1342,161052,194,CHEMBL3589378,PI3-kinase p110-alpha subunit,Unspecified,"Selectivity index, ratio of IC50 for His-tagged p110gamma (unknown origin) to IC50 for GST-tagged bovine p110alpha"
1343,161052,194,CHEMBL3589378,PI3-kinase p110-alpha subunit,Unspecified,"Selectivity index, ratio of IC50 for GST-tagged p110delta (unknown origin) to IC50 for GST-tagged bovine p110alpha"
1344,161052,194,CHEMBL3589378,PI3-kinase p110-alpha subunit,Unspecified,"Selectivity index, ratio of IC50 for Glu-tagged PI3KC2beta (unknown origin) to IC50 for GST-tagged bovine p110alpha"
1345,161052,194,CHEMBL3589378,PI3-kinase p110-alpha subunit,Active,Cytotoxic activity against human HeLa cells over-expressing PI3K p110alpha incubated for 72 hrs by SRB assay
1346,161052,194,CHEMBL3589378,PI3-kinase p110-alpha subunit,Active,Cytotoxic activity against human SKOV3 cells expressing PIK3CA mutant incubated for 72 hrs by SRB assay
1347,161053,194,CHEMBL3589379,PI3-kinase p110-alpha subunit,Active,Inhibition of GST-tagged bovine p110alpha expressed in Sf9/Baculovirus system using [gamma-33P]ATP by scintillation proximity assay
1348,161053,194,CHEMBL3589379,PI3-kinase p110-alpha subunit,Unspecified,"Selectivity index, ratio of IC50 for GST-tagged human p110beta to IC50 for GST-tagged bovine p110alpha"
1349,161053,194,CHEMBL3589379,PI3-kinase p110-alpha subunit,Unspecified,"Selectivity index, ratio of IC50 for His-tagged p110gamma (unknown origin) to IC50 for GST-tagged bovine p110alpha"
1350,161053,194,CHEMBL3589379,PI3-kinase p110-alpha subunit,Unspecified,"Selectivity index, ratio of IC50 for GST-tagged p110delta (unknown origin) to IC50 for GST-tagged bovine p110alpha"
1351,161053,194,CHEMBL3589379,PI3-kinase p110-alpha subunit,Unspecified,"Selectivity index, ratio of IC50 for Glu-tagged PI3KC2beta (unknown origin) to IC50 for GST-tagged bovine p110alpha"
1352,161053,194,CHEMBL3589379,PI3-kinase p110-alpha subunit,Active,Cytotoxic activity against human HeLa cells over-expressing PI3K p110alpha incubated for 72 hrs by SRB assay
1353,161053,194,CHEMBL3589379,PI3-kinase p110-alpha subunit,Active,Cytotoxic activity against human SKOV3 cells expressing PIK3CA mutant incubated for 72 hrs by SRB assay
1354,38014,194,CHEMBL1645100,PI3-kinase p110-alpha subunit,Active,Inhibition of human p110alpha PI3K fragment by AlphaScreen assay
1355,279209,162,CHEMBL4081997,Matrix metalloproteinase 9,Unspecified,Inhibition of MMP9 (unknown origin) using fTHP-15 as substrate preincubated for 30 mins followed by substrate addition measured immediately by fluorescence assay
1356,279003,162,CHEMBL4081049,Matrix metalloproteinase 9,Unspecified,Inhibition of MMP9 (unknown origin) using fTHP-15 as substrate preincubated for 30 mins followed by substrate addition measured immediately by fluorescence assay
1357,110244,90,CHEMBL2432054,Serotonin transporter,Unspecified,Displacement of [3H]-citalopram from human SERT expressed in HEK cell membranes at 10 uM relative to control
1358,214763,18,CHEMBL3735756,Serotonin 1b (5-HT1b) receptor,Inactive,Displacement of [3H]5-CT from human recombinant 5-HT1B receptor stably expressed in HEK cell membrane after 90 mins by scintillation counting method
1359,117364,214,CHEMBL259084,Ribosomal protein S6 kinase 1,Unspecified,Binding constant for S6K1 kinase domain
1360,58003,133,CHEMBL191003,Focal adhesion kinase 1,Unspecified,Binding constant for PTK2 kinase domain
1361,58003,133,CHEMBL191003,Focal adhesion kinase 1,Unspecified,"Millipore: Percentage of residual kinase activity of PTK2 at 1uM relative to control. Control inhibitor: Staurosporine at 10.0uM. Buffer: 8 mM MOPS pH 7.0, 0.2 mM EDTA"
1362,58003,133,CHEMBL191003,Focal adhesion kinase 1,Unspecified,"Millipore: Percentage of residual kinase activity of PTK2 at 10uM relative to control. Control inhibitor: Staurosporine at 10.0uM. Buffer: 8 mM MOPS pH 7.0, 0.2 mM EDTA"
1363,316767,103,CHEMBL549,Dopamine transporter,Active,Displacement of [3H]WIN-35428 from DAT in rat caudate-putamen by scintillation counting
1364,316767,103,CHEMBL549,Dopamine transporter,Unspecified,Selectivity ratio of Ki for DAT in rat caudate-putamen to Ki for SERT in rat brain stem
1365,316767,103,CHEMBL549,Dopamine transporter,Unspecified,Inhibition of [3H]dopamine uptake at human DAT expressed in COS7 cells after 3 mins by beta-counting
